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ABSTRACT 
 
The purpose of this study was to produce a reagent to use in investigation of 
antibodies directed against the Knops blood group system antigens.   A novel 
reagent based on sr-proteins was produced and used in a new test to inhibit 
these antibodies. 
 
 
Current investigation of patients with alloantibodies directed against Knops 
blood group system antigens can be a difficult, time-consuming process and 
the provision of blood for transfusion of these patients can often be delayed.  
This is because these antibodies are hard to identify and the most commonly 
found anti-Knops antibodies react with most reagent or donor cells that they 
are tested with because the corresponding Knops antigens are found at high 
frequency in most populations.  The presence of Knops related antibodies can 
mask underlying antibodies that are clinically significant.   
 
The Knops antigens are carried on Complement Receptor 1 (CR1) located on 
the red blood cell membrane.  Two DNA constructs encoding different parts of 
CR1 termed long homologous repeat (LHR) C and D were used to transfect 
human embryonic kidney (HEK293) cells.  The cells were grown in different 
culture systems.   Cell culture supernatant containing soluble recombinant 
(sr)-LHRC or sr-LHR-D was harvested and purified by affinity gel 
chromatography.  The production and purification processes were optimised 
in terms of protein yield and cost.   
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The resulting purified sr-LHR-C and sr-LHR-D proteins were used to create a 
novel reagent containing both proteins.  This reagent was used in a new 
inhibition test based on an indirect antiglobulin technique using commercial 
gel cards.    Using the reagent all examples of previously identified Knops 
antibodies were inhibited.  In addition once these antibodies had been 
inhibited, underlying antibodies were then detected and identified in some 
samples. 
 
For the first time Knops specific antibodies can be detected and identified 
using one unique test.  Any underlying clinically significant antibodies will be 
rapidly identified if present due to inhibition of the KN antibodies.  Introduction 
of the inhibition test into nine NHSBT patient testing laboratories will reduce 
the time taken for investigation of these patients and make provision of blood 
for patients a safer, faster process. 
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1.0 INTRODUCTION 
1.1 Blood group antigens 
Blood group antigens are inherited markers found on the external surface of 
red blood cells.  Currently, over 300 blood group antigens are recognised and 
they may be located on proteins, glycoproteins or glycolipid structures that 
protrude from the red cell membrane (Daniels and Reid, 2010).  These 
structures have various functions that have now been mostly elucidated.  For 
instance, the Colton blood group system is carried on the water channel 
aquaporin 1 (AQP1) (Murakata et al., 2000).  The glycoprotein carrying Kell 
antigens is an active endopeptidase enzyme that processes big endothelin-3 
to endothelin-3, a potent vaso-constrictor (Turner et al., 2001) and Knops 
antigens featured in this study are carried on complement receptor 1 (CR1) a 
complement receptor protein that binds immune complexes (Moulds, 2010).  
Nomenclature of the antigens and their corresponding antibodies has been 
inconsistent.  Many antigens have been named after the first person found to 
have the antigen or more often the antibody e.g. Knops (abbreviated to Kn, 
first two letters) and Duffy (abbreviated to Fy, last two letters) or some have 
been named from part of a name like Kell (Kelleher), or even from initials like 
JMH, from John Milton Hagen. In 1980 an International Society of Blood 
Transfusion (ISBT) Working Party on Terminology for Red Cell Surface 
Antigens was set up to devise a uniform naming system that should be eye 
and machine readable (Garratty et al., 2000).  Since 1980 the Working Party 
has published guidance on nomenclature and in 2004 the terminology was 
described and tabulated (Daniels et al., 2004).  With machine readable i.e. 
numeric notation, a blood group antigen system is identified by a three-digit 
number e.g. ABO is 001, and then each ABO antigen is also given a three-
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digit number so that the A antigen is 001 and the B antigen is 002.  These are 
put together to form six digit numbers for each antigen, 001001 for the A 
antigen or 001002 for the B antigen.  Leading zeros may be dropped so that 
the A antigen becomes 1.1 and the B antigen 1.2.  However, more readily 
accessible symbols have also been agreed so that ABO is retained as a 
symbol and for example Duffy becomes FY, Kell becomes KEL and Knops 
becomes KN.   
 
All antigens now fall into one of four classifications: systems, collections, low-
incidence antigens (700 series) or high-incidence antigens (901 series).  The 
majority of antigens belong to one of 33 systems (ISBT, 2014; Table 1.1).  
Each system is genetically discrete from the other systems but they have 
been grouped together because they all contain one or more antigens 
controlled at a single gene locus or by two or more closely linked homologous 
genes.  In addition the gene encoding the antigen must have been identified 
and sequenced and the chromosomal location must be known. 
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Table 1.1 The 33 blood group systems 
System 
number 
System name System 
symbol 
Gene name Chromosomal 
location 
CD 
numbers 
001 ABO ABO ABO 9q34.2 * 
002 MNS MNS GYPA, GYPB, 
GYPE 
4q31.21 CD235 
003 P P1  22q11.2-qter * 
004 Rh RH RHD, RHCE 1p36.11 CD240 
005 Lutheran LU LU 19q13.32 CD239 
006 Kell KEL KEL 7q34 CD238 
007 Lewis LE Fut3 19p13.3 * 
008 Duffy FY FY 1q23.2 CD234 
009 Kidd JK SLC14A1 18q12.3 * 
010 Diego DI SLC4A1 17q21.31 * 
011 Yt YT ACHE 7q22.1 * 
012 Xg XG XG, MIC2 Xp22.33, 
Yp11.3 
CD99 
013 Scianna SC ERMAP 1p34.2 * 
014 Dombrock DO DO 12p12.3 * 
015 Colton CO AQP1 7p14.3 * 
016 Landsteiner-
Wiener 
LW ICAM4 19p13.2 CD242 
017 Chido/Rodgers CH/RG C4A, C4B 6p21.3 * 
018 H H FUT1 19q13.33 CD173 
019 Kx XK XK Xp21.1 * 
020 Gerbich GE GYPC 2q14.3 CD236 
021 Cromer CROM DAF 1q32.2 CD55 
022 Knops KN CR1 1q32.2 CD35 
023 Indian IN CD44 11p13 CD44 
024 Ok OK BSG 19p13.3 CD147 
025 Raph RAPH CD151 11p15.5 CD151 
026 John Milton Hagen JMH SEMA7A 15q24.1 CD108 
027 I I GCNT2 6p24.2 * 
028 Globoside GLOB B3GALT3 3q26.1 * 
029 Gill GIL AQP3 9p13.3 * 
030 Rh-associated 
glycoprotein 
RHAG RHAG 6p12.3 CD241 
031 FORS FORS GBGT1 9q34.13 * 
032 JR JR ABCG2 4q22 * 
033 LAN LAN ABCB6 2q36 * 
 
The symbols, gene name(s), chromosomal locations and cluster of 
differentiation (CD) numbers (ISBT, 2014) for the known blood group systems 
are shown.  CD numbers were assigned to certain blood group systems 
during the 7th Human Leucocyte Differentiation Antigens (HDLA) workshop 
(Zola et al., 2003).  An * indicates that no CD number has been assigned. 
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There are seven blood group collections (Table 1.2).  These do not fit the 
criteria needed to be allocated as systems but the antigens in each collection 
have been shown to be related in some way either serologically, biochemically 
or genetically.   
 
Table 1.2 Blood group collections 
Number Name Symbol 
205 Cost COST 
207 Ii I 
208 Er ER 
209 * GLOB 
210 * Lec, Led 
212 Vel VEL 
213 MNCHO MNCHO 
 
These cannot be allocated to systems but the antigens in each collection have 
been shown to be related either biochemically, serologically or genetically; an 
* indicates that no name has been assigned (ISBT, 2014). 
 
The 700 series contains low-incidence antigens (Table 1.3).  These have an 
occurrence of fewer than 1% in most populations but they cannot be assigned 
to any existing system or collection.   
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Table 1.3 The 700 series of low frequency antigens 
 
Number Name Symbol Number Name Symbol 
700002 Batty By 700040 Rasmusen RASM 
700003 Christiansen Chra 700044 * JKV 
700005 Biles Bi 700045 Katagiri Kg 
700006 Box Bxa 700047 Jones JONES 
700017 Torkildsen Toa 700049 * HUK 
700018 Peters Pta 700050 * HOFM 
700019 Reid Rea 700052 * SARA 
700021 Jensen Jea 700054 * REIT 
700028 Livesay Lia    
700039 Milne **    
 
These antigens have a frequency of less than 1% in most populations tested 
(ISBT, 2014).  An * indicates that no name has been assigned and ** indicates 
that there is no symbol for this antigen. 
  
Likewise, the 901 series of high-frequency antigens cannot be assigned to 
systems or collections (Table 1.4).  These antigens occur at an incidence of 
greater than 90% in most populations (Reid et al., 2012).  
 
Table 1.4 The 901 series of high frequency antigens  
Number Name Symbol 
901002 Langereis Lan 
901003 August Ata 
901008 * Emm 
901009 Anton AnWj 
901012 Sid Sda 
901014 * PEL 
901016 * MAM 
 
These antigens have a frequency of greater than 90% in most populations 
tested (ISBT, 2014).  An * indicates that no name has been assigned. 
 
Knowledge of gene sequence has allowed the amino acid sequence of 
molecules carrying blood group antigens to be determined and their structures 
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within the red blood cell (RBC) membrane predicted.  Figure 1.1 shows a 
variety of blood group antigen systems.  The antigens may be carried by 
integral blood cell membrane proteins with a single transmembrane domain.  
These are further categorised as type I, like MNS or KN with the N-terminus 
lying outside the membrane or type II, like KEL where the N-terminus lies 
inside the membrane.  Other antigens have multiple transmembrane domains 
e.g. RH and FY.  Others are glycosylphosphatidylinositol (GPI) linked proteins 
e.g. Cromer (CROM) (Reid et al., 2012).  Carbohydrate antigens of the ABO 
system are defined by immunodominant sugars attached to different types of 
oligosaccharide chains carried on glycosphingolipid and glycoprotein 
molecules (Daniels, 2013).    Many antigenic proteins are glycosylated and 
potential sites of glycosylation are shown in Figure 1.1.  N-linked glycosylation 
can occur at any extracellular asparagine in the sequence asparagine -X- 
serine / threonine except where X is proline.  O-linked glycosylation occurs at 
serine or threonine.  However, not all of the potential sites will be glycosylated 
(Reid et al., 2012).   
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Figure 1.1 Model of red blood cell membrane components.  These carry blood 
group antigens.  Potential sites of glycosylation are shown as branches off the 
main antigen structure (Reid et al., 2012).  See Tables 1.1 to 1.4 for antigen 
nomenclature. 
 
 
RBC antigens are generally carried on extracellular domains and allelic 
variation within blood group systems is determined predominantly by single 
nucleotide polymorphisms (SNPs), for example the Fya/Fyb (FY1/FY2) blood 
group polymorphism is determined by a 125G>A nucleotide change resulting 
in the presence of glycine for Fya or aspartic acid for Fyb at amino acid 42 in 
the N-terminal extracellular domain (Dean, 2005). 
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1.2 KN blood group antigens 
The nine antigens of the KN system (also known as Knops) are carried on 
complement receptor 1 (CR1) a type I membrane glycoprotein.  The antigens 
are all associated with nucleotide changes in CR1.  There are three 
antithetical antigen pairs: Kna and Knb, McCa and McCb, Sla and Vil.   The 
other three antigens are: Sl3, KCAM and Yka (Covas et al., 2007 and 
Veldhuisen et al., 2011).   The antigens, nucleotide SNPs and resulting amino 
acids are shown in Table 1.5.  
 
Table 1.5  Antigens of the KN blood group system 
ISBT 
terminology 
Original antigen 
names 
SNP 
(Counted from 
initiation codon 
AUG) 
SNP 
 (without 27 
nucleotide leader 
sequence) 
Amino acid 
KN1 / KN2 Kn
a
 / Kn
b
 4681 G>A 4708 G>A Val1561Met 
KN3 / KN6 McC
a
 / McC
b
 4768 A>G 4795 A>G Lys1590Glu 
KN4 / KN7 Sl1 (Sl
a
) / Sl2 (Vil) 4801 A>G 4828 A>G Arg1601Gly 
KN8 Sl3 4801A 
4828T 
4828A 
4855T 
Arg1601 
Ser1610 
KN9 KCAM+ / KCAM- 4843 A>G 4870 A>G Ile1615Val 
KN5 Yk
a
 4223C 4250C Thr1408 
 
The KN system has nine antigens.  The SNPs and resulting amino acid 
changes are shown.  Current publications use SNP positions counted from the 
initiation codon but older publications use the positions without the 27 
nucleotide leader sequence.  
 
All the KN polymorphisms are associated with SNPs in exon 29 of the CR1 
gene located on chromosome 1 (1q32).  There is a wide variation in the 
frequency of KN antigens in different populations as shown in Table 1.6.  Kna, 
McCa and Yka antigens are found at high frequency in Caucasian and Black 
populations.  McCb and Sl2 antigens are extremely rare in Caucasian 
populations but occur at frequencies of 45% and 80% respectively in 
 9  
individuals of African descent (Tetteh-Quarcoo et al., 2012).  This uneven 
distribution of KN antigens implies that they might be under some selection 
pressure and it has been speculated that the distribution of McCb and Sl2 
antigens reflect a survival advantage where malaria caused by the 
Plasmodium falciparum parasite is endemic (Rowe et al., 1997).  However, 
the situation is far from clear as a study in 2012 (Tetteh-Quarcoo et al.) found 
no evidence that these Knops blood group antigens could protect red blood 
cells from invasion by P.falciparum.  The CR1 receptor, Knops antigens and 
malaria are discussed further in section 1.9. 
 
Table 1.6  Frequency of KN antigens in different ethnic groups (Moulds, 2010) 
1.3 Antibody detection and identification 
All blood group antigens are defined serologically by alloantibodies.  Most 
alloantibodies are formed after people lacking particular antigens are exposed 
to them either through blood transfusion or pregnancy.  However, some 
alloantibodies are naturally occurring such as anti-A or anti-B of the ABO 
blood group system.  These are thought to be caused by exposure to 
oligosaccharides commonly occurring in nature, so that, for example, blood 
group A or O individuals become immunised to type-B carbohydrate antigen 
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present on bacteria (Spalter et al., 1999).  Immune antibodies are usually IgG 
whereas naturally occurring antibodies like anti-A are usually IgM (Figure 1.2).   
 
Figure 1.2 The basic structural unit of immunoglobulins and an IgM molecule.  
The basic structural unit has two heavy and two light chains.  If the heavy 
chains in the basic structural unit were gamma chains then this would be IgG.  
IgM structural units have mu heavy chains and five of these form the IgM 
pentamer (Flynn, 1998). 
 
The basic structural unit for IgG and IgM molecules is the same; it is formed of 
two heavy and two light chains.  Light chains are common to both IgG and 
IgM molecules and these are always of the same type in each molecule i.e. 
both are kappa light chains or both are lambda.  The heavy chains are unique 
to each type of immunoglobulin.  Heavy chains are gamma in IgG molecules 
and mu in IgM molecules.  The heavy and light chains can be further divided 
into variable and constant domains.  Both chains have terminal variable 
regions that are involved in antigen binding.  IgM molecules are pentamers 
formed of five IgM monomers joined together by disulphide bonds and a 
joining or J chain that joins two of the monomers (Czajkowsky and Chao, 
2009).  If the basic structural unit is cleaved by use of proteolytic enzymes 
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then the antibody binding regions can be released.  These are termed 
fragment of antigen binding or Fab fragments.  The remaining tail piece or Fc 
fragment (c for crystallisable) are responsible for effector functions such as 
complement activation (Moulds, 2009). 
 
Detection of both types of antibody in the laboratory relies on 
haemagglutination techniques.  Red cells are negatively charged so when 
they are suspended in solutions such as saline they attract positive ions which 
surround the cells and cause them to repel each other (Fernandes et al., 
2011). The large molecular size of IgM antibodies means that they can bridge 
the gap between red cells and if they bind to antigens on different red cells 
can cause them to clump together or agglutinate (Flynn, 1998).  This 
agglutination can be seen by the naked eye and can be brought about by 
simple incubation of plasma containing the antibody and cells with the 
corresponding antigen, or alternatively plasma and cells may be mixed in 
tubes and immediately centrifuged and the tubes are examined for 
agglutination of the red cells indicating a positive reaction (Daniels and 
Bromilow, 2007).  These direct agglutination techniques, however, are not 
suitable for detection of IgG antibodies.  IgG exists as a single molecule and 
so being much smaller than IgM molecules they cannot bridge the gap 
between antigens on different red cells to bring about agglutination without an 
enhanced technique (Flynn, 1998; Figure 1.3). 
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Figure 1.3 Sensitisation and agglutination of red blood cells. IgM blood group 
antibodies bring about direct agglutination of red cells They can bridge the 
gap between adjacent red cells which are held apart by a positive charge that 
surrounds them. IgG antibodies cannot bring about direct agglutination as 
they are too small to bridge the gap.  IgG blood group antibodies can bind to 
the red cell surface and cause them to be sensitised (Flynn, 1998). 
 
The most widely used technique in blood group serology is the indirect 
antiglobulin technique (IAT) for detection of IgG antibodies.  Traditionally, the 
IAT is a two stage test where patient’s plasma and phenotyped reagent red 
cells are first incubated together to induce sensitisation of the cells with 
antibody if the corresponding antigen is present on the cells (Figure 1.4).  The 
second stage involves washing away any unbound antibodies and plasma 
and then addition of anti-human globulin reagent (AHG) containing anti-IgG 
and anti-complement component C3d followed by centrifugation.  Positive 
reactions will be observed where the AHG has combined with IgG or 
complement molecules attached to the red cell antigens and caused the red 
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cells to agglutinate.  The wash stage ensures that the antiglobulin reagent is 
not neutralised by unbound antibodies or plasma (Klein and Anstee, 2005). 
 
Figure 1.4 Principle of the indirect antiglobulin test.  In the first stage 
sensitisation of red cells occurs if antibodies bind to their corresponding 
antigens on the red cells (bound antibodies shown in blue). This is followed by 
washing to remove any unbound antibodies (shown in red and yellow).  In the 
second stage AHG is added (shown in green) and agglutination of the red 
cells is brought about by centrifugation (Daniels and Bromilow, 2007). 
 
 IAT reactions have traditionally been performed in glass tubes but now 
commercial systems are available where a plastic card with columns 
containing gel or glass microbeads pre-mixed with anti-IgG and C3d are used.  
Plasma and reagent red cells are added to the top of the column, incubated 
and then the cards are centrifuged using pre-set parameters.  Red cells 
coated with antibody are agglutinated and unable to pass through the gel.  
The agglutinated cells appear as layers of cells on the top of the column or as 
agglutinates dispersed through the gel matrix.  In negative reactions 
unagglutinated cells can pass through the gel or beads and appear as buttons 
of cells at the bottom of the column (Figure 1.5).  As plasma proteins are less 
dense than the gel or beads they do not pass through the column and so do 
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not neutralise the AHG and thus a washing step is not needed (Lapierre et al., 
1990 and Reis et al., 1993). 
 
Figure 1.5 Principle of the gel indirect antiglobulin test.  AHG is incorporated in 
the gel matrix.  Red cells and plasma containing antibodies are incubated 
together at the top of the column.  On centrifugation, sensitised cells react 
with the AHG in the gel.  Agglutinates form that cannot pass through the gel 
thus giving a positive reaction.  A negative reaction is seen when non-
sensitised cells are centrifuged to the bottom of the column (adapted from 
Daniels and Bromilow, 2007). 
 
Generally, screening tests using IAT may reveal the presence of an antibody 
in a patient’s plasma sample.  Then identification of the antibody is essential 
as many are clinically significant, with the potential to cause haemolytic 
transfusion reactions (HTRs) and haemolytic disease of the foetus and 
newborn (HDFN) (Daniels et al., 2002). Identification involves testing patient 
plasma against panels of reagent red cells prepared from donor blood.  These 
panel cells must be selected to express a minimum defined set of RBC 
antigens (National Blood Service, 2013).  However, mixtures of antibodies can 
make detection and identification of clinically significant antibodies difficult 
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when using panel reagent cells with multiple antigen expression.  Detection of 
clinically significant antibodies can sometimes present a challenge as they are 
often found in antibody mixtures; levels of these antibodies can often become 
undetectable in plasma by IAT or the antibodies may only react with red cells 
having homozygous expression of the antigen.  Also, clinically significant 
antibodies may be masked by the presence of antibodies to high frequency 
antigens that will react with most or all panel reagent cells tested and the 
presence of these antibodies can make crossmatching difficult (Moulds and 
Rowe, 1996).    
 
1.4 Haemolytic transfusion reactions 
Before donor blood can be transfused, the compatibility of donor and recipient 
must be assessed.  Antibodies of the ABO system, anti-A, anti-B and anti-A,B, 
are naturally occurring, IgM antibodies, so that if mismatched blood is 
transfused reaction between recipient antibodies with the corresponding donor 
antigen occurs during or within 24 hours of the transfusion.  These acute 
HTRs are caused by activation of the complement cascade of proteins by 
bound antibodies (Stowell et al., 2012). 
   
The complement system consists of over 30 soluble or membrane bound 
proteins and can be activated via three pathways:  the alternative pathway; 
the classical pathway or the lectin pathway.  The alternative and lectin 
pathways play a key role in immunity against bacterial molecules.  The 
alternative pathway is activated by recognition of pathogen associated 
molecular patterns on bacterial surfaces; the lectin pathway by detection of 
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bacterial sugars (Berentson and Sundic, 2014).  It is the classical pathway 
that is activated by antigen-antibody complexes.  All pathways converge on 
formation of an enzyme that converts complement component C3 into the 
active products C3a and C3b (Figure 1.6).  The classical pathway, initiated by 
antibody binding with antigen, can be activated when red blood cell antibodies 
bind to their corresponding antigen on the red cell surface (Stowell et al., 
2012).  This pathway starts with activation of complement component C1, 
which consists of three proteins, C1q, C1r and C1s.  When C1q binds to the 
Fc portions of immunoglobulins (Daha et al, 2011) it causes a conformational 
change in C1r allowing it to cleave C1s, resulting in an active C1s protease.  
This complex activates components C2 and C4 generating red cell bound C2a 
and C4b and release of soluble C2b and C4a.  Bound C4b and C2a form C3 
convertase that cleaves C3 to C3a and C3b (Stoermer and Morrison, 2011).  
C3b facilitates continuation of the complement cascade when it attaches to 
the target cell membrane.  Bound C3b facilitates conversion of C5 to C5a and 
C5b.  Soluble components C3a and C5a are anaphylatoxins and promote 
chemotaxis and regulate a wide variety of systemic factors in immunity.  
Bound C5b continues the cascade and together  with components C6, C7, C8 
and C9 forms the membrane attack complex (MAC) that results in the 
insertion and polymerization of C9 in the target membrane and intravascular 
haemolysis (Goldfarb and Parillo, 2005).  
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Figure 1.6 The complement cascade.  On complement activation the 
complement components interact with each other sequentially causing a 
cascade of reactions involving enzymatic cleavage of inert components into 
active fragments which then contribute to activation of the next component.  
Ultimately, the membrane attack unit (C5b6789) may be formed (Stowell et al, 
2012). 
 
In the case of activation by red blood cell antibodies, red blood cells would be 
destroyed rapidly in the circulation resulting in the presence of free 
haemoglobin in the plasma (haemoglobinaemia) and urine (haemoglobinuria) 
and these reactions may be fatal (McLelland, 2001). 
 
Other clinically significant antibodies tend to be immune and IgG in nature.  
These usually cause delayed HTRs typically 5-8 days post transfusion 
(Strobel, 2008).  These occur because antibody present in the recipient due to 
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previous sensitisation is not detected prior to transfusion sometimes because 
it is at such low levels that it is not detected by serological techniques.  A 
secondary immune response follows transfusion of incompatible units where 
antibody levels rise and transfused red cells become coated with antibody 
(Garratty, 2008).  Extravascular haemolysis occurs when macrophages with 
receptors for the Fc region of immunoglobulin molecules, particularly in the 
spleen, trap and ingest the antibody coated red cells thus removing them from 
the circulation.  The interaction between IgG and Fc receptors is modulated by 
the structure of the IgG N-linked glycans (Aricescu and Owens, 2013).  
Sensitised RBCs may be completely or partially ingested by the 
macrophages.  Partial ingestion leads to the formation of spherocytes, which 
may undergo further destruction during subsequent passages through the 
spleen (Berentsen and Sundic, 2014).  Also, part or all of the RBC destruction 
may occur external to the macrophage by antibody-dependant cellular 
cytotoxicity (Garratty, 2008).  Delayed HTRs are characterised by a fall in 
haemoglobin levels, jaundice and fever (Murphy and Pamphilon, 2001).  CR1 
as a member of the complement control protein super family helps to regulate 
complement activation as it can bind and transport complement coated 
immune complexes, parasites or bacteria to the spleen and liver where they 
can be removed from the circulation.  Failure to remove such complexes can 
result in tissue injuries (Tham et al., 2011).  
 
1.5 Haemolytic disease of the foetus and newborn 
Also, in the Red Cell Immunohaematology (RCI) laboratory, it is important to 
identify antibodies that can cause HDFN.  This is caused by maternal IgG 
 19  
antibodies that are actively transported across the placenta during pregnancy 
(Mathiesen et al., 2013).  If the foetus carries the corresponding antigen, 
inherited from its father, then maternal antibody can sensitise foetal red cells 
causing them to be destroyed by foetal macrophages and thus causing foetal 
anaemia.  The anaemia may be so severe that the foetus could die from heart 
failure unless transfused in utero or, if less severe, then immediately after birth 
(Ross and de Alarcon, 2013).  Exchange transfusion may be required if 
haemoglobin levels are low or bilirubin levels from the breakdown of red cells 
are particularly high (McLelland, 2001).  Anti-D, formed against the RhD 
antigen can cause severe and fatal HDFN.  Antibodies directed against other 
blood group antigens e.g. those of the KEL, FY and JK (Kidd) systems are all 
normally IgG and can cause HDFN and transfusion reactions of varying 
severity (Garratty, 2012).   
 
1.6 Clinical significance of antibodies 
Whether a red cell antibody is clinically significant or not depends on several 
factors.  Thermal amplitude is important as the antibody must react at body 
temperature i.e. 37ºC. Activation of complement depends on immunoglobulin 
type and subclass.  Activation of C1 requires changes in two separate CH2 
domains on antibody immunoglobulin heavy chains.  As IgM is a pentameric 
molecule it has multiple antigen binding sites and only one bound molecule of 
IgM is needed to activate C1.  However, two of the smaller IgG molecules are 
needed for complement activation and these must attach to epitopes within 
20-30 nm of each other to activate C1 (Stowell et al, 2012).  In addition IgG 
has four subclasses that have different hinge regions that affect the 
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conformational flexibility of the IgG heavy chain.  This affects the ability of the 
CH2 domain to activate complement (Stowell et al, 2012). IgG1 and IgG3 are 
good activators of complement, IgG2 is a poor activator and IgG4 does not 
activate complement at all (Moulds, 2009).   
 
1.7 KN blood group antibodies 
Not all IgG antibodies are clinically significant and these include a group of 
antibodies that tend to give weak and variable reactions by IAT with the 
majority of red cells, reactions which are not always reproducible (Ensley, 
2012).  These antibodies were previously known as high titre, low avidity 
(HTLA) antibodies.  This was because if they are titrated i.e. doubling dilutions 
of plasma are prepared and tested by IAT against antigen positive cells, then 
they often react at high dilutions e.g. > 1 in 64 despite giving weak reactions 
(Ensley, 2012).  Most other red cell antibodies that react weakly when 
undiluted will generally be non-reactive when diluted (Moulds and Rowe, 
1996).  Antibodies to the KN system of antigens fall into this HTLA group.  KN 
antigens can occur at high frequency on RBCs so the antibodies will react 
with nearly all reagent or donor red cells by IAT (Moulds, 2010).  They can 
mask the presence of clinically significant antibodies that may also be present.  
Approximately 50% of patient samples containing KN antibodies also contain 
other alloantibodies (Daniels, 2013).  Investigation of patients with these 
antibodies can be difficult and time consuming.  Crossmatching, the process 
for ensuring that patient plasma is compatible with donor units, can take a lot 
longer if KN antibodies are present as nearly all donor units will be 
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incompatible and often incompatible units may have to be issued to avoid 
delays in supply of units to the patient (personal experience). 
 
Typically, the specificity of antibodies to high frequency antigens can be 
identified by testing patient plasma with rare cells that are negative for high 
frequency antigens.  If, for instance, no reactions were obtained by reacting 
patient plasma with cells that were negative for the high frequency Kna (KN1) 
antigen then it would be suspected that the antibody specificity was anti-Kna.  
However, these rare cells are not always available.  Chemical reagents and 
enzymes are often used to destroy some blood group antigens.  This chemical 
or enzyme modification of intact red cells often aids in the identification of 
antibody specificity (Reverberi and Reverberi, 2008).   The effects of 
proteinase enzymes such as papain, ficin, trypsin and sialidase and chemicals 
such as 2-aminoethylisothiouronium (AET) and dithiothreitol (DTT) on blood 
group antigens are well known and documented (Daniels, 1992 and 
Fernandes et al., 2011).  KN antigens are variable in their susceptibility to 
enzyme treatment but they are weakened or destroyed by the disulphide bond 
reducing agents AET and DTT (Reid, 2012). If the presence of KN antibodies 
is suspected then reagent red cells treated with either AET or DTT can be 
tested with patient’s plasma by IAT and negative or weakened reactions 
would be obtained if the antibody had KN specificity.  Unfortunately, other 
antigens are also destroyed by AET and DTT and these can be clinically 
significant e.g. KEL antigens and the high frequency antigens Gya and Hy 
(part of the Dombrock, (DO) blood group system) so interpretation of results 
needs to be done with experience and caution (Costa et al., 2010).  Even if a 
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specificity can be defined in this way there is still the problem of being able to 
distinguish the non-clinically significant anti-KN antibodies from potentially 
clinically significant antibodies that may also be present (Torres et al., 2010). 
 
If RCI laboratories cannot identify an antibody specificity then samples can be 
referred to the Red Cell Reference (RCR) laboratory, part of the International 
Blood Group Reference Laboratory (IBGRL), based at National Health Service 
Blood and Transplant (NHSBT), Filton.  RCR can repeat the testing that RCI 
laboratories have performed but with the advantage of having access to more 
rare cells negative for high frequency antigens and patient’s plasma referred 
from all over the world containing rare antibodies.   
 
RCR can also perform a monoclonal antibody-specific immobilization of 
erythrocyte antigens assay (MAIEA) that can confirm that an antibody is 
directed at specific red cell membrane proteins (Petty et al., 1997).  As shown 
in Figure 1.6, two antibodies are used; one a human alloantibody and the 
other a non-human, usually mouse monoclonal antibody.  These antibodies 
whilst being specific for the same protein recognise epitopes on different 
regions of the protein.  The antibodies are incubated with intact human red 
cells.  Then the red cells are haemolysed and red cell membranes solubilised.  
In a positive reaction a trimolecular complex of the two antibodies and 
membrane protein is formed.  This complex is immobilised on a multi-well 
plate coated with anti-mouse immunoglobulin and detected by use of 
peroxidase-conjugated goat anti-human immunoglobulin.  However, this test 
takes between two to three days to perform (Nicole Thornton, Head of RCR 
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personal communication) so is not suitable for investigation of urgent samples 
from patients requiring transfusion. 
 
  
Figure 1.7 Principle of the monoclonal antibody-specific immobilization of 
erythrocyte antigens assay.  Y = mouse IgG, Y = human IgG, Y = anti-mouse 
IgG,  = peroxidase conjugated anti-human IgG.  1.  Human and mouse 
antibodies binding to different epitopes on the same red cell membrane.  2.  
Solubilisation of the membrane to release the trimolecular complex.  3.  
Capture of the complex by immobilised anti-mouse IgG.  4.  Detection of the 
complex with peroxidase conjugated anti-human IgG (from Petty et al., 1997). 
 
Other antibodies in the ‘HTLA’ group include anti-CH/RG antibodies.  CH/RG 
antigens are found on complement components that bind to the RBC surface 
(Kahwash et al., 2005).  Complement is found in soluble form in plasma and 
thus incubation of the antibody with plasma can inhibit the antibody.  Inhibition 
of these antibodies in this way is a useful way of ensuring that there are no 
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other underlying antibodies present that could be clinically significant.  KN 
antigens are found in soluble form in plasma but only at very low levels so 
plasma cannot be used to inhibit these antibodies (Moulds, 2010).  However, 
the increasing availability of soluble recombinant (sr) blood group antigens 
does offer the possibility of inhibiting antibodies whose antigens are not 
available in any other soluble form.  Inhibition of any KN specific antibodies 
present would allow detection and identification of any underlying clinically 
significant antibodies that might also be present.  This would give the 
opportunity to provide safe blood for patients with problematic antibodies 
(Denomme and Flegel, 2008). 
 
1.8 Recombinant antigens 
Detailed knowledge of the molecular structure and genetic background of 
antigens has enabled soluble recombinant blood group antigens to be 
developed that retain their antigenic activity but are free of the RBC 
membrane.  These include: soluble recombinant (sr)-FY antigens (Sheffield et 
al., 2006 and Ridgwell et al., 2007); sr-K antigens (Ridgwell et al., 2007); sr-
LU antigens (Ridgwell et al., 2007 and Seltsam et al., 2008) and sr-JMH 
antigen (Seltsam et al., 2008). 
 
Use of recombinant antigens, in a soluble form, offers new opportunities for 
blood transfusion science.  Current antibody detection and identification 
techniques rely on the availability of panels of human red cells that must be 
selected to express a minimum defined set of RBC antigens (National Blood 
Service, 2013).  Positive reactions indicate that an antibody to one or more 
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antigens on the cells is present in the patient’s sample.  Analysis of patterns of 
reactivity against up to ten different cells contained in the panel indicates what 
the specificity of the antibody might be.  Some workers argue that if single 
soluble recombinant RBC antigens were available, then antibody identification 
would be simpler with a positive reaction unambiguously confirming the 
specificity of the antibody.  Panels of single specificity sr-RBC antigens could 
be assembled and would replace the need for donor blood to create panels.  
This would have the advantage of releasing donor units for transfusion 
(Seltsam and Blasczyk, 2009).  However, to use recombinant antigens in this 
way they must be available in soluble form and it is the 3D structure of the 
proteins within the red cell membrane that largely determines whether soluble 
versions can be generated (Seltsam et al., 2008).  For some single pass 
proteins with a single large extracellular domain (ECD), the ECDs have been 
expressed as soluble recombinant molecules.  Soluble recombinant KEL and 
Lutheran (LU) proteins have been produced and shown to retain blood group 
antigen expression (Ridgwell et al., 2007).  KEL antigens are carried on a 
single-pass type II red blood cell membrane glycoprotein and LU antigens on 
a single-pass type I membrane glycoprotein (Figure 1.1).  FY1 and FY2 sr-
antigens have also been produced (Sheffield et al., 2006 and Ridgwell et al., 
2007).  The FY antigens are carried on a type III membrane glycoprotein 
which spans the RBC membrane seven times.  However, the FY1/FY2 
polymorphism is located on the N-terminal extracellular domain (Sheffield et 
al., 2006).  It has proved difficult to produce soluble recombinant (sr)-proteins 
with blood group specificity for multipass proteins or those with a complex 
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structure of the extracellular domain or antigens requiring significant post-
translational modification (Seltsam, 2009).   
 
Soluble recombinant KEL, LU and FY antigens that have been produced were 
used in a solid-phase enzyme-linked immunosorbent assay (ELISA) technique 
to detect corresponding antibodies in human samples (Ridgwell et al., 2007).  
Recombinant Semaphorin 7A, the protein carrying high-frequency antigens of 
the JMH system, was produced and coupled onto superparamagnetic 
particles.  These coated particles were used in a particle gel immunoassay to 
detect anti-JMH antibodies (Seltsam et al., 2008).  Semaphorin 7A is a 
glcosylphosphatidylinositol-linked protein (Figure 1.1). Of the sr-proteins with 
blood group specificity that have been produced only KEL and FY would be 
included in a panel for antibody identification based on current guidelines 
(National Blood Service, 2013) as their corresponding antibodies are clinically 
significant.  Use of these proteins, as published, would involve developing 
techniques not routinely used in blood group serology currently e.g. solid-
phase ELISA assays (Ridgwell et al., 2007).  Another way that sr-RBC 
antigens can be used in blood group serology now is to use them to inhibit 
haemagglutination reactions.  Use of sr-antigens could be implemented easily 
as part of the haemagglutination process.  Patient’s plasma could be pre-
treated by incubation with sr-antigen before the IAT test was performed.  Sr-
recombinant CR1 protein that carries the KN antigens was used (Moulds and 
Rowe, 1996) to inhibit anti-KN antibodies.  There is no need to identify these 
antibodies if they can be inhibited as they are not clinically significant so 
development of a solid-phase assay using these proteins to detect and 
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identify them would not be cost effective or particularly useful.  However, if 
they can be “removed” from patient’s plasma this offers a quick and simple 
way of identifying whether any clinically significant antibodies are also present 
in the patient’s plasma.  
 
1.9 Complement receptor 1  
As discussed in section 1.5, CR1 as a complement control protein can 
regulate complement activation.  As well as clearing  up complement coated 
immune complexes it can also regulate further complement activation by 
accelerating the decay of C3 and C5 convertases and it can act as a co-factor 
for cleavage of C3b and C4b (Yazdanbakhsh, 2005).   
 
CR1 exists in four forms with the most common designated as CR1*1.  The 
ECD can be divided into 30 short complement regulator (SCR) domains (also 
known as complement control protein modules) each having 60 to 70 amino 
acids.  The first 28 SCRs are arranged into four longer regions termed long 
homologous repeats (LHRs) called LHR-A, LHR-B, LHR-C and LHR-D.  They 
consist of seven SCRs each (Tham et al., 2011) (Figure 1.8). 
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Figure 1.8 A best-fit scattering model for complement receptor 1.  The four 
LHR regions are shown with the 28 SCR domains numbered (seven in each 
LHR).  The final two SCRs are 29 and 30, these lie next to the red blood cell 
membrane (from Furtado et al., 2008). 
 
CR1 is a membrane bound glycoprotein found on most human peripheral 
blood cells.  As red blood cells are the most numerous cells in blood, they 
carry most of the CR1 in the body.  However, the number of CR1 molecules 
varies from between 300 to 800 per red blood cell.  This accounts for the 
variability in reactions seen in haemagglutination tests when KN antibodies 
are tested with reagent cells and also because CR1 can be lost from the red 
cell surface during storage (Moulds, 2010).  CR1 has a major role in removing 
immune complexes from circulation.  Immune complexes opsonised by C3b 
can bind to CR1 on the red cell surface.  When red cells circulate through the 
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liver and spleen the immune complexes are removed by macrophages and 
red cells may also lose CR1 molecules during the process.  In conditions 
where a high level of immune complexes are processed such as haemolytic 
anaemia, insulin-dependent diabetes mellitus or human immunodeficiency 
virus (HIV) infection, Knops antigens are found to be depressed due to loss of 
CR1 (Stoute, 2011). 
 
Three sites have been identified on CR1 where complement components are 
bound.  These are on LHR-A, LHR-B and LHR-C, whilst Knops antigens are 
located on LHR-D (Figure 1.9).   
 
 
 
Figure 1.9 A diagrammatic representation of the short consensus repeats 
(SCRs) in complement receptor 1 (Stoute, 2011).  The three binding sites for 
complement components C3b and C4b are shown.  The Knops antigens are 
located in SCR25 of LHR-D. 
 
The biological significance of blood group polymorphisms is not known but 
they probably arose due to a past selective advantage which may now have 
disappeared (Daniels, 2013).  However, glycoproteins that carry blood group 
antigens are often used as receptors by pathogenic micro-organisms for 
attachment to red cells and subsequent invasion (Lisowska, 2002).  The 
diversity in the distribution of Knops antigens Sl2 and McCb (Table 1.6) was 
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speculated to be due to a survival advantage in places where P.falciparum 
was endemic (Rowe et al. 1997).  However, the Knops antigens are carried on 
LHR-D and so do not occupy the known functional sites of the CR1 molecule 
(Tetteh-Quarcoo et al., 2012).  The P.falciparum adhesin protein, PfRh4, 
binds to red cells but only at short concensus repeats (SCRs) 1 to 3 (the C4b 
binding site), which is remote from the site of the Knops antigens in LHR-D 
(Tham et al., 2011).  It is possible that the distribution of Knops variants could 
arise from less well understood interactions between CR1 and pathogenic 
organisms.  It is known that CR1 on red cells binds immune complexes 
formed during invasion of bacteria such as Mycobacterium tuberculosis, the 
main cause of tuberculosis in sub-Saharan Africa.  The presence of McCb and 
Sl2 antigens appears to confer resistance to tuberculosis infection so could 
explain the selection of these antigens in this population (Noumsi et al., 2011).   
 
1.10 Sr-protein expression systems 
There are several steps required for expression of a foreign gene in a host 
organism so that recombinant protein (r-protein) is produced.  The first step 
generally requires the insertion of that gene into an expression vector.  Either 
full length or modified versions of the gene have been used for expression.  
With blood group antigens expression of the ECD is often used as antigens 
are present on this part of the molecule.  To enhance solubility and facilitate 
purification of the protein, DNA that encodes for a fusion partner (such as the 
FLAG peptide) may be present in the vector.   Recombinant proteins 
produced from a FLAG vector carry a short peptide, amino acid sequence: 
Asp-Tyr-Lys-Xaa-Xaa-Asp, encoded by the expression vector at their amino 
or carboxyl termini. This peptide, known as an affinity tag, provides a means 
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of isolating and purifying the protein, for instance by using anti-FLAG 
monoclonal antibodies to capture FLAG tagged proteins in an agarose affinity 
gel column system (Terpe, 2003).  The 3XFLAG tag developed from the 
FLAG tag has three adjacent FLAG epitopes.  The p3XFLAG-cytomegalovirus 
(CMV)™-13 expression vector is designed to establish stable expression of C-
terminal 3XFLAG-tagged proteins in mammalian cells (Figure 1.8).  Presence 
of the preprotrypsin leader sequence (PPT LS) results in secretion of the 
3XFLAG fusion protein into the culture medium.  The promoter regulatory 
region (CMV promoter) of the human cytomegalovirus drives transcription of 
3xFLAG-fusion constructs.  FLAG expression vectors encode the 
aminoglycoside phosphotransferase II gene (neor) that confers resistance to 
aminoglycosides such as geneticin sulphate (G418).  This vector also 
contains the pMB1 origin of replication in bacterial cells which is a derivative 
of pBR322, the β-lactamase gene for ampicillin resistance selection in 
bacteria (ampr), hGH polyA and the f1 origin. 
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Figure 1.9 The p3xFLAG-CMV-13 vector.  This vector contains the strong 
CMV promoter for high-level expression in mammalian cells.  Three adjacent 
FLAG epitopes, Asp-Tyr-Lys-Xaa-Xaa-Asp (3xFLAG) are downstream of the 
multiple cloning site (MCS).  The preprotrypsin leader sequence (PPT LS) 
directs secretion into the culture medium.  Neor and ampr confer resistance to 
aminoglycosides and ampicilin respectively (Sigma-Aldrich, 2010). 
 
The expression vector must be integrated into a host cell’s genome to 
produce a stable recombinant cell line.  Mammalian cell lines such as human 
embryonic kidney (HEK293) and COS-7 have been used successfully to 
express recombinant blood group antigens and have the advantage that they 
can perform post-translational modifications needed, such as glycosylation 
and di-sulphide bond formation, needed for appropriate protein folding 
(Sweich et al., 2012).  This is important as recombinant blood group antigens 
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must mimic the structure and conformation of RBC antigens so that they can 
be detected by human alloantibodies (Yazdanbakhsh, 2007).  Glycosylation is 
an important post-translational modification.  It can be extremely complex with 
mono, oligo or long and complex polysaccharides attached to proteins at 
multiple sites (Ellis and Noid, 2014). Glycosylation is important for protein 
folding.  Some proteins do not fold properly unless they are glycosylated 
whilst some are not stable unless they contain N-linked polysaccharides 
(Aricescu and Owens, 2013).  It is also important for protein mobility and 
signal transduction (Roth et al., 2012).  However, mammalian expression 
systems are the most expensive to use and protein yields can be significantly 
less than in other systems (Seltsam et al., 2007).  Other expression systems 
available include insect cells, bacteria and yeast.  These may produce higher 
yields than mammalian cells but they cannot perform all the necessary post-
translational modifications, in particular they cannot perform glycosylation and 
blood group antigens are often glycosylated (Sweich et al., 2012).   
 
Adherent cells like HEK293 need a surface on which they can grow.  At its 
simplest this involves growing the cells in plastic flasks or dishes that provide 
a rigid substrate (McAteer et al., 2002).  Cells also need to be grown in a 
medium such as Dulbecco’s Minimal Eagle’s Medium (DMEM) that provides 
nutrients, salt and pH control.  Supplements are often added to facilitate 
growth; the amino acid glutamine is an important energy source and provides 
amines essential for the synthesis of nucleic acids and other compounds. 
Added protein helps buffer the culture system.  Protein is normally added in 
the form of albumin contained in foetal calf serum (FCS), which also provides 
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growth factors.  The most frequently used antibiotics are mixtures of penicillin 
and streptomycin because of their combined action against gram-positive and 
gram-negative bacteria.  A pH indicator like phenol red can be added to 
DMEM to indicate whether the pH is within optimum range (normally pH7.0 – 
7.5 for most cells).  At this range the colour is red but any change to yellow 
indicates that the medium has become more acidic (Cartwright and Shah, 
2002) which could be due waste products produced by the cells and is an 
indication that the medium needs to be replaced.  Mammalian cells have 
efficient systems for secreting proteins into the culture medium, this makes 
harvesting the r-protein a relatively simple process (Brown, 2010).  Purification 
of the protein can then be based on an attached affinity tag, such as the 
3xFLAG tag, which can result in sr-protein of high purity (Lichty et al., 2005).   
 
1.11 Previous work on soluble CR1 
As high frequency antibodies of the Knops system cannot be inhibited by 
serum, saliva or urine as other antibodies are, Moulds and Rowe (1996) 
obtained some soluble recombinant CR1, lacking the transmembrane and 
cytoplasmic domains, to assess whether this could be used to inhibit them.  
The sr-CR1 had been produced using a cDNA sequence encoding the CR1*1 
allotype modified by introduction of a stop codon at the junction of the 
extracellular and transmembrane regions.  They labelled the sr-CR1 with 125I 
and used examples of human and monoclonal antibodies with anti-KN 
specificities to immunoprecipitate complexes which they eluted and ran on 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
gels under non-reducing conditions.  All antibodies tested immunoprecipitated 
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a protein of approximately 190 kDa, corresponding to the predicted molecular 
mass of the sr-CR1 molecule.  An inhibition technique was developed where 
human sera containing examples of Knops system antibodies were incubated 
with sr-CR1 prior to testing with KN antigen positive cells in a standard IAT 
technique.  Samples containing individual KN antibodies e.g. anti-Kna and 
anti-Sla and samples containing mixtures of KN antibodies e.g. anti-Kna plus 
anti-McCa were tested.  Only one example of anti-Kna was not inhibited by this 
technique.  No examples of non-Knops related antibodies also tested were 
inhibited.  It was concluded that use of sr-CR1 offered a valuable alternative to 
the current serological techniques.   
 
Yazdanbakhsh et al. (2000) speculated that mouse erythroleukaemic (MEL) 
cells might be used to express individual blood group antigens that could be 
used to replace RBCs to absorb specific antibodies as part of the antibody 
identification and detection process before compatibility testing.  This was 
because MEL cells had been used as an erythroid tissue culture model.  They 
used a whole CR1 cDNA sequence to transfect MEL cells.  Stable clones of 
transfected cells were established and surface expression of CR1 was 
confirmed by flow cytometry using a monoclonal anti-CR1 antibody.  
Absorption of sera containing Knops antibodies with the transfected mouse 
cells did lead to inhibition of anti-Knops antibodies.   
 
Truncated CR1 proteins were produced as a step towards mapping the 
epitopes of Knops system antigens (Tamasauskas et al., 2001).  As part of 
this study the ability of the individual LHRs they had produced to inhibit 
antibodies with anti-KN specificity was assessed. PCR primer pairs were 
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developed to amplify the four LHR regions from the same sr-CR1 ECD 
construct used by earlier workers (Moulds and Rowe, 1996).  Human 
embryonic kidney cells (HEK293) were transfected with the individual LHRs 
and culture supernatants harvested and purified.  The recombinant proteins 
produced were used to inhibit sera containing anti-KN antibodies.  They found 
that three out of six sera containing anti-Kna were almost completely inhibited 
by soluble recombinant (sr)-LHR-C and the other three by soluble 
recombinant (sr)-LHR-D.  Two sera containing anti-McCa were inhibited by 
LHR-D, whilst seven out of eight examples of anti-Sla showed reduced activity 
with LHR-D only.  They concluded that McCa, Sla and Yka antigens reside 
within LHR-D and that some of the Kna epitopes are within LHR-C and some 
within LHR-D.  Their study also suggested that the sr-CR1 ECD was 
sometimes not as efficient as that of sr-LHR-D in inhibiting Knops system 
antibodies.  They concluded that it might prove more cost effective and be 
more efficient to express the smaller LHRs rather than the whole CR1 
molecule.  In 2005 Yazdanbakhsh, one of the co-authors of the above work 
speculated that a mixture of sr-LHR-C and sr-LHR-D could be sufficient for KN 
antibody inhibition. 
 
In 2007, Dr K. Ridgwell obtained full length human CR1*1 from Dr K. 
Marchbank, University of Cardiff.  The CR1*1 was cloned into the pCDM8 
vector (Invitrogen, Figure 1.9).  Dr Ridgwell designed PCR primers to amplify 
the LHR-C and LHR-D regions of CR1.  These regions were ligated into 
p3xFLAG-13 expression vectors (Sigma-Aldrich) (Figure 1.8).  HEK293 cells 
were transfected and cultured.  Proteins purified from the cell culture 
supernatant were used to perform some preliminary investigations into their 
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ability to inhibit samples containing antibodies directed against KN system 
antigens. It was shown that Knops antibodies were inhibited, some with sr-
LHR-C and some with sr-LHR-D. This work was promising but not pursued at 
the time due to other commitments, including producing other sr-blood group 
antigens as part of a commercial contract. 
 
    
Figure 1.10 The pCDM8 vector.  The ECD region of CR1*1 was cloned into a 
pCDM8  vector (Invitrogen) which was obtained from Dr K Marchbank. 
 
There is now a growing interest in developing the use of sr-blood group 
antigens for RCI and recognition that blood bank scientists increasingly need 
to be familiar with molecular theory and techniques (Denomme and Flegel, 
2008).  This study was devised to produce and investigate the use of both sr-
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LHR-C and sr-LHR-D for inhibition of Knops system antibodies.  This 
approach has been suggested by several workers as described above but 
there is no reagent currently available for the reference laboratories of NHSBT 
to use.  Although KN antibodies are not clinically significant they are not 
uncommon and are often difficult to identify.  This makes them a nuisance as 
they can cause an incompatible crossmatch and must ideally be identified 
before transfusion of incompatible blood can be recommended.   This means 
that investigation of patient samples containing KN antibodies can be a time 
consuming process and can cause delays in provision of blood for transfusion.  
This can potentially put patients’ lives at risk if provision of blood is delayed or 
if investigation has not identified underlying clinically significant antibodies 
then the patient is at risk of suffering a haemolytic transfusion reaction. 
   
1.12 Aims and objectives 
The aims of this research were to: 
 Produce sr-LHR-C and sr-LHR-D proteins to be used in NHSBT 
laboratories for investigation of patient samples and in the crossmatch 
procedure. 
 Optimise a haemagglutination inhibition technique for use in the above 
laboratories using the two sr-LHR proteins. 
 Analyse the cost benefit of this approach. 
The objectives to achieve these aims were to: 
 Transfect HEK293 cells to produce sr-LHR-C or sr-LHR-D protein 
 Clone transfected cells to select those producing the most protein and set 
up frozen cell banks for future use 
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 Optimise the protein purification process  
 Develop an inhibition test and an ELISA to test sr-protein antigenicity 
using the purified sr-LHR proteins 
 Calculate the cost of the process to provide sufficient reagent to nine 
NHSBT laboratories 
 Investigate CE marking the product for distribution more widely 
 
1.13 Assay validation 
An assay for use in RCI laboratories would need to be fully validated before 
use.  Within NHSBT a change control process would need to be established 
and full validation script written before the reagent could be distributed.  This 
would be so that  intra- and inter- assay variability was minimised. 
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2.0 MATERIALS AND METHODS 
2.1 DNA techniques 
2.1.1 Preparation of recombinant plasmid DNA for transfection 
A plasmid DNA preparation of p3xFLAG-LHR-D was kindly donated by Dr K 
Ridgwell for this study but a plasmid DNA preparation of p3xFLAG-LHR-C 
was not available.  However, a frozen sample of p3xFLAG-LHR-C transfected 
E.coli preserved in glycerol was obtained from Dr K Ridgwell.  In this study, 
the transfected E.coli cells were streaked onto an agar plate containing 100 
µg mL-1 ampicillin.  After overnight incubation at 37 ºC, colonies had grown 
and these were used to inoculate 5 mL 2.5% Luria broth.  The broth samples 
were incubated overnight at 37 ºC with shaking.  From these samples some 
cells were frozen in glycerol for stock by adding 500 µL cell culture to 125 µL 
75% glycerol (final glycerol concentration 15%) in a 2 mL cryovial and freezing 
at -80 ºC.  Plasmid DNA was purified from the remaining cell sample using the 
Wizard® Plus SV Minipreps DNA Purification System (Promega) according to 
manufacturer’s instructions.  Briefly, this involved production of a cleared cell 
lysate and then binding the plasmid DNA onto a DNA binding resin in a mini 
column collection tube.  The DNA was then washed and eluted from the 
column and suspended in nuclease-free water.  To check that LHR-C and 
LHR-D inserts of the correct size were present, plasmid DNA was cut using 
restriction enzymes, Cla1 and Kpn1 (Sigma-Aldrich). These enzymes had 
been used previously to clone the CR1 inserts into the 3XFLAG vector.  For 
10 µL restriction enzyme digest, 2 µL DNA was used with 0.5 µL of Cla1 (5 
units) and 0.5 µL of Kpa1 (5 units), 1 µL 10x concentration Bovine Serum 
Albumin (BSA) and 1 μL 10x concentration restriction enzyme SL buffer 
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(Sigma-Aldrich).  SL buffer contained 100 mM Tris-hydrochloric acid (HCl) pH 
7.5, 100 mM MgCl2 and 10 mM 1,4-Dithioerythritol (DTE).  The restriction 
mixture was incubated at 37 ºC for 1.5 hours. This was followed by 1% 
agarose gel electrophoresis of cut and uncut samples (Method 2.1.2).   
 
2.1.2 Agarose gel electrophoresis 
Agarose gel was prepared by dissolving 0.2 g agarose (Invitrogen) in 20 mL 
0.5x Tris-acetate EDTA buffer (2 M Tris-acetate and 50 mM EDTA) to make 
the required 1% gel.  SYBR® Safe DNA gel stain (Invitrogen) was added (2 µL 
of x10,000 concentrate).  Samples were suspended in blue/orange 6x loading 
dye (Promega).  This ready to use mixture contained: 0.4% orange G, 0.03% 
bromophenol blue, 0.03% xylene cyanol FF, 15% Ficoll® 400, 10 mM Tris-HCl 
(pH 7.5) and 50 mM EDTA (pH 8.0).  Samples were loaded onto gels together 
with a Smart Ladder molecular size marker (Eurogentec).  This marker gave 
14 bands from 200 to 10,000 base pairs spaced in multiples of 100 base 
pairs. Gels were run at 100 V for approximately 20 minutes on a Mupid®-eXu 
submarine electrophoresis system (Advance Co Ltd) or until the coloured 
markers had reached the bottom of the gel and then DNA bands were 
visualised with UV transillumination (302 nm) read on a Bio-Doc-It™ Imaging 
System (Ultra-Violet Products Ltd).  
 
2.1.3 Spectrophotometric analysis of p3xFLAG-LHR-C plasmid DNA 
DNA sample purity was measured by reading absorbance at 260 and 280 nm 
on a spectrophotometer (Multiskan EX, Thermo Scientific) and the ratio 
A260/A280 determined.  DNA concentration was determined by multiplying 
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A260 obtained by 50 µg mL-1 and sample dilution (based on an absorbance of 
1 equal to 50 μg mL-1 DNA). 
 
2.1.4 3xFLAG-LHR-C and 3xFLAG-LHR-D plasmid DNA sequencing 
To confirm that LHR-D and LHR-C had been correctly inserted into the 
p3xFLAG-CMV vector, DNA samples of p3xFLAG-LHR-D (from KR) and 
p3xFLAG-LHR-C (current research) were mixed with appropriate primers prior 
to Sanger di-deoxy chain termination sequencing.  Two vector sequencing 
primers, N-CMV-30 (Sigma-Aldrich) and C-CMV-24 (Sigma-Aldrich) and an in-
house designed primer, CR1-F3 were used.  To a final concentration of 10 μM 
for each primer, was added 1 μg DNA.  N-CMV-30 (sequence 5’-AAT GTC 
GTA ATA ACC CCG CCC CGT TGA CGC-3’) was used to sequence at the 3’ 
end of the LHR insert within the vector.  Reverse primer, C-CMV-24 
(sequence 5’-TAT TAG GAC AAG GCT GGT GGG CAC-3’) was used to 
sequence at the 5’ end of the LHR insert.  CR1-F3 (5’-AAG GTG TTT GAG 
CTT GTG GGG-3’) was designed to detect the LHR inserts within the vector 
and was complimentary to sequences within both LHR-C and LHR-D.  The 
samples were sent to Peter Martin (Bristol Institute for Transfusion Sciences 
(BITS)/IBGRL) for sequencing.  The DNA sequences, when received, were 
analysed on SeqScape software (Invitrogen) and compared by eye to the 
sequences of LHR-C and LHR-D within CR1 GenBank accession number 
Y00816. 
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2.1.5 Transfection of HEK293 cells with p3xFLAG-CMV-LHR-C or 
p3xFLAG-CMV-LHR-D 
 
HEK293 cells were obtained from Mathew Hazell (BITS/IBGRL).  In this study, 
these cells were transfected with p3xFLAG-CMV-LHR-C or p3xFLAG-CMV-
LHR-D recombinant vector DNA preparations using the FuGENE® HD 
Transfection Reagent (Promega).  The manufacturer’s standard protocols 
were used and reactions were set up in a 6-well plate.  HEK293 cells (2 mL; 2 
x 104) in cell culture medium DMEM (Sigma-Aldrich) containing 10% FCS 
(Hyclone®, Fetalclone®, Thermo Scientific), 1% penicillin-streptomycin (PS) 
(stock solution containing 10,000 units penicillin and 10 mg streptomycin per 
mL, Sigma-Aldrich) and 1% L-Glutamine (LG, stock solution containing 200 
mM L-Glutamine, Sigma-Aldrich) were added to each well of the two 6-well 
plates the day before transfection.  For transfection the reagent was warmed 
to room temperature (RT) and mixed well before use.  Serum free medium (to 
make a final volume of 100 μL) was added to Eppendorf tubes and DNA or 
water was added.  The transfection mixture was added and incubated at RT 
for 25 minutes.  Two different ratios of transfection reagent to DNA were used 
for both LHR-C and LHR-D.  These were 3:1 (6 µL:2 µg) and 1.5:1 (3 μL: 2 
μg).    The medium was gently removed from the HEK293 cells and 1 mL of 
fresh medium was added to each well.  The transfection reagent was added to 
each well and the plate mixed carefully prior to incubation in a 7% CO2 
incubator at 37 ºC.  After 24 hours, G418 (Gibco) at a final concentration of 
400 µg mL-1, was added to the wells.  This was to select for cells containing 
transfected DNA as the vector contained the aminoglycoside 
phophotransferase gene that conferred resistance to G418. At regular 
intervals (3 to 4 days) cell culture supernatant was removed from the wells 
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and retained and fresh culture medium containing 200 µg mL-1 G418 was 
added.  An ELISA (see Method 2.3.1) was performed on the supernatants to 
determine if the cells were producing sr-LHR-C and sr-LHR-D protein.  After 4 
weeks the selected cells were removed from the appropriate well by trypsin 
treatment (see Method 2.2.1) and transferred to individual T-75 flasks (BD 
Falcon™).   
 
2.2 Cell culture techniques 
2.2.1 Cloning of stably transfected HEK293 cells producing sr-LHR 
proteins 
 
When the cells in the flasks were confluent i.e. cells adhered onto the bottom 
of the flask with few or no gaps between them, the cells were dislodged from 
the bottom of the flask by trypsin treatment.  Trypsin-EDTA solution (0.5 M, 
Sigma) had been pre-warmed to 37 ºC.  Culture medium was decanted from 
the flask and residual culture medium in the flasks was removed by washing 
with phosphate buffered saline (PBS).  Trypsin-EDTA was added just to cover 
the cell layer in the base of the flask (3 to 5 mL).  The flasks were incubated at 
room temperature for 2 to 5 minutes until the cells could be dislodged by 
tapping the flask.  When the cells had been dislodged the trypsin was 
neutralised by adding 3 to 5 mL cell culture medium.  The cell suspension was 
mixed gently and then decanted into sterile centrifuge tubes and centrifuged 
at 470 g for three minutes. A sample was prepared for cell counting.  The 
neutralised cells were resuspended in 10 mL cell culture medium.  To 50 μL of 
this cell suspension, 50 μL 0.2% Tryphan blue was added.  The preparation 
was applied to a haemocytometer and cells were counted in duplicate.  In 
order to be able to select individual cell colonies increasing dilutions of cells 
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were prepared in cell culture medium, from 1/10 to 1/1,000,000.  These were 
used to seed six petri dishes (20 mm, Falcon BD).  Over several days as the 
colonies developed, the petri dishes were examined under a microscope in a 
flow cabinet and individual cell colonies were selected.  These were picked 
using a sterile pipette tip and transferred to individual wells of a 24-well plate.  
From these plates the six colonies producing the highest amounts of sr-LHR-
C and sr-LHR-D as measured by ELISA (see Method 2.3.1) were transferred 
to 6-well plates and then into T-75 flasks.  This cloning process was repeated 
twice more.  After the third round of cloning the cells producing the most sr-
LHR-C and sr-LHR-D as seen from the ELISA results were selected and 
master and working Cell Banks were prepared and frozen at -80 °C (see 
Method 2.2.2). 
 
2.2.2 Freezing cloned stably transfected cells for liquid nitrogen 
storage 
 
Sterile freezing medium (90% FCS, 10% dimethyl sulphoxide) was prepared 
and pre-chilled on ice.  Freezing medium was added to a pellet of HEK293 
cells and they were mixed gently.  The cell suspension was transferred to 
properly labelled freezing vials that had been pre-cooled on ice.  Filled vials 
were frozen gradually, over 2 to 3 hours, at -80 ºC in a ‘Mr Frosty’ freezing 
container (Nalgene) which was filled with 100% isopropyl alcohol, with a 
cooling rate of -1 ºC minute-1, and then stored in liquid nitrogen. 
 
Stably transfected HEK293 cells from two flasks of confluent T-175 flasks 
were suspended in sterile freezing medium and 1 mL was added to each of 10 
vials and frozen as detailed above to form the Master Cell Bank.  Each vial 
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contained approximately 3 x 107 cells.  The contents of three confluent T-175 
flasks were suspended in freezing medium and 1 mL was added to each of 12 
vials to form the Working Cell Bank, with a cell count of approximately 4 x 107 
per vial. 
 
2.2.3 Recovery of cells from liquid nitrogen storage 
Cell culture medium was pre-warmed at 37 ºC.  One vial each of HEK293-
LHR-C and HEK293-LHR-D cells from the Working Cell Bank were taken from 
liquid nitrogen storage and immediately thawed at 37 ºC in a waterbath.  In a 
flow cabinet the thawed cells were transferred to 10 mL of warmed culture 
medium in a sterile 25 mL Universal container, mixed and centrifuged at 470 g 
for three minutes.  Supernatant was discarded and the cells were 
resuspended, in residual cell culture medium remaining in the tube, by 
agitation.  A 20 mL volume of warm culture medium containing G418 (200 µg 
mL-1) was added and the cell suspension transferred to a T-75 culture flask.  
Flasks were incubated in a 7% CO2 incubator at 37 ºC. 
 
2.2.4 Production of sr-LHR-C and sr-LHR-D in HEK293 cells 
Cloned cells were recovered from frozen storage as described in Method 
2.2.3 and were cultured in three different growing systems:  T-175 flasks, 
spinner flasks (Integra Biosciences) and CellMax™ Hollow Fiber Bioreactors 
(Spectrum Europe BV).  Supernatant was collected and stored frozen at -30 
ºC until sufficient volumes had been obtained for protein extraction (Methods 
2.2.5, 2.2.6 and 2.2.7).  
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2.2.5 Transfected HEK293 cell culture in T-175 flasks 
When cells in one T-75 flask were 70 to 80% confluent (approximately 6 x 107 
cells) they were expanded into three T-175 flasks (four different sized culture 
flasks are in Figure 2.1).  The cells were removed by trypsin treatment as 
described in Method 2.2.1.  The cells from the T-75 flask were transferred into 
three T-175 flasks (cell count approximately 2 x 107 per flask). Culture 
medium containing 10% FCS, 1% PS, 1% LG was added to 25 mL and G418 
antibiotic was added (final concentration 200 µg mL-1) and the flasks placed in 
a 7% CO2 incubator at 37 ºC. 
 
    
Figure 2.1 Four cell culture flasks of various sizes in a flow cabinet.  From left 
to right, T-225, T-175, T-75 and T-25 flasks containing cell culture 
supernatant. 
 
Flasks were checked regularly until cells were confluent, this was about 5 to 6 
days.  At this point supernatant was harvested, centrifuged to remove debris 
and stored frozen at -30 ºC.  The cells in the flasks were trypsin treated 
(Method 2.2.1) then cells were pooled from the three flasks and split between 
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five T-175 flasks (approximate cell count per flask 3 x 107).  Five flasks were 
maintained and supernatant was collected every 5 to 6 days when cells were 
confluent.  The cells were pooled, centrifuged and approximately 20% were 
used to reseed five flasks with the rest being discarded.  Harvested 
supernatant was collected and stored frozen at -30 ºC until sufficient volumes 
had been obtained for protein extraction.  Prior to extraction by using anti-
FLAG agarose affinity gel columns, supernatant of the same type i.e. 
containing sr-LHR-C or sr-LHR-D was pooled and filtered using a 0.22 µm 
vacuum filtration unit (Millipore) to remove any remaining cells and cell debris. 
 
2.2.6 Transfected HEK293 cell culture in spinner flasks 
The cells harvested from three confluent T-175 flasks were transferred to a 
Cellspin 250 spinner flask (approximately 2 x 107 cells) and the volume made 
up to 250 mL with culture medium containing 10% FCS, 1% PS, 1% LG and 
G418 (200 µg mL-1).  Two spinner flasks on a stirrer platform are shown in 
Figure 2.2. 
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Figure 2.2 Two spinner flasks shown on a stirrer platform.   (from 
www.bioresearchonline.com). 
 
The screw tops on the side ports were loosened slightly and the spinner flasks 
were incubated at 37 ºC on a Cellspin stirrer platform (stirring at 20 rpm) 
(Integra Biosciences) for approximately 14 days when the cell culture medium 
had just started to turn from red to yellow.  Then supernatant was harvested in 
a flow cabinet.  HEK293 cells were allowed to settle to the bottom of the flask.  
Supernatant was removed with a pipette and filtered through a 0.22 µm 
vacuum filtration unit (Millipore) to remove cells and cell debris.  The spinner 
flask was topped up with culture medium and antibiotic as before and returned 
to the incubator.  Harvested supernatant was frozen at -30 ºC until protein 
extraction could take place. 
 
2.2.7 Transfected HEK293 cell culture in Hollow Fiber Bioreactors 
Polysulphone cartridges (12 mL) with a 30 kDa molecular weight cut-off and a 
surface area of 1,700 cm2 were used in the CellMax™ Hollow Fiber Bioreactor 
system (Spectrum Europe).  Prior to use the bioreactor cartridge was flushed 
Redacted due to copyright
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through with culture medium containing 10% FCS, 1% PS, 1% LG and G418 
(200 µg mL-1) following the manufacturer’s instructions.  This priming 
operation was done on two successive days before cells were introduced to 
the system.  The confluent cells from five T-175 flasks (approximately 2 x 108 
cells) were washed, trypsin treated, neutralised and resuspended to 30 mL in 
cell culture medium containing 10% FCS, 1% PS, 1% LG and G418 (200 µg 
mL-1). The bioreactor was isolated by closing the inlet and outlet slide clamps 
and the cells were collected in a syringe and introduced into the isolated 
bioreactor via the left hand port on the cartridge (shown in Figure 2.3).  The 
cell suspension was flushed backwards and forwards three to four times 
through the extra capillary space to uniformly distribute the cells.  This was 
done by fixing an empty syringe to the outlet port and gently pushing the fluid 
between the inlet and outlet ports.  A fresh bottle of culture medium containing 
5% FCS, 1% PS, 1% LG and G418 (200 µg mL-1) was attached to the 
bioreactor. 
 
Figure 2.3 A CellMax bioreactor.  This is shown prior to being primed with cell 
culture medium.  Inlet and outlet ports of the cartridge are shown in blue (from 
www.fisher.co.uk). 
Redacted due to copyright
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Two bioreactors containing HEK293 cells transfected with LHR-C and LHR-D 
were set up and were connected to a CellMax(R) Pump System and placed at 
37 ºC in a 7% CO2 incubator (Figure 2.4 shows a bioreactor set up in a flow 
cabinet).  Supernatant (30 mL) was harvested at regular intervals according to 
the manufacturer’s instructions and stored frozen at -30 ºC.  Prior to protein 
extraction an ELISA was performed to determine the samples with the highest 
protein concentration (Method 2.3.1).  Selected supernatant samples of the 
same type i.e. containing sr-LHR-C or sr-LHR-D were pooled and filtered 
using a 0.22 µm vacuum filtration unit (Millipore) to remove cells and cell 
debris. 
 
   
Figure 2.4 A Bioreactor system.  This system has two cartridges (one on the 
other side, not seen) linked to cell culture medium.  Bioreactors and cell 
culture medium bottles are located on a platform with pump so that the 
medium is constantly pumped through the cartridge. NB the cartridge seen 
here is from NBS Biologicals.  These have now replaced the CellMax 
bioreactors which are no longer available. 
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2.3 Protein detection and purification techniques 
2.3.1 ELISA for sr-LHR-C and sr-LHR-D protein detection  
The wells of a high protein binding 96 well microtitre plate (Immulon 2HB, 
Thermo Scientific) were coated with 100 µL goat anti-mouse IgG (Fc specific) 
(Sigma) at a concentration of 1 µg mL-1 in carbonate coating buffer pH 9.6 
(0.015 M Na2CO3, 0.035 M NaHCO3).  After overnight incubation at 4 ºC the 
plate was washed once with PBS pH 7.2 containing 0.05% Tween® 20 
(PBST) (Sigma) by filling up the wells with PBST and then flicking it off into a 
sink.  The plate was then blocked with PBST containing 5% low fat milk 
powder (PBSTM), by adding 100 μL to each well, and incubated with shaking 
for one hour at 37 ºC.  The plate was washed once with PBST as before.  
Mouse monoclonal anti-CD35 (anti-CR1, clone E-11, Santa Cruz 
Biotechnology Inc) was added at a concentration of 10 µg mL-1, 100 μL per 
well and the plate was incubated with shaking for one hour at 37 ºC.  The 
plate was washed four times with PBST.  Culture samples were added (100 
μL) and the plate incubated with shaking for one hour at 37 ºC.  The plate was 
washed four times in PBST and then 100 μL of rabbit anti-Flag antibody 
(Sigma) was added to each well at a concentration of 1 µg mL-1 in PBSTM 
and the plate incubated with shaking for one hour at 37 ºC.  After being 
washed four times in PBST, horse radish peroxidase goat horseradish 
peroxidase (HRP)-conjugated anti-rabbit immunoglobulin (Dako) was added 
at a concentration of 1 µg mL-1 and the plate incubated with shaking at 37 ºC 
for one hour.  After four washes in PBST, 100 μL of developer was added to 
each well (0.1% O-phenylenediamine dihydrochloride (OPD) in pH 5.0 citrate 
buffer (0.024 M citric acid, 0.051 M Na2HPO4) with 0.015% hydrogen peroxide 
added just before use.  Reactions were stopped by adding 100 μL 1 M HCl 
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when colour in the wells had developed sufficiently (10 to 15 minutes).  The 
absorbance of each well at 492 nm was measured using a microplate 
photometer (Multiskan EX, Thermo Scientific).  Standards were prepared by 
diluting purified sr-LHR-C and sr-LHR-D in culture medium containing 10% 
FCS, 1% PS and 1% LG. 
 
2.3.2 Immunopurification of sr-3X-FLAG fusion proteins using anti-
FLAG agarose affinity gel column 
 
The column was prepared by adding 1 mL anti-FLAG M2 agarose affinity gel 
(Sigma) to a glass column (length 100 mm, internal diameter 10 mm) 
(Amersham Biosciences).  It was washed with a minimum of 25 column 
volumes of Tris-buffered saline (TBS) wash buffer (0.5 M Tris pH 7.4, 1.5 M 
NaCl).  Any residual, unbound antibody was removed from the column by 
washing with five column volumes of 0.1 M glycine HCl at pH 3.5 and then 
washed with at least 10 column volumes of TBS.  Pooled, filtered culture 
supernatant was added to the column coupled to a peristaltic pump using a 
flow rate of 1 mL minute-1.  Flow through from this stage, containing unbound 
material, was retained for further purification.  The column was washed with at 
least 10 column volumes TBS.  
 
2.3.2.1 Acid elution 
3xFLAG fusion protein was eluted under acid conditions using 0.1 M glycine-
HCl at pH 3.5, followed by one column volume of TBS to wash through the 
acid, under gravity flow.  The eluate was neutralised by addition of 200 µL Tris 
buffer (0.5 M, pH 7.4).  The column was neutralised with 25 column volumes 
of TBS. 
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2.3.2.2 3xFLAG elution 
Competitive elution was performed using five column volumes of 3xFLAG 
peptide (Sigma-Aldrich) at 100 µg mL-1 in TBS.  After application of the 
3xFLAG peptide, the gel was washed through with 1 mL TBS.  After the 
peptide elution step the gel was washed with 25 mL TBS and then flushed 
through with 10 mL glycine-HCl pH 3.5 to remove all traces of peptide and 
regenerate the column.  This was followed by washing the column with 25 mL 
TBS. 
 
Use of TBS for immunopurification was recommended by the manufacturer 
(Sigma-Aldrich, 2010).  After elution from the affinity column the TBS buffer 
was exchanged with PBS.  This was because all serological techniques are 
performed in PBS rather than TBS.  Buffer exchange was achieved by 
washing the eluates from both elution methods three times in PBS in a 30,000 
kDa molecular weight cut off (MWCO) Vivaspin ultracentrifugation unit 
(Sartorius).  The Vivaspin tubes were centrifuged at 4000 g for 25 minutes 
each time and concentrated to a minimum volume in PBS.    
 
2.3.3 Bicinchoninic acid protein assay 
The protein content of the eluate from the affinity column was determined by 
QuantiPro bicinchoninic acid (BCA) assay (Sigma) following the 
manufacturer’s instructions and was then stored frozen at -30 ºC.  This assay 
is similar to the Lowry procedure, where formation of a Cu2+ protein complex 
under alkaline conditions is followed by reduction of Cu2+ to Cu1+.  The 
amount of reduction is proportional to the amount of protein present.  BCA 
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forms a purple complex with Cu1+ in alkaline conditions so the amount of 
purple colour produced can be measured on a spectrophotometer at 562 nm 
and by comparison with a known standard the amount of protein present can 
be calculated (Noble et al., 2007).  
 
2.3.4 SDS-PAGE analysis of sr-proteins 
Proteins were assessed using SDS-PAGE.  The gels were either stained for 
total protein or western blot was performed.  Commercial Mini-PROTEAN 
precast gradient gels (BIO-RAD) were used.  Samples for analysis were 
prepared by mixing sample (2 μg) with sample buffer (5% SDS, 5 mM EDTA, 
20 mM Tris pH 8.0, 10% glycerol with 6% mercaptoethanol added just prior to 
use) and water to a volume of 18 L and then heated at 100 ºC for 2 minutes. 
  
Gels were mounted in the Mini-PROTEAN Tetra Cell (BIO-RAD) and running 
buffer was added to the inner and outer chambers.  Samples and a protein 
standard, ProSeive® (Invitrogen) were loaded into the wells.  The gel was run 
at 100 V until the tracking dye in the sample buffer had reached the bottom of 
the gel (approximately one hour).   
 
2.3.5 Semi-dry electro blotting (western blotting) from SDS-PAGE gels 
Sr-protein samples run on SDS-PAGE gels were transferred onto 0.2 µM 
polyvinylidene difluoride (PVDF) membrane, using the Trans-Blot™ Turbo™ 
Mini PVDF Transfer System (BIO-RAD) and Trans-Blot™ Turbo™ Transfer 
Packs (BIO-RAD).  For each blot one PVDF membrane was soaked in 100% 
methanol until transparent (2-3 minutes) and was then transferred to transfer 
buffer solution (200 mL 5x concentrate transfer buffer (BIO-RAD) added to 
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600 mL H2O and 200 mL ethanol).  Two stacks of four pieces of filter paper 
were soaked in transfer buffer for 3-4 minutes until wet.  One stack of filter 
paper was placed on the anode side of the semi-dry apparatus and PVDF 
membrane was placed on top.  The SDS-PAGE gel (see Method 2.3.4) was 
placed on top of the membrane and the second filter paper stack placed on 
top, any bubbles were rolled out at this point and then the cathode assembly 
was placed onto the transfer pack and placed into the Transfer System. 
 
2.3.6 Development of western blots 
After removing from the transfer system, the PVDF membrane was blocked 
using PBSTM (PBS containing 0.2% Tween20 and 5% milk powder) for 30 
minutes at RT or at 4 ºC overnight.  It was then rinsed in PBST (containing 
0.2% Tween20) and HRP-conjugated antibody was added.  In this study HRP-
conjugated anti-mouse IgG (Dako), HRP-conjugated anti-bovine serum 
albumin (BSA) (Immune Systems Ltd) and anti-Flag-M2-peroxidase (HRP) 
(Sigma-Aldrich) were used at a concentration of 1 μg mL-1 in PBSTM.  The 
membrane was incubated at RT with mixing on an automated rocker for one 
hour (Gyro-Rocker STR9, Bibby Stuart).  The membrane was placed in PBST 
to wash for 10 minutes at RT.  The wash stage was repeated twice more 
before the membrane was put into developing reagent (300 μg mL-1 3, 3’-
diaminobenzidine (DAB, Sigma), 0.03% H2O2 (Sigma, 1 in 1000 dilution of 
30% stock, added just before use).  When brown bands had developed in the 
marker positive control sample (up to 15 minutes) the PVDF membrane was 
washed in water to stop the reaction and dried on tissues.  Anti-CD35 clones 
E-11 and J3D3 (Santa Cruz Biotechnology Inc.) were also used in a two stage 
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process.  First anti-CD35 was added as a primary antibody in the process 
above at a concentration of 1 μg mL-1 in PBSTM.  After the incubation and 
washing stages as described, HRP-conjugated anti-mouse was added as a 
secondary antibody (1 μg mL-1 in PBSTM) and the incubation and washing 
stages repeated before addition of the DAB developing reagent. 
 
2.3.7 Protein staining of SDS-PAGE gels and western blots 
SDS-PAGE gels were washed in deionised water three times and then 
immersed in SimplyBlue™ SafeStain (Invitrogen) for one hour at room 
temperature.  They were then washed a further three times in deionised water 
and examined for protein bands.  Blotted PVDF membranes were washed in 
water and then immersed in G-250 membrane stain (3 g Coomassie brilliant 
blue G-250 (Molekula) dissolved in 450 mL ethanol, 100 mL acetic acid added 
and made to 1 L with water) for 3 to 4 minutes and washed in water and then 
ethanol.  
 
2.3.8 Mass spectrometry analysis of sr-proteins 
Stained samples from SDS-PAGE gels were cut out with a scalpel and placed 
in Eppendorf tubes and sent to Dr K Heesom at Bristol University for Matrix-
Assisted Laser Desorption / Ionization – Time of Flight (MALDI-TOF) 
assessment.  This method uses a soft ionisation technique which is useful for 
the analysis of proteins as they tend to be fragile and fragment easily.  The 
samples submitted in-gel were subjected to tryptic digestion and the resulting 
peptides analysed by MALDI-TOF to generate a peptide mass fingerprint and 
peptide sequence information.  These were searched against the SwissProt 
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human databases to identify the protein present (personal communication 
from Dr K Heesom). 
 
2.4 Patient testing 
2.4.1 Clinical material  
Plasma samples were provided by several RCI reference laboratories and 
RCR/IBGRL laboratory.  These samples had been referred to these 
laboratories from hospital transfusion laboratories for further testing and in 
some cases for provision of compatible blood.  All of the plasma samples had 
either been confirmed as containing KN related antibodies or they had reacted 
in such a way during investigation that laboratories suspected they might 
contain KN related antibodies.  The samples were stored frozen at -30 ºC.  
Each sample had been labelled with the NHSBT sample number and sample 
date. These identifiers were then used to collect details, from the NHSBT 
diagnostic laboratory computer system, of the antibody specificities where 
known. 
 
2.4.2 Ethical considerations 
Ethical approval was not applied for under advice from NHSBT National 
Research and Development Manager as the testing performed was a 
continuation of the clinical investigation of these samples.  Consent is implicit 
when samples are initially referred from hospital laboratories to NHSBT for 
testing.  Plasma samples are not regulated by the Human Tissue Act, 2004, 
as they do not contain human cells (Royal College of Pathologists, 2009). 
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Investigation of one sample during this study did lead to a changed diagnosis 
of antibody specificity.  However, the patient did not need blood transfusion 
and a modified report was written after the sample had been referred to 
IBGRL for further testing.  Samples may be referred to IBGRL if an RCI 
laboratory cannot identify antibody specificity and in these cases reports may 
need to be updated if the IBGRL findings are different to RCI initial findings. 
 
2.4.3 Antigenicity ELISA 
Sr-LHR-C and sr-LHR-D were diluted in carbonate coating buffer pH 9.6 (see 
Method 2.3.1 for ELISA buffer compositions; sr-protein concentration 10 μg 
mL-1) and 100 μL was added to the wells of a Maxisorp 96 well plate (Nunc).  
The plate was incubated for one hour at 37 ºC with shaking and then washed 
four times with PBST.  The plate was blocked by addition of 100 μL PBSTM 
per well and incubation at 37 ºC with shaking for 30 minutes.  After washing 
the plate four times with PBST, 100 μL per well of human patient plasma, 
diluted 1 in 5 in PBSTM was added.  The plate was incubated for one hour at 
37 ºC with shaking, followed by four washes in PBST and then 100 μL of 
HRP-anti-human IgG (stock concentration 5.5 mg mL-1, Sigma-Aldrich) diluted 
1/1000 in PBSTM was added to each well.  The plate was again incubated for 
one hour at 37 ºC with shaking.  The plate was washed four times in PBST 
and 100 μL OPD developer (1 μg µL-1) was added to each well.  The plate 
was incubated at RT for 5 to 15 minutes until yellow colour had developed.  
Reactions were stopped by adding 1M HCl and the plate absorbances read at 
492 nm.  A positive result was indicated by a ratio of greater than 2:1 of mean 
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test absorbance value to negative control absorbance.  This would indicate 
the presence of a KN related antibody. 
 
2.4.4 Monoclonal antibody-specific immobilization of erythrocyte 
antigens assay (MAIEA) 
 
This test as described by Petty et al. in 1997 was used by IBGRL staff to 
determine anti-KN specificity of patient samples used in this study.  The 
principles of the method are described in the Introduction, section 1.4. 
 
2.5 Patient testing using serological techniques 
2.5.1 Red cell reagents in CellStab 
In this study red cell reagents provided by NHSBT Reagents, Liverpool were 
used.  These are manufactured in accordance with guidelines published by 
the UK Blood Transfusion Services (National Blood Service, 2013).  An 
identification (ID) panel and 3 Cell Screening set, both in the diluent CellStab 
(glycine buffered saline containing sugars, trimethroprim and sulfanethaxazol 
as preservatives supplied by BIO-RAD), were used.  Both panels are made 
from donated red cells and are provided as 0.8% cell suspensions in CellStab 
(0.8% refers to the volume of packed red cells in relation to the diluent).  Both 
panels have an expiry date of three weeks from manufacture which is stated 
on the forms that accompany them when they are issued from Reagents.  
They must not be used beyond the expiry date.  The ID panel consists of 10 
cell samples that between them cover all the clinically significant antigens with 
homozygous and heterozygous expression.  The clinically significant antigens 
are defined as the Rh antigens D, C, E, c, e and Fya, Fyb, Jk
a
, Jk
b, S, s, M, Kpa 
and Cw.  In addition cell samples 1-2 must cover K+, k+, Fya, Fyb, Jka, Jkb, S 
 61  
and s.  Also included on the panel are Lua+, Kpa+, MM and NN cells.  Ideally, 
if available then k- and / or Lea-b- cells should be included.  The 3 Cell 
Screening set consists of O R1wR1, O R2R2 and Orr cells that cover the Rh 
antigens D, C, E, c and Cw in both homozygous and heterozygous form.  The 
set must also have homozygous expression of Fya, Fyb, Jk
a
, Jk
b, S and s.  
Between the cells the following antigens must be expressed: Cw, M, N, P1, K, 
k, Kpa, Lea and Leb. 
 
2.5.2 Column indirect antiglobulin test  
An appropriate number of IAT cards (BIO-VUE) were selected and 50 µL 
0.8% cell suspension of reagent cells in cellstab (BIO-VUE) was pipetted into 
the top of each required column.  After addition of 25 µL plasma to each 
column the cards were incubated for 15 minutes at 37 ºC.  The cards were 
then centrifuged in a BIO-VUE gelcard centrifuge with preset parameters.  
Cards were read by eye and results graded (Figure 2.5). 
 
 
 
 
 
Figure 2.5 Grading of reactions on a gel IAT card.  0 = negative, where 
unagglutinated cells have passed through the column.  Positive reactions are 
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graded 1 to 5 in order of increasing strength of reaction and hence size of 
agglutinates that either all remain on top of the gel when too large to pass 
through (grade 5) or are dispersed through the gel to varying degrees, grade 4 
to grade 1.  (Adapted from NHSBT, RCI, INF335 Grading of reactions). 
 
2.5.3 Inhibition of KN antibodies 
A serological inhibition technique was developed using the column indirect 
antiglobulin test (CAT) described in Method 2.5.2.  Prior to performing the 
CAT test, 1 in 20 dilutions of approximately 1 mg mL-1 sr-LHR-C, sr-LHR-D, a 
1 in 10 dilution of a 1:1 mixture of sr-LHR-C and sr-LHR-D (KN inhibition 
reagent (KNIR)) or PBS were prepared with patient or donor plasma and 
incubated for 30 minutes at RT.  The CAT test was then performed using 50 
µL 0.8% reagent red cells and 25 µL of treated patient plasma as described 
above.  After incubation and centrifugation as described in Method 2.5.2, the 
reactions were read by eye and graded as described in Figure 2.5. 
 
2.6 Statistical methods used in this study 
Two statistical tests were used in this study.  These were the one-way 
Analysis of Variance (ANOVA) and Student’s t-tests (Kirkman, 1996 and 
Ashcroft and Pereira, 2003).  ANOVA was used to compare the yield of 
protein from three different culture methods in Protein Production section 
3.3.3.  Student’s t-test was used to compare the yield of protein using two 
different elution techniques in Protein Purification section 4.3.1.  These 
parametric statistical tests were chosen with the assumption that a normal 
distribution of results would be expected from the culture techniques used and 
from the two elution techniques. 
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3.0 SR-LHR-C AND SR-LHR-D PROTEIN PRODUCTION IN HEK293 
CELLS 
3.1 Introduction 
The aim of this part of the study was to produce sufficient protein to develop a 
reagent for use in NHSBT laboratories.  The first objective to achieve this aim 
was to transfect HEK293 cells to produce sr-LHR-C and sr-LHR-D protein.  If 
these proteins were produced then a further objective would be to clone the 
transfected cells to select those producing the most protein so that frozen cell 
banks could be set up for future use.  In addition comparison of different 
culture systems for growing the HEK293 cells,  would allow selection of the 
best system for protein production in terms of ease of use, cost and yield of 
protein, which would be important factors for future reagent production.   
 
The HEK293 cell line is derived from human embryonic kidney cells.  It is one 
of the most widely used cell lines for research purposes as, unlike bacterial or 
yeast expression systems, it can express human proteins with complex post-
translational modifications.  The cells are also easy to grow, are highly 
transfectable and can secrete proteins into the cell culture medium, which can 
then be collected and purified to isolate the required protein (Burnouf, 2011).   
 
Cloned, stably transfected HEK293 cells expressing 3xFLAG tagged sr-LHR-
C or sr-LHR-D proteins were produced by drug selection using G418.  Those 
cells that had taken up the expression vector had G418 resistance conferred 
by the aminoglycoside phosphotransferase II gene in the expression vector.    
Stably transfected cells were then subjected to a cloning process (Materials 
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and Methods section 2.2.1) where the colonies producing the highest amount 
of sr protein were selected using an ELISA technique (Materials and Methods 
section 2.3.1). 
 
Although HEK293 is an adherent fibroblast cell line, the cells can be grown in 
suspension in cell culture medium (Chapple et al., 2006).  In this study the 
cloned cells were grown in spinner flasks, T-175 disposable flasks, and in a 
commercial system CellMax® Duo Hollow Fiber Cell Culture System 
(Spectrum Labs).  In T-175 flasks, cells can adhere to the bottom of the flasks 
whilst in spinner flasks the cells are suspended in the cell culture medium and 
continuously agitated.  In the CellMax® system, hollow fibres provide a large 
surface area on which the cells can grow.  The cell culture supernatant was 
collected at various intervals, pooled and purified on affinity gel columns.  The 
yield of protein, ease of use and cost of production were assessed for each 
culture system.  The purified protein was assessed for antigen activity, 
mobility on SDS-PAGE and submitted for MALDI-TOF analysis (described in 
Materials and Methods section 2.3.8). 
 
3.2 Materials and Methods 
3.2.1 Primer design 
Plasmid DNA, p3xFLAG-LHR-C and p3xFLAG-LHR-D, was sequenced to 
ensure that cDNA encoding LHR-C or LHR-D had been correctly inserted.  
The method and primers used are described in Materials and Methods section 
2.1.4.  A new primer was designed to sequence LHR-D around the SNP 
encoding the Kna / Knb polymorphism as when sequenced with the original 
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primers (C-CMV-24, N-CMV-30 and CR1-F3) this region was missed (Figure 
3.1).  The LHR regions are highly homologous so the potential primer was 
checked for matching sequences using LALIGN (part of the FASTA package 
of sequence analysis program, European Bioinformatics Institute) and 
EMBOSS Water (European Bioinformatics Institute).  Using both packages no 
other matching sequences were found in LHR-D. 
 
4201 CGTGCTGGTC ACTGTAAAAC CCCAGAGCAG TTTCCATTTG CCAGTCCTAC GATCCCAATT 
4261 AATGACTTTG AGTTTCCAGT CGGGACATCT TTGAATTATG AATGCCGTCC TGGGTATTTT 
4321 GGGAAAATGT TCTCTATCTC CTGCCTAGAA AACTTGGTCT GGTCAAGTGT TGAAGACAAC 
4381 TGTAGACGAA AATCATGTGG ACCTCCACCA GAACCCTTCA ATGGAATGGT GCATATAAAC 
4441 ACAGATACAC AGTTTGGATC AACAGTTAAT TATTCTTGTA ATGAAGGGTT TCGACTCATT 
4501 GGTTCCCCAT CTACTACTTG TCTCGTCTCA GGCAATAATG TCACATGGGA TAAGAAGGCA 
4561 CCTATTTGTG AGATCATATC TTGTGAGCCA CCTCCAACCA TATCCAATGG AGACTTCTAC 
4621 AGCAACAATA GAACATCTTT TCACAATGGA ACGGTGGTAA CTTACCAGTG CCACACTGGA 
4681 CCAGATGGAG AACAGCTGTT TGAGCTTGTG GGAGAACGGT CAATATATTG CACCAGCAAA 
4741 GATGATCAAG TTGGTGTTTG GAGCAGCCCT CCCCCTCGGT GTATTTCTAC TAATAAATGC 
4801 ACAGCTCCAG AAGTTGAAAA TGCAATTAGA GTACCAGGAA ACAGGAGTTT CTTTTCCCTC 
4861 ACTGAGATCA TCAGATTTAG GGGTTTGTCA ATGTCAGCCC TGGTAGGGTC CCACACTGTG 
 
Figure 3.1 The primer designed to detect the Kna/Knb SNP.  Part of the 
nucleotide sequence for LHR-D is shown (taken from CR1 reference 
sequence, GenBank accession number: Y00816).  Kna / Knb SNP at position 
4708 (shown in blue) matches reference sequence, G at 4708 for Kna.  The 
new primer is shown in red 4495 to 4511. 
 
3.2.2 Development of an ELISA for detection of sr-3xFLAG tagged sr-
LHR-C and sr-LHR-D protein 
 
N.B. All volumes stated in these methods are per well. 
3.2.2.1 ELISA development method one 
A high protein binding 96 well microtitre plate (NUNC Maxisorp, Sigma-
Aldrich) was coated with 100 µL mouse monoclonal anti-CD35 (E-11; Santa 
Cruz Biotechnology Inc, Dallas, Texas) at a concentration of 20 µg mL-1 in 
carbonate coating buffer pH 9.6 (0.015 M Na2CO3, 0.035 M NaHCO3) and 
then incubated with shaking for one hour at 37 ºC.  Wells were washed four 
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times with PBS pH 7.2 containing 0.05% Tween® 20 (PBST; Sigma-Aldrich).  
Either 100 μL purified srLHR-D or sr-LHR-C or cell culture supernatants were 
added, prior to incubation with shaking for one hour at 37 ºC followed by again 
washing four times with PBST.  Goat HRP-conjugated anti-FLAG M2 antibody 
(Sigma) was added, at a concentration of 1 μg mL-1 in PBSTM (PBST 
containing 5% low fat milk powder) and the plate incubated with shaking for 
one hour at 37 ºC.  After being washed four times in PBST, plates were 
developed with 100 µL 0.1% OPD in pH 5.0 citrate buffer (0.024  M citric acid, 
0.051 M Na2HPO4) with hydrogen peroxide at a final concentration of 0.015% 
added just before use.  Reactions were stopped by adding 100 µL 1 M HCl 
when colour in the wells had developed sufficiently (15 minutes).  The 
absorbance of each well at 492 nm was measured using a microplate 
photometer (Multiskan EX, Thermo Scientific).  The basic principle of the 
ELISA method is shown in Figure 3.2.  
 
    
Figure 3.2 ELISA development method one.  Coloured antibodies 
denoted Y: blue is mouse monoclonal anti-CD35, green is goat HRP-
conjugated anti-FLAG.  
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3.2.2.2 ELISA development method two 
This was the same as method one except after addition of the sr-FLAG 
tagged protein and four washes in PBST, 100μL rabbit anti-FLAG (Sigma-
Aldrich) at a concentration of 1 μg mL-1 diluted in PBSTM was added.  The 
plate was incubated for one hour at 37 ºC with shaking, washed four times in 
PBST and then 100 μL goat HRP-conjugated anti-rabbit immunoglobulin at a 
concentration of 1 µg mL-1 in PBSTM was added.  After incubation with 
shaking at 37 ºC for one hour, the plate was washed four times in PBST, OPD 
developer was added and the plate read in the same way as method one 
(Figure 3.3). 
 
    
Figure 3.3 ELISA development method two.  Coloured antibodies denoted Y: 
Blue is anti-CD35, green is rabbit anti-FLAG, orange is goat HRP-conjugated 
anti-rabbit Ig.  
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3.2.2.3 ELISA development method three 
High protein binding microtitre plates (Immulon™ 2HB) were first sensitised 
with 100 μL goat anti-mouse IgG (Sigma-Aldrich) at a concentration of 1 μg 
mL-1 in pH 9.6 carbonate coating buffer.  Plates were left at 4 ºC prior to use 
(minimum 12 hours), before washing once in PBST followed by incubation 
with 100 μL PBSTM for one hour at 37 ºC with shaking.  The plates were then 
washed once in PBST and anti-CD35 added.  Then method two was followed 
(Figure 3.4). 
  
    
Figure 3.4 ELISA development method three.  Coloured antibodies denoted Y: 
grey is goat anti-mouse IgG, blue is mouse monoclonal anti-CD35, green is 
rabbit anti-FLAG, orange is goat HRP-conjugated anti-rabbit Ig.  
 
Method three was also used with anti-CD35 (clone J3D3; Santa Cruz 
Biotechnology Inc, Dallas Texas) an alternative mouse monoclonal antibody 
raised against full length native CD35 of human origin. 
HRP 
1. Sensitise plate 
with anti-IgG 
 
 
 
2. Add anti-CD35 
 
 
3. Add FLAG 
tagged protein 
 
 
 
4. Add rabbit anti-
FLAG 
 
 
5. Add anti-rabbit 
HRP-conjugated 
antibody 
 69  
3.2.3 Comparison of different cell culture methods 
HEK293 cells stably transfected with 3xFLAG -LHR-C were grown in three cell 
culture systems.  The intention was to grow them in all systems for the same 
amount of time.  Five T-175 flasks were seeded with stably transfected 
HEK293 cells and cultured over a period of 35 days.  Supernatant was 
harvested when the cells were approximately 80% confluent (between 5 to 7 
days) and then flasks were reseeded (Materials and Methods section 2.2.5).  
Harvested supernatant was stored frozen at -30 ºC.  Prior to purification the 
supernatant was thawed and 0.2 μm filtered.  A total of 650 mL supernatant 
was collected and pooled.  
   
A spinner flask containing HEK293 cells stably transfected with 3xFLAG-LHR-
C was cultured over a period of 34 days (following the method described in 
Materials and Methods section 2.2.6).  Cell culture supernatant was harvested 
at approximately 11 day intervals and 0.2 μm filtered.  The flask was topped 
up with fresh culture medium after each harvest.  A total of 800 mL cell culture 
supernatant was collected and stored frozen at -30 ºC.  Prior to purification 
the supernatants were thawed and pooled.   
 
The CellMax® system once primed with stably transfected HEK293 cells was 
cultured for 29 days (Materials and Methods section 2.2.7) and then had to be 
stopped due to a fungal infection in the system, probably due to a loose tube 
connection.  Whilst it was in operation, cell culture supernatant was harvested 
twice weekly and stored frozen at -30 ºC.  It was thawed, 0.2 μm filtered and 
pooled prior to use, giving a total volume of 720 mL.  Three 100 mL aliquots of 
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pooled cell culture supernatant from each of the systems were purified on 1 
mL anti-FLAG affinity gel columns, at a flow rate of 1 mL per minute, and 
eluted with 3xFLAG peptide (Materials and Methods section 2.3.2).  The yield 
of protein (µg) produced from each culture system was calculated by BCA 
protein assay (Materials and Methods section 2.3.3).  The approximate 
molecular weight (Mr) of the purified protein was assessed by SDS-PAGE 
(Materials and Methods section 2.3.4) followed by western blotting onto PVDF 
membranes (Materials and Methods section 2.3.5).  The membranes were 
Coomassie blue protein stained (Materials and Methods section 2.3.7) or 
immunoblotted with anti-FLAG M2-Peroxidase or anti-CD35 clones E-11 and 
J3D3 (Materials and Methods 2.3.6).  Protein purity was assessed by 
immunoblotting with anti-mouse-HRP and anti-BSA-HRP (Materials and 
Methods section 2.3.6).  For all the blots described, 2 μg of purified protein 
was used.  Protein antigenicity i.e. whether it expressed functional KN 
antigens was measured by its ability to inhibit anti-KN antibodies using the 
CAT inhibition test (described in Materials and Methods section 2.5.3).    
  
3.3 Results 
3.3.1 Sequencing of p3xFLAG-LHR-C and p3xFLAG-LHR-D plasmid 
DNA used to transfect HEK293 cells 
 
Sequencing results for both p3xFLAG-LHR-C and p3xFLAG-LHR-D were as 
expected and matched the CR1 reference sequence (GenBank accession 
number Y00816).  The nucleotides giving rise to KN antigens were as 
expected as shown in Table 3.1 below. 
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Table 3.1  The KN antigens in the CR1 reference sequence 
Position Nucleotide  KN antigen 
4708 G Kna (KN1) 
4795 A McCa (KN3) 
4828 A Sla (KN4) 
4223 C Yka (KN5) 
4870 A KCAM (KN9) 
 
Nucleotides giving rise to KN antigens in the CR1 reference sequence 
GenBank accession number Y00816, are shown. 
 
A primer was designed to sequence p3xFLAG-LHR-D around the Kna / Knb 
polymorphism.  The Kna SNP that was detected by the newly designed primer 
is shown in the sequence fragment for p3xFLAG-LHR-D illustrated in Figure 
3.5.  G is seen at position 4708 which codes for the Kna antigen (the full 
sequence analysis is included in Appendix 1). 
 
 
    
Figure 3.5 Sequence fragment showing the Kna/Knb SNP.  This sequence 
fragment for p3xFLAG-LHR-D shows G at position 4708 coding for the Kna 
antigen (chromatogram and sequence analysed using SeqScape software). 
 
G   A  G  C  T  T G  T   G  G  G   A  G  A 
4708 
↓ 
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3.3.2 ELISA for detection of 3xFLAG tagged sr-LHR-C and sr-LHR-D 
protein 
 
The three ELISA methods described were compared for sensitivity so that 
protein production by transfected HEK293 cells could be measured during 
cloning to ensure that the highest protein producing clones were selected.  No 
reactions were obtained with sr-LHR-C by either method one or two.  
Monoclonal anti-CD35 E-11 was used in both methods as this was reported to 
react with both sr-LHR-C and sr-LHR-D (Nickells et al., 1998).  Using method 
three, reactions were obtained with both sr-LHR-C and sr-LHR-D protein.  
Although the reactions with sr-LHR-C were not as strong as for sr-LHR-D they 
were still strong enough to be able to distinguish the highest sr-LHR-C 
secreting clones during the cloning process.  This ELISA method was used 
during the cloning process to test cell culture supernatants.   During the 
cloning process typical OD 492 values for sr-LHR-C were around 0.2 and for 
sr-LHR-D 0.5 with a background of 0.05.  These values were sufficiently 
different from the background to be distinguishable. 
 
Purified protein was used to establish standard curves so that the initial 
concentration of protein in the cell culture supernatants could be calculated.  
Some success was achieved with sr-LHR-D.  Figure 3.6 shows a curve for sr-
LHR-D based on duplicate samples, diluted from 0 to 600 ng mL-1 sr-LHR-D.  
However, the linear part of the curve was within a very narrow range.  One sr-
LHR-D cell culture supernatant tested on this plate, in duplicate, had a mean 
OD 492 reading of 0.381 which, from the graph gives a value of approximately 
80 ng mL-1.  This supernatant had a volume of 100 mL so therefore appeared 
to contain 8 μg protein.  After purification the protein yield was estimated by 
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BCA assay as 42 μg which is much higher than expected.  It was found with 
several cell culture supernatants that this ELISA method was not quantitative.  
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Figure 3.6 Standard curve for sr-LHR-D tested by ELISA method three (n=3).  
Error bars represent standard deviations calculated from the the data.   
 
After the cloning had been performed another monoclonal anti-CD35, clone 
J3D3, was obtained.  This was reported to react with LHR-C but not LHR-D 
(Nickells et al., 1998).  A comparison of the two monoclonal anti-CD35 
reagents and reactions with sr-LHR-C proteins was performed by ELISA 
(Figure 3.7). Although slightly stronger reactions were obtained using anti-
CD35 antibody J3D3 the OD 492 readings were still very low.   
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Figure 3.7 Standard curves for sr-LHR-C.  Two clones of anti-CD35, E-11 and 
J3D3 were tested against sr-LHR-C flag tagged protein by ELISA method 3 
(n=3).  Error bars represent standard deviations calculated from the the data.   
 
Western blotting with both anti-CD35 reagents gave very weak reactions with 
purified sr-LHR-C protein.  The same amount of purified sr-LHR-D was also 
used (i.e. 2 µg) and much stronger reactions were obtained with both anti-
CD35 reagents (Figure 3.8).  It appeared that anti-CD35 clone J3D3 had 
reacted with sr-LHR-D.  This is contrary to the report by Nickells et al., (1998) 
which stated that anti-CD35 clone J3D3 did not react with LHR-D.  However, 
when compared to reactions with anti-CD35 E-11, no band can be seen at 
approximately 65-80 kDa which is probable sr-LHR-D.  Bands were seen with 
both anti-CD35 reagents on the sr-LHR-D samples at approximately 20-25 
kDa and 50 kDa.  It was thought that these could be due to mouse 
immunoglobulins in the eluate reacting with HRP-conjugated anti-mouse 
secondary antibody used to detect the mouse derived anti-CD35 reagents.  
The mouse immunoglobulins could be anti-FLAG M2 antibodies eluted from 
the affinity gel column during the purification process.  During the purification 
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process using an affinity gel column, the sr-LHR-D had been eluted by acid 
whereas the sr-LHR-C had been eluted with 3XFLAG peptide.  A difference 
was seen in that mouse IgG appeared to be only in samples eluted with acid.  
This was investigated further (section 3.3.3) and also in the Protein 
Purification Results section 4.3.1. 
  
 
 
 
  
 
 
 
 
 
 
Figure 3.8 Western blots probed with two different clones of anti-CD35. 
Proteins were immunostained with a) anti-CD35 clone J3D3 and b) anti-CD35 
clone E-11. Purified sr-LHR-C protein from supernatants harvested from: 
spinner flasks (SF) are in lanes 2 and 7; flasks (F) in lanes 3 and 8 and 
CellMax® (CM) in lanes 4 and 9.  A purified pooled sr-LHR-D sample was also 
tested for comparison (LHR-D) (lanes 5 and 10).  M= molecular marker in 
lanes 1 and 6. 
M      SF     F       CM    LHR-D   M     SF       F        CM   LHR-D 
1        2       3         4         5         6       7        8          9      10 
a)  Anti-CD35 J3D3                                   b) Anti-CD35 E-11 
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3.3.3 Comparison of different culture methods 
Figure 3.9 shows the sr-LHR-C protein yield from cell culture supernatant 
grown in spinner flasks, T-175 flasks and in the CellMax® system.  A 1 mL 
affinity gel column was used for each method to purify three 100 mL aliquots 
of pooled material from each culture system.  It was recognised that the 
number of uses of the gel may possibly affect yield but the same regime was 
used for all three systems so that the gels were used a total of 3 times for 
each system and the mean protein yield (μg) was calculated. 
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Figure 3.9 The yield of protein from three different culture methods.  The 
protein yield obtained from culture supernatants grown in spinner flasks, T-
175 flasks and the CellMax system, after purification by affinity gel 
chromatography, is compared. Error bars represent standard deviations 
calculated from the data (n=3). 
      
Mean protein yield appeared to decrease from spinner flasks (308 µg) to T-
175 flasks (230 µg) to CellMax® (156 µg).  An ANOVA statistical test was 
performed on the data (Kirkman, 1996) assuming the null hypothesis that 
there was no difference in protein yields between the culture methods used.  
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Based on between samples variance (dfB) of 2, within samples variance (dfw) 
of 6, confidence interval of 0.05, the probability of this result, assuming the 
null hypothesis, was 0.304.  This is less than the critical value of 5.14 (from 
tables in Ashcroft and Pereira, 2003), so the null hypothesis cannot be 
rejected i.e. there is no statistical significance between yields for the three 
techniques used. 
 
Protein staining and an immunoblot with HRP-conjugated anti-FLAG are 
shown in Figure 3.10. The protein detected had an approximate Mr of 65-80 
kDa which is larger than the estimated Mr of approximately 50 kDa for LHR-C 
based on amino acid sequence but not accounting for glycosylation. 
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Figure 3.10 Protein stain and western blot for sr-LHR-C purified from supernatants 
from different culture methods.  a) Protein stained western blot and b) immunoblot 
using HRP-conjugated anti-FLAG.  Three samples from each culture system were 
run in sequential order of number of times the affinity gel had been used for 
purification.  On both blots: lanes 1, 5 and 8 are samples from spinner flasks; lanes 2, 
6 and 9 are samples from T-175 flasks and lanes 3, 7 and 10 are samples from the 
CellMax system.  A marker was run in lane 4.  . 
 
The nine purified samples were tested by SDS-PAGE and the gels were 
western blotted and tested with anti-mouse immunoglobulin (to detect mouse 
anti-FLAG contamination from the affinity column) and anti-BSA (to detect 
bovine albumin contamination from the cell culture medium) as presence of 
either could affect the overall sr-protein yield.  The blots in Figures 3.11 and 
3.12 show that there are only trace amounts of both proteins present.  BSA 
standards were included on the gel (Figure 3.12) at 1.0, 0.5 and 0.25 µg.  
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BSA was not present in all of the samples but in those that it was, it was well 
below 0.25 µg.  The level of BSA contamination is investigated further in 
Protein Purification Results section 4.0. 
   
Figure 3.11 Western blot to check for contaminating mouse Ig in purified sr-
LHR-C samples.  Purified sr-LHR-C protein from supernatants harvested from   
SF = spinner flask, F = T-175 flask, CM = CellMax system were tested using 
HRP-conjugated anti-mouse immunoglobulin.  Samples were purified on 
affinity gels that had been used either once, twice or three times, hence three 
samples from each growth system were obtained. Samples from spinner 
flasks were run in lanes 1, 5 and 8.  Samples from T-175 flasks were run in 
lanes 2, 6 and 9 and samples from the CellMax system were run in lanes 3, 7 
and 10.  All were eluted with 3XFLAG peptide. An acid eluted sample 
containing mouse Ig was included for comparison (lane 11). A molecular 
marker (M) was run in lane 4. 
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Figure 3.12 Western blot to check for contaminating BSA in purified sr-LHR-C 
samples.  Purified sr-LHR-C protein from supernatants harvested from: SF = 
spinner flask, F = T-175 flask, CM = CellMax system were tested using HRP-
conjugated anti-BSA.   Samples were purified on affinity gels that had been 
used either once (1), twice (2) or three times (3), hence three samples from 
each growth system were obtained.  All were eluted with 3XFLAG peptide.  
Three standards are included containing 1 µg, 0.5 µg and 0.25 µg BSA 
respectively.  A molecular marker was run as indicated. 
 
Sr-LHR-D was also produced in all three systems, and yield of protein was 
very similar to that obtained for sr-LHR-C.  Although only based on purification 
of one 200 mL cell culture supernatant from each system, purified on one mL 
gels that had been used a variable number of times, yields of 610 µg, 273 µg 
and 209 µg were obtained for spinner flask, T-175 flask and CellMax® 
respectively.  They showed the same order of decreasing protein yield from 
spinner flask to T-175 flasks to CellMax® as for sr-LHR-C in section 3.3.3 
(where yields were 308 µg, 230 µg and 156 µg respectively).  Figure 3.13 
shows the purified sr-LHR-D compared to purified sr-LHR-C.   
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Figure 3.13 A comparison of purified sr-LHR-C and sr-LHR-D proteins.  a) a 
protein stained western blot b) an immunoblot probed with HRP-conjugated 
rabbit anti-mouse immunoglobulin and c) an immunoblot probed with mouse 
monoclonal anti-CD35 (clone E-11) primary antibody and HRP-conjugated 
rabbit anti-mouse immunoglobulin secondary antibody, M=marker. 
 
A difference is again seen between sr-LHR-C and sr-LHR-D with mouse 
immunoglobulins seen in the acid eluted sr-LHR-D sample but not the peptide 
eluted sr-LHR-C sample.  Reactions with anti-CD35 (clone E-11) are much 
stronger with sr-LHR-D, with a band seen at approximately 65-80 kDa which 
corresponds with the band seen on the protein stained membrane.  The sr-
LHR-C protein appears to be slightly smaller than sr-LHR-D. 
 
3.3.4 Mass spectrometry analysis of sr-LHR-C and sr-LHR-D peptides 
Analysis of sr-LHR-C and sr-LHR-D peptides was performed on bands cut 
from a Coomassie-Blue stained SDS-PAGE gel by Dr K. Heesom at Bristol 
University.  Pooled purified protein samples for both sr-LHR-C and sr-LHR-D 
were run on the gel and after tryptic digestion these were analysed by MALDI-
        a) Protein stain                         b)  anti-mouse Ig                    c) anti-CD35 (E-11) 
   kDa       M       LHR-D     LHR-C   M                  LHR-D   LHR-C     M      LHR-D      LHR-C 
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TOF.  The protein-peptide summary results sheet returned from MALDI-TOF 
analysis shows the top 20 hits for each sample resulting from a search of the 
UniProtKB/Swiss-Prot protein sequence database (Swiss Institute of 
Bioinformatics, 2014).  The top 20 hits for each protein are summarised in 
tables below.  The key value for each hit is the protein score.  For this search, 
proteins with a score >56 are classed as significant identification (p<0.05).  
The higher the score above this value, the more confidence there is in the 
identification (personal communication, Dr K. Heesom).  The top hit for both 
sr-LHR-C and sr-LHR-D is Complement receptor type 1 protein, with protein 
scores of 129 and 170 respectively.  The next best matches have much lower 
scores than this.  The results for sr-LHR-C and sr-LHR-D are summarised in 
Tables 3.2 and 3.3 respectively. 
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Table 3.2 MALDI-TOF analysis showing the top 20 hits for sr-LHR-C. 
Rank Protein name Species Protein accession 
number 
Protein 
score 
1 Complement receptor type 1 Homo sapiens CR1_HUMAN 129 
2 DNA primase  Marek’s disease 
herpesvirus type 1 strain 
PRIM_GAHVM 59 
3 Isopentenyl-diphosphate 
delta-isomerase 
Chlorobium limicola DSM 
245 
ID12-CHLL2 54 
4 Leucine-tRNA ligase Enterobacter sp.638 SYL_ENT38 52 
5 Acetate kinase Mycoplasma pneumoniae ACKA_MYCPN 52 
6 Leucine-tRNA ligase Ignicoccus hospitalis SYL_IGNH4 50 
7 Annexin A8 Homo sapiens ANXA8_HUMAN 49 
8 Annexin A8-like protein 2 Homos sapiens AXA82_HUMAN 49 
9 Uncharacterised protein 
KIAA0753 
Mus musculus K0753_MOUSE 49 
10 Uncharacterised protein 
MJ1518 
Methanocaldococcus 
jannaschii DSM 
Y1518_METJA 49 
11 DNA mismatch repair protein 
Msh2 
Bos taurus MSH2_BOVIN 48 
12 Thiopurine S-
methyltransferase 
Photobacterium profundum TPMT_PHOPR 48 
13 Spectrin alpha chain, 
erythrocyte 
Mus musculus SPTA1_MOUSE 48 
14 NADH-quinone oxireductase 
subunit D 
Xylella fastidosa Temecula 
1 
NUOD_XYLFT 48 
15 Casein kinase II subunit 
alpha 
Schizosaccharomyces 
pombe 972h- 
CSK2A_SCHPO 48 
16 Ornithine 
carbamoyltransferase 
Campylobacter jejuni 
subsp. Jejuni 81116 
OTC_CAMJ8 48 
17 Heparin cofactor 2 Rattus norvegicus HEP2_RAT 46 
18 30S ribosomal protein S3 Sinorhizobium meliloti RS3_RHIME 46 
19 30S ribosomal protein S3 Sinorhizobium medicae RS3_SINMW 46 
20 Lipoyl synthase Methylocella silvestris BL2 LIPA_METSB 46 
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Table 3.3 MALDI-TOF analysis showing the top 20 hits for sr-LHR-D. 
Rank Protein name Species Protein accession 
number 
Protein 
score 
1 Complement receptor type 1 Homo sapiens CR1_HUMAN 170 
2 Serum albúmina Bos taurus ALBU_BOVIN 68 
3 P53 and DNA damaged 
regulated protein 1 
Pongo abelii PDRG1_PONAB 61 
4 Calcium-binding mitochondrial 
cancer protein 
Xenopus (Silurana) 
tropicalis 
SCMC2_XENTR 60 
5 ATP synthase subunit alpha Granulobacter 
bethesdensis CGDNIH1 
ATPA_GRABC 60 
6 Structural maintenance of 
chromosome protein 3 
Dictyostelium discoideum SMC3_DICDI 57 
7 DNA polymerase catalytic 
subunit 
Human herpesvirus 6 
strain Z29 
DPOL_HHV6Z 56 
8 Cytoplasmic FMR1-interacting 
protein 2 
Pongo abelii CYFP2_PONAB 55 
9 Tetratricopeptide repeat 
protein 12 
Homo sapiens TTC12_HUMAN 54 
10 Exodeoxyribonuclease 7 large 
subunit 
Listeria monocytogenes 
serotype 4b 
EX7L_LISMF 53 
11 ComG operon protein 1 
homolog 
Bacillus halodurans COMGA_BACHD 52 
12 Exodeoxyribonuclease 7 large 
subunit 
Listeria monocytogenes EX7L_LISMO 52 
13 DNA ligase  Thioalkalivibrio 
sulfidophilus HL-EbGr7 
DNLJ_THISH 52 
14 NusA protein homolog Methanocaldococcus 
jannaschii DSM 
NUSA_METJA 52 
15 Aspartate-tRNA ligase Nitrospira multiformis 
ATCC 25196 
SYD_MITMU 51 
16 Probable GTP-binding protein 
EngB 
Mycoplasma pneumoniae ENGB_MYCPN 51 
17 Ribosome biogenesis GTPase 
A 
Bacillus cereus ATCC 
14579 
RBGA_BACCR 50 
18 Uncharacterised protein 
AF_0844 
Archaeoglobus fulgidus 
DSM 4304 
Y844_ARCFU 50 
19 Succinyl-CoA ligase [ADP 
forming] subunit beta 
Sulfurimonas denitrificans 
DSM 1251 
SUCC_SULDN 49 
20 Putative uncharacterised 
protein y4kQ 
Sinorhizobium fredii 
NGR234 
Y4KQ_RHISN 49 
 
 
In addition, in this mass spectrometry investigation, the most intense peaks in 
the identified protein (CR1) were selected for sequencing and these results 
were reported as ion scores (Dr K.Heesom, personal communication).  This 
means that they were run in the MSMS mode of the mass spectrometer and 
the resulting amino acid sequence matched the identified protein which again 
increased confidence in the identification.  Three sequences for both LHRs 
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were reported, those for LHR-C are shown in Figure 3.14 and sequences for 
LHR-D are shown in Figure 3.15. 
 
QAPDHFLFAKLKTQTNA 
      961 SDFPIGTSLKYECRPEYYGRPFSITCLDNLVWSSPKDVCKRKSCKTPPDPVNGMVHVITD 
     1021 IQVGSRINYSCTTGHRLIGHSSAECILSGNTAHWSTKPPICQRIPCGLPPTIANGDFIST 
     1081 NRENFHYGSVVTYRCNLGSRGRKVFELVGEPSIYCTSNDDQVGIWSGPAPQCIIPNKCTP 
     1141 PNVENGILVSDNRSLFSLNEVVEFRCQPGFVMKGPRRVKCQALNKWEPELPSCSRVCQPP 
     1201 PEILHGEHTPSHQDNFSPGQEVFYSCEPGYDLRGAASLHCTPQGDWSPEAPRCAVKSCDD 
     1261 FLGQLPHGRVLFPLNLQLGAKVSFVCDEGFRLKGSSVSH VLVGMRSLWNNSVPVCEHIF 
     1321 CPNPPAILNGRHTGTPSGDIPYGKEISYTCDPHPDRGMTFNLIGESTIRCTSDPHGNGVW 
     1381 SSPAPRCELSVRAG 
 
Figure 3.14 Mass spectrometry results for sr-LHR-C.  The amino acid 
sequence for LHR-C is shown with the three mass spectrometry sequences 
highlighted.  These were the three most intense peaks obtained for the top hit, 
CR1, which were selected, and successfully sequenced.  They matched 
sequences in the specified protein (CR1), giving further confidence that the 
protein is CR1. 
 
 
         HCKTPEQFPFASPTIPINDFEFPVGTSLNYECRPGYFGKMFSISCL 
     1441 ENLVWSSVEDNCRRKSCGPPPEPFNGMVHINTDTQFGSTVNYSCNEGFRLIGSPSTTCLV 
     1501 SGNNVTWDKKAPICEIISCEPPPTISNGDFYSNNRTSFHNGTVVTYQCHTGPDGEQLFEL 
     1561 VGERSIYCTSKDDQVGVWSSPPPRCISTNKCTAPEVENAIRVPGNRSFFTLTEIIRFRCQ 
     1621 PGFVMVGSHTVQCQTNGRWGPKLPHCSRVCQPPPEILHGEHTLSHQDNFSPGQEVFYSCE 
     1681 PSYDLRGAASLHCTPQGDWSPEAPRCTVKSCDDFLGQLPHGRVLLPLNLQLGAKVSFVCD 
     1741 EGFRLKGRSASHCVLAGMKALWNSSVPVCEQIFCPNPPA LNGRHTGTPFGDIPYGKEIS 
     1801 YACDTHPDRGMTFNLIGESSIRCTSDPQGNGVWSSPAPRCELSVPA 
 
Figure 3.15 Mass spectrometry results for sr-LHR-D.  The amino acid 
sequence for LHR-D is shown with the three mass spectrometry sequences 
highlighted.  These were the three most intense peaks obtained for the top hit, 
CR1, which were selected, and successfully sequenced.  They matched the 
sequences in the specified protein (CR1), giving further confidence that the 
protein is CR1.  
 
The second hit for sr-LHR-D is BSA (Table 3.3), which could be a possible 
contaminant of the purified protein, from the cell culture medium.  The 
peptides mapped to CR1 are mostly distinct from those mapped to BSA (only 
two, of mass 1439 and 2462, are common to both) and neither of these was 
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sequenced.  Therefore this might imply that BSA is present at low amounts.  
However, given the much higher score for CR1 it is probably most likely that 
these peptides come from CR1 rather than BSA.  If they were removed from 
the BSA list this may well drop the protein score for BSA below the 
significance threshold (K. Heesom, personal communication). 
 
3.3.5 Antigenicity of purified proteins 
The nine purified protein sr-LHR-C samples were used in the CAT inhibition 
test.  This test is described in Materials and Methods section 2.5.3.  A patient 
plasma sample (5635H) containing anti-KN antibodies was used.  When 
tested with a reagent screening cell this sample gave a positive reaction 
indicating that KN specific antibodies in the patient’s plasma had reacted with 
a KN specific antigen on the red cells and caused agglutination (positive 
control).  A full investigation of this sample (performed as part of routine 
investigation in RCI, Filton) determined that no other antibodies directed 
against red blood cell antigens were present. Samples of this patient plasma 
were incubated with purified sr-LHR-C protein (nine samples tested 
individually) prior to performing the CAT test.  All samples were negative by 
CAT, post incubation, indicating that the purified protein had inhibited the 
antibody so that it could not react with antigen on the reagent screening cell.  
A control sr-protein, specifically a type I sr-protein like the CR1 protein, could 
have been used in these tests instead of PBS.  However, this would have 
added cost to the test, so a control containing the same volume of PBS 
substituted for purified protein was used.  A positive reaction confirms that the 
negative reactions obtained with sr-protein were not due to a dilution of the 
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antibody samples.  The inhibition test was only performed with one patient 
plasma sample due to the rarity of samples, and the quantity of sample 
needed for this testing, but it is does show that all the purified protein samples 
had KN antigen specificity (results shown in Table 3.4). 
 
Table 3.4 CAT inhibition test using sr-LHR-C  
 
 Neat plasma plus: 
 
Neat 
Plasma 
PBS SF1 SF2 SF3 F1 F2 F3 CM1 CM2 CM3 
5635H 2 2 0 0 0 0 0 0 0 0 0 
 
Nine purified samples of sr-LHR-C, three each from cell culture grown in 
spinner flask (SF1, SF2 and SF3), T-175 flasks (F1, F2,F3) and CellMaxTM 
(CM1, CM2 and CM3) were used in the CAT inhibition test against patient 
plasma (sample 5635H) known to contain a KN related antibody.  Positive 
reactions were scored on a scale of 1 to 5 where 5 is the strongest reaction, a 
negative test is recorded as 0.  The antibody can be seen to be reactive in the 
plasma sample and when diluted with an equal volume of PBS rather than sr-
LHR-C. The negative reactions when sr-LHR-C is added to patient’s plasma 
indicate that all the purified sr-LHR-C preparations inhibited the KN related 
antibody.   
 
3.3.6 Comparison of costing for different culture methods 
The cost of equipment and reagents used for cell culture in the three different 
systems, shown in Table 3.5, was compared from the point when the systems 
were seeded with transfected HEK293 cells. Some of the equipment is 
reusable: spinner flasks and the reservoir caps for the CellMax® system can 
be washed, sterilised and reused but for the purposes of this calculation it was 
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assumed that this was the first time of use to offset the handling costs.  The 
Duo system pump for CellMax® system can also be reused many times so its 
cost was not included in the calculations.  T-175 flasks can be used several 
times but more often new flasks were used so it was assumed that new flasks 
were used each time the flasks were reseeded. 
 
Table 3.5 The cost of equipment and reagents needed for the three culture 
systems. 
 
Equipment 
Cost (£) Reagent Cost (£ per litre) 
500 mL spinner flask 415.00 DMEM     5.32 
T-175 flask 1.75 FCS 165.50 
CM reservoir cap 206.00 PS   46.50 
  LG   35.00 
  Trypsin-EDTA   42.50 
 
 
Culture medium was used with 10% FCS added for the spinner flask, T-175 
flasks and for flushing the bioreactor in the CellMax™ system.  For the 
reservoirs for the CM system 5% FCS was used.  Costs per litre for the two 
types of culture medium, both containing 1% PS and 1% LG are shown in 
Table 3.6.  Equipment and reagent costs are shown in Table 3.7. 
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Table 3.6 The constituents and cost of cell culture medium containing 5% or 
10% FCS. 
 
Culture medium 
constituent 
Cost (£ per litre cell 
culture medium) 
DMEM   5.32 
10% FCS 16.55 
  5% FCS   8.28 
  1% PS   0.47 
  1% LG   0.35 
Total 10% FCS 22.69 
Total   5% FCS 14.42 
 
Table 3.7 The equipment and reagent costs for pools of sr-protein produced 
from each system 
 
Cell culture 
system 
Equipment / reagents Cost (£) 
Spinner flask 
(600 mL pool) 
500 mL spinner flask 415.00 
750 mL culture medium (10% FCS)   17.02 
T-175 flask 
(650 mL pool) 
26 x T-175 flasks   45.50 
650 mL culture medium (10% FCS)   14.75 
130 mL trypsin-EDTA     5.53 
CellMax™ 
(720 mL pool) 
Reservoir cap 206.00 
20 kDa MWCO bioreactor 355.00 
720 mL culture medium (10% FCS)   16.34 
4000 mL culture medium (5% FCS)   57.68 
 Total spinner flask 432.02 
 Total T-175 flask   65.78 
 Total CellMax™ 635.02 
 
 
The actual volume from each pool that was purified was 300 mL.  The total 
cost of equipment and reagents needed to produce 1 mL protein with a 
concentration of 1 mg mL-1 was calculated and is shown in Table 3.8. 
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Table 3.8 The equipment and reagent costs to produce 1 mg of protein from 
each system. 
 
System Cost (£ for 300 
mL) 
Total protein yield 
(µg) from 300 mL 
Cost of 1 mL 
protein with 
concentration of 1 
mg mL-1 (£) 
Spinner flask 216.01 924 233.78 
T-175 flask   30.36 691   64.40 
CellMax™ 264.59 467 566.57 
 
 
Finally, staff costs, shown in Table 3.9, were calculated assuming a 
Biomedical Scientist Specialist did this work, paid at midpoint of the AFC band 
6 grade with 22% added for ‘on costs’ i.e.  National Insurance and pension 
payments.  This would be £36,600 per annum, at an hourly rate of £18.77. 
 
Table 3.9 Staff costs to produce 1 mg of sr-protein. 
 
System Hands on 
time (hours) 
Cost per pool 
(£) 
Cost for 300 
mL (£) 
Cost of 1 mL 
protein (1 mg 
per mL) 
Spinner flask   2   37.54 14.08     6.35 
T-175 flask   6 112.62 51.98   75.22 
CellMax™ 10 187.70 78.21 167.47 
 
An assumption was made that a minimum of 9 mL of reagent (at 1 mg mL-1) 
would be needed for NHSBT laboratories per year.  This was based on 
approximately 30 panels using 30 µL of KNIR each time being performed by 
each laboratory per year (personal experience).  Based on this then annual 
production costs would be:  
 
Spinner flasks (233.78 + 6.35) x 9 = £2161.17 
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T-175 flasks (64.40 + 75.22) x 9 = £1256.58 
CellMax™ (566.57 + 167.47) x 9 = £6606.36 
  
The cost of protein purification is calculated in the next results section, Protein 
Purification. 
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3.4 Discussion 
The purpose of this part of the study was to maximise production of sr-LHR 
protein from transfected HEK293 cells so that a reagent could be produced 
and supplied to eight NHSBT RCI laboratories and also IBGRL based in 
Filton.  In addition it had to be shown that the protein produced was of the 
correct specificity and retained its blood group antigenicity.    
 
The plasmids used to produce sr-proteins were validated by DNA sequencing 
prior to transfection into HEK293 cells.  Samples of both sr-LHR-C and sr-
LHR-D purified protein were sent for mass spectrometry analysis, which 
showed that the protein produced was CR1 related. This protein inhibited anti-
KN antibody in the CAT inhibition test.  It was also found that there was very 
little contamination with BSA or mouse immunoglobulin.  
 
Traditionally, production of sr-proteins in mammalian cells has been based on 
transfection and then isolation of clonal cell lines stably expressing the 
required gene product (Pham et al., 2006).  This was the approach taken in 
this study, which enabled a frozen cell bank of stably transfected HEK293 
cells expressing sr-LHR-C or sr-LHR-D protein, to be set up for future use.  To 
enable the highest protein producing clones to be selected an ELISA method 
was developed (section 3.3.2).  The first method tested was the simplest and 
fastest to perform relying on direct detection of sr-3xFLAG tagged protein with 
an HRP-conjugated anti-FLAG antibody. However, this method failed to detect 
sr-LHR-C protein.  In this method monoclonal anti-CD35, clone E-11 was 
used to sensitise the microtitre plate.  This antibody had been reported to 
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react with both LHR-C and LHR-D regions of the CR1 (CD35) molecule 
(Nickells et al., 1998).  However, it was reported by Tamasauskas et al., 
(2001), that although LHR-D completely inhibited reactivity of anti-CD35 E-11 
as measured by flow cytometry, only 50% reduction of reactivity was seen 
using sr-LHR-C indicating that sr-LHR-C would not react as strongly as sr-
LHR-D with this anti-CD35.  The second ELISA method was then used to 
increase sensitivity.  This method, like the first, started with sensitisation of the 
plate with anti-CD35 followed by addition of FLAG-tagged protein but then an 
additional step was introduced where a primary rabbit anti-FLAG antibody was 
added.  This was followed by addition of a secondary HRP-conjugated anti-
rabbit Ig antibody.  This indirect ELISA technique is generally more sensitive 
than a direct one due to signal amplification gained by use of the secondary 
antibody (Kemeny, 1991).  Sr-LHR-C protein was still not detected by this 
technique.  The third method was effectively a capture sandwich assay 
technique.  Anti-mouse immunoglobulin was initially used to sensitise the 
plate so that the mouse anti-CD35 antibodies would be captured on the plate 
in the correct orientation to react more efficiently with the CD35 protein in the 
culture supernatant.  Positive reactions were obtained with sr-LHR-C by this 
method, although reactions were not as strong as seen with sr-LHR-D-
3xFLAG protein.  Reactions were suitably strong enough to be able to 
distinguish the highest secreting clones during the cloning process.  
 
It was hoped that this ELISA could be used to assess initial concentrations of 
FLAG tagged proteins in the cell culture supernatants.  If estimates of the sr- 
protein in the starting material could be made then percentage recovery 
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during the purification process could be calculated. Attempts at using purified 
sr-LHR protein of known concentration to set up standard curves were not 
very successful (Figures 3.6 and 3.7).  When a ‘curve’ was produced then 
generally the linear part of the curve lay within a very small range, typically 
between 100 to 200 ng mL-1 for sr-LHR-D.  This meant that it was difficult to 
get sample OD readings within this range.  The main problem was that the 
assay did not appear to be quantitative.  Protein estimates from the starting 
cell culture supernatant appeared to be too low when compared to the purified 
protein obtained.  It did not appear as though there was a linear relationship 
between optical densities (492 nm) or protein concentration and probably 
reflected deficiencies in assay optimisation which would have taken a lot of 
time to overcome.  As it was not necessary to have a precise measure of 
concentration of a given sample, optimisation of the assay was not pursued as 
part of this study.   
 
An alternative anti-CD35, antibody clone J3D3, was compared to anti-CD35 
clone E-11 with slightly stronger reactions obtained with this reagent by 
ELISA.  Each sr-LHR protein gave very weak reactions when blotted with 
either anti-CD35 reagents.  A sr-LHR-D sample included as comparison 
seemed to react with both anti-CD35 reagents.  These results appeared to 
contradict a study reported by Nickells et al., (1998).  This group reported that 
anti-CD35 clone J3D3 did not react with sr-LHR-D protein, whilst anti-CD35 
clone E-11 did react with sr-LHR-D.  However, on closer inspection of the 
western blots in Figure 3.8 it was clear that anti-CD35 clone J3D3 had not 
reacted with sr-LHR-D.  A band at just below 80 kDa seen on the blot with 
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anti-CD35 clone E-11 was missing from the anti-CD35 clone J3D3 blot.  The 
reactions seen were due to HRP-conjugated anti-mouse IgG reacting with 
mouse immunoglobulin in the sr-LHR-D preparation.  There was apparently 
no mouse immunoglobulin in the sr-LHR-C protein.  The presence of mouse 
immunoglobulins in the purified sr-protein preparations is investigated and 
discussed further in section 4.0, Protein Purification. 
 
The cloning process was time consuming taking approximately 14 weeks to 
perform three rounds of cloning.  Although a frozen cell bank has now been 
established it might be that a future development would be to use transiently 
transfected cells.  HEK293E cells expressing the Epstein-Barr virus nuclear 
antigen (EBNA) have enhanced productivity of r-protein due to high levels of 
plasmid amplification.  These cells have been used for large scale transient 
gene expression (Swiech et al., 2012).  This is a rapid technique with cells 
capable of producing milligram to gram amounts of recombinant protein, but it 
does require large numbers of cells and large amounts of purified plasmid and 
as a method is less easy to standardise (Pham et al., 2006). 
 
HEK293 cells were grown in three systems where they were treated in 
different ways and had different supernatant harvesting regimes based on 
standard laboratory procedures.  Cells in the spinner flasks were left for up to 
two weeks before harvesting.  This timescale was based on protocols and 
experience within the laboratory and fitting in with when time could be spent in 
the laboratory to do the harvesting work. Prior to harvesting, the cells were 
allowed to settle and supernatant gently removed and new cell medium 
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added.  So with the exception of the stirring itself the cells suffered little 
disturbance and they tended to form aggregates so they effectively adhered to 
each other rather than the flask (Cartwright et al., 2002).  This culture method 
must have been conducive for cells to produce sr-protein as protein yield from 
this system was the highest at around 300 μg from 100 mL of supernatant.  
This yield compares favourably to that of another sr-blood group antigen 
grown in HEK293 cells.  Lub of the Lutheran blood group system was 
measured at a concentration of 250 µg per litre in pre-purified cell supernatant 
(Seltsam et al., 2007).  The protein produced was V5-His-tagged Lub protein 
but the culture method used was not recorded.  The V5-His tag was used in a 
sandwich ELISA to measure sr-Lub concentration, anti-V5 was used as the 
capture antibody and HRP-anti-His as the detection antibody.  Predefined 
amounts of V5-His-tagged Class I protein were used as a reference to 
calculate quantity of V5-His-tagged protein present, but not specifically sr-Lub 
protein present.   
 
In addition, it was found in this current study that the spinner flask system was 
very simple to look after with little hands on time needed, so staff costs were 
lower than for the other systems used.  A disadvantage with the spinner flasks 
is that in the BITS/IBGRL laboratory Filton, there is evidence that they can 
become easily infected.  However, this was not a problem for the 34 days the 
cells were grown in this study.  Also, the flasks do take time to clean and 
sterilise and this was not included in staff costs for this system.  This was 
because a support grade member of staff would carry this out as part of 
general cleaning duties within the laboratory. 
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The T-175 flasks once seeded with HEK293 cells were cultured without 
moving to allow the cells to adhere to the plastic surface.  The cells were 
allowed to grow until they had reached approximately 80% confluency.  This 
took about one week and at this point the flasks needed to be reseeded to 
prevent cells reaching 100% confluency.  At this cell density it is reported that 
protein synthesis does decrease (McAteer and Davis, 2002).  However, 
whether protein production from cells in this study decreased at greater than 
80% confluency was not known.  Optimum harvest time and the effect that cell 
density i.e. confluency had on protein production could have been determined 
using the ELISA but this was not pursued as part of this study due to time 
constraints.    Cells were dislodged from the flasks by disruption of cell to cell 
and cell to plastic interactions by use of the protease enzyme trypsin with 
EDTA.  Cells were then washed and resuspended in cell culture medium prior 
to reseeding the flasks.  This meant that cells had to reattach to the flask 
surface, grow and start protein synthesis again.   Despite the disruption, yields 
from the flasks were around 75% of those from spinner flasks.  This system is 
the cheapest one as it does not require expensive equipment but it does 
require more “hands-on” time. 
 
In the CellMax system HEK293 cells and secreted protein are held in a 
bioreactor which is essentially a separate compartment from which 
supernatant can be periodically harvested.  This means that cells are exposed 
to a local microenvironment rather than being exposed to the bulk medium.  
Adequate medium flow is therefore essential to this system to prevent 
depletion of nutrients in the bioreactor.  Supernatant was harvested twice 
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weekly with a syringe.  Unfortunately, the bioreactor became infected so the 
cells may not have had sufficient time to fully colonise the bioreactor 
membrane, grow and produce protein.  This was the most expensive system 
in terms of staff costs and equipment.  However, the system had not been 
running as long as the others so protein yield was from a shorter culture time.  
There is evidence in the laboratory that this system can produce high yields of 
protein e.g. 42 mg sr-Fya from 190 mL cell culture supernatant from CellMax® 
compared to 6 mg sr-Fya from 200 mL cell culture supernatant from T-225 
flasks, and can run for many months (Fran Green BITS/IBGRL, personal 
communication).  If this concentration of protein could be produced either by 
using the CellMax® system or transiently transfected cells, then it raises the 
possibility of being able to use non-purified culture supernatants as reagents, 
which would save substantial time and money, compensating for the cost of 
the CellMax® system both in terms of equipment and staff time.  Cell culture 
supernatants containing individual sr-blood group proteins of K, k, Fya, Fyb or 
Lub specificities have been used in BITS/IBGRL to inhibit antibodies at 1 in 10 
dilutions of cell culture supernatant to plasma (Fran Green BITS/IBGRL, 
personal communication).  Obviously, contaminants such as BSA would be 
present in the supernatant and that might prove to be a problem in reagent 
production where consistency between each batch would need to be 
assessed.  However, it might be worth pursuing one or both of these 
approaches for future reagent production.  
 
Mammalian cells are used to express human proteins because they can 
perform the complex post-translational modifications widely thought to be 
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needed for appropriate protein folding and function.  This is especially 
important for sr-blood group proteins as the 3-D structure seems to be 
important for them to retain their antigenicity.  Seltsam et al. (2007) compared 
production of sr-Lub in eukaryotic and prokaryotic systems.  HEK293 stable 
cell lines were transformed with the eukaryotic pcDNA3.1/V5-His-Lub 
expression construct and the prokaryotic expression plasmid pcRT7/CT-His-
Lub was used to transfect E. coli cells.  Sr-Lub protein produced from both cell 
lines was able to inhibit anti-Lub in samples tested in a haemagglutination 
inhibition test, indicating that the protein showed Lub antigenicity.  However, 
protein produced from E .coli cells had to be refolded to show this reactivity.  
This is because r-proteins can become insoluble in inclusion bodies and can 
be difficult to recover as functional proteins (Villaverde and Mar Carrio, 2003).  
Also, most post-translational modifications are not added by bacterial systems 
(Assenberg et al., 2013).  
 
The exact time required for the cloning process for HEK293 cells was not 
recorded by Seltsam et al., (2007) but clones were selected to obtain stable 
cell lines after 10 to 16 days, whereas protein from bacterial cells was 
obtained in around seven working days but then required a process to refold 
the prokaryotic Lub molecules.  However, Seltsam et al. reported that correct 
protein refolding occurred spontaneously after removal of the prokaryotic Lub 
protein from the denaturing environment which simplified the process.  His 
study demonstrated that eukaryotic and re-folded prokaryotic r-Lub proteins 
were equally suited to antibody identification but whereas µg of protein was 
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produced from HEK293 cells, 5 to 10 mg of protein was produced from E.coli 
cells, but starting volumes of cell culture supernatant are not given.     
 
Lutheran, like Knops, is a single pass membrane protein with an extracellular 
domain, which carries the blood group antigens, segmented into several 
discrete immunoglobulin superfamily (IgSF) domains, rather like the LHRs of 
CR1 (Kikkawa et al., 2011).  This raises the possibility that functional sr-LHR 
proteins might be produced in bacterial cells or another non-mammalian 
system.  Peptide fragments of the CR1 molecule have been produced from 
Pischia pastoris yeast cells (Pham et al., 2010).  Nuclear magnetic resonance 
spectroscopy was used to confirm protein folding and results of this were 
consistent with compactly folded protein domains.  The recombinant 
fragments were used to study the binding of the Plasmodium falciparum 
adhesin PfTh4 to areas of the CR1 molecule, so it is not known whether these 
fragments displayed any blood group antigenicity (Pham et al., 2010). 
 
The aim to transfect HEK293 cells to produce sr-LHR-C and LHR-D was fully 
met with both proteins identified as CR1 by mass spectrometry.  Stably 
transfected HEK293 cells were cloned and a frozen cell bank has been set up 
for future use.  It was shown that functional sr-LHR protein could be produced 
relatively cheaply, with production costs of less than £2K per annum using T-
175 flasks.  As this culture system was also easy to use it was recommended 
for the production of protein for use as a reagent for NHSBT laboratories. 
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4.0 SR-LHR-C AND SR-LHR-D PROTEIN PURIFICATION 
4.1 Introduction 
The purification process aims to separate sr-LHR-C or sr-LHR-D protein, 
secreted by transfected HEK293 cells, from other secreted proteins and from 
other proteins contained in the culture medium e.g. bovine serum albumin 
(BSA).  Affinity chromatography is the purification method of choice as the sr-
LHR-C and sr-LHR-D proteins are fusion constructs with the 3xFLAG affinity 
tag located at their C-terminal ends.  When culture medium is applied to an 
agarose gel with anti-FLAG M2 monoclonal antibody covalently attached, the 
FLAG tagged proteins will bind to the antibody.  Any 3XFLAG protein bound to 
the gel can be eluted by competition with high concentrations of the 3XFLAG 
peptide or by reducing the pH.  These elution conditions help to preserve the 
structure of protein complexes (Sigma-Aldrich, 2000).  
 
The aim of this part of the study was to optimise a purification process based 
on affinity gel purification, to maximise protein yield and economy so that a 
routine diagnostic test could be developed for use in Red Cell 
Immunohaematology (RCI) departments.  The purified protein must also retain 
its blood group antigen specificity.  The immunopurification method was 
therefore assessed in several ways.  As one of the major costs of purification 
is incurred through purchase of the 3XFLAG peptide, development included a 
comparison of yields of sr-LHR-C-FLAG and sr-LHR-D-FLAG protein obtained 
by competitive elution with those obtained by acid elution.  Also, protein eluted 
by both methods was used in the inhibition test to ensure that blood group 
antigenicity had not been affected by the elution technique used.  Another 
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expense is the cost of the affinity gel so the number of times the gels could be 
used and how this affected protein yield and antigenicity was assessed.  
Finally, whether yields could be increased if supernatant that had been 
applied to the gels was retained and reapplied to the gels again was 
assessed.  The purity of the final product was investigated and the cost to 
purify enough protein (concentration 1 mg mL-1) to provide as a reagent to 
internal NHS Blood and Transplant (NHSBT) laboratories for one year was 
calculated.  It is recognised that other factors could affect yield such as flow 
rate through the gels, size of gel column used, temperature at which the 
purification is performed but material, time and cost meant that all these 
factors were not assessed but kept constant for all the purification procedures 
described i.e. 1 mL gels were used, supernatant was applied at a flow rate of 
1 mL minute-1, and all purification procedures were performed at room 
temperature (18 to 25 ºC). 
 
4.2 Materials and Methods 
4.2.1 Acid vs competitive elution of sr-proteins from anti-FLAG agarose 
gel 
 
Elution using glycine-HCl pH 3.5 (acid elution) or 3XFLAG peptide 
(competitive elution) was compared.  Both methods are recommended by the 
manufacturer (Sigma-Aldrich, 2010) and both are described in Materials and 
Methods section 2.3.2.  Cell culture supernatant harvested from LHR-C 
transfected HEK293 cells grown in spinner flasks, T-175 flasks and in the 
CellMax® system were pooled giving a  total volume of 1175 mL.  Six 1 mL 
affinity gels in separate 10 mL glass columns were prepared.  One 100 mL 
aliquot of the pooled material was run through each gel.  Three gels were 
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eluted with 3XFLAG-peptide and three gels eluted with glycine-HCl pH 3.5.  
The yield of protein was assessed by BCA assay (Materials and Methods 
section 2.3.3) with a mean of three assays used for the final result.  The 
approximate molecular weight (Mr) of the purified protein was assessed by 
SDS-PAGE (Materials and Methods section 2.3.4) followed by western 
blotting onto PVDF membranes (Materials and Methods section 2.3.5) and 
Coomassie blue protein staining (Materials and Methods section 2.3.7).  
Protein purity was assessed by immunoblotting with HRP-conjugated anti-
mouse IgG and HRP-conjugated anti-BSA (Materials and Methods section 
2.3.6).  For all the blots described 2 μg of purified protein was used.  Protein 
antigenicity i.e. whether it expressed functional KN antigens was measured by 
its ability to inhibit anti-KN antibodies using the CAT inhibition test (described 
in Materials and Methods section 2.5.3).    
 
4.2.2 Number of uses of the affinity gel 
Five further 100 mL aliquots of the pooled material from 4.2.1 were used.  
One affinity gel eluted by acid above was selected and the five 100 mL 
aliquots were applied successively to the affinity gel and eluted with acid pH 
3.5 each time.  The yield of protein from each elution was assessed by BCA 
assay (Materials and Methods section 2.3.3) with a mean of three assays 
used for the final result. 
 
4.2.3 Recovery of protein 
The investigations described in 4.2.1 and 4.2.2 were performed on 
supernatant material but the starting concentration of protein was not known.  
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In order to better assess recovery of protein some ‘spiked’ samples were 
prepared.  Six 100 mL aliquots of cell culture medium were prepared and 50 
μg of purified sr-LHR-C was added to each.  Six 1 mL affinity gels were 
prepared (Materials and Methods section 2.3.2).  Three of the ‘spiked’ aliquots 
were applied to three of the affinity gels and eluted with acid (first elution).  A 
second acid elution was then performed to assess whether any protein might 
be left on the gel which could be eluted (second elution).  The culture medium 
was retained from this first application and applied to three new gels and 
termed flow through (FT) material.  After the flow through material had been 
run through the column acid elution was performed (first elution FT) and then 
a second acid elution was performed (second elution FT).  Further as part of 
the procedure Vivaspin centrifuge tubes are reused, so to check that no 
protein was retained in the Vivaspin membrane a final membrane wash with 
just PBS was performed and the PBS retained.  For all the above samples, 
protein yield was assessed by BCA assay performed in triplicate and the 
mean protein yield calculated. 
 
4.2.4 Purification of sr-LHR-D from culture supernatant 
When the purification method had been optimised this method was used to 
purify some supernatant preparations containing sr-LHR-D to ensure that 
yields consistent with those for sr-LHR-C were obtained and that the purified 
sr-LHR-D protein obtained was functionally active.  This work was performed 
by a member of staff in BITS/IBGRL using the methods as described in this 
study.  Supernatant containing sr-LHR-D from spinner flasks was pooled and 
split into three 100 mL aliquots.  Three one mL affinity gels were prepared and 
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100 mL was applied to each gel.  The flow through material was retained for 
each column and was put back through that column again.  
 
4.3 Results 
4.3.1 Acid vs competitive elution of sr-LHR-C from anti-FLAG agarose 
gel 
 
This work was performed to assess whether there was any difference in yield 
or activity of eluted protein between elution of bound protein using glycine-HCl 
pH 3.5 or 3xFLAG peptide.  Identical pooled culture supernatant was applied 
to six new gels and three gels were eluted by each technique and mean yield 
of protein was calculated.  New gels were used for each purification and there 
was little variation between the three runs for each elution method as shown 
by the error bars (Figure 4.1).  The mean yield (μg) from 3XFLAG eluted 
columns was slightly higher than from acid pH 3.5 eluted columns (148 μg vs 
140 µg).  Student’s t-test was performed on the results (Kirkman, 1996) and 
gave a probability (P-value) of 0.004.  This is low and provides statistical 
evidence that the null hypothesis can be rejected and that there is a significant 
difference in the results obtained from the two elution methods. 
 106  
    
Figure 4.1 Comparison of methods for elution of sr-LHR-C protein.  
Yield of sr-LHR-C protein from cell culture supernatant using elution 
with 3XFLAG peptide and acid elution with glycine-HCl pH 3.5 is 
compared.  Error bars represent standard deviations calculated from 
the data (n=3).  Student’s t-test P-value = 0.004. 
 
The protein stained western blot for the six samples (Figure 4.2) shows that 
the eluted protein had Mr of approximately 65-80 kDa, which is comparable to 
that found in Protein Production section 3.3.3, for sr-LHR-C.  There was no 
difference in gel mobility of the protein eluted by the two techniques. 
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Figure 4.2 Protein stained western blot comparing elution techniques. Three 
acid eluted samples in lanes 1, 2 and 3 were compared to three 3XFLAG 
eluated samples in lanes 4, 5 and 6.  The eluates were from culture 
supernatant containing sr-LHR-C.  No difference in mobility of the eluted 
proteins could be seen between the two different elution techniques. 
 
All the samples on the blot seem to show double bands, a darker band being 
seen at the bottom at approximately 65 kDa where BSA might appear (BSA 
Mr is 66.5 kDa ).  A western blot was performed with HRP-conjugated anti-
BSA (Figure 4.3) to check for the presence of BSA in the samples (following 
on from work in Results section 3.3.3; Figure 3.12).  Some BSA was detected 
on the blot in all of the samples at approximately the same level.  In 
comparison with the standards there was significantly less than 0.25 μg of 
BSA present.   
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Figure 4.3 BSA contamination in acid and 3XFLAG eluted samples.  Western 
blot with HRP-conjugated anti-BSA: three BSA standards at 1, 0.5 and 0.25 
µg are shown in lanes 2, 3 and 4.  Three samples eluted with glycine-HCl pH 
3.5 are labelled A1, A2 and A3 in lanes 5 to 7 and three samples eluted with 
3XFLAG peptide are labelled F1, F2 and F3 in lanes 8 to 10.  M=marker in 
lane 1. 
 
Even if 0.25 μg had been detected in the samples then this would amount to 
0.25 μg in 2 μg of sample applied to the gel.  This would mean that 12.5% of 
the sample applied was BSA and would be reported as having a purity of 
87.5%.  This would be an acceptable level of purity for commercial reagents. 
In actual fact the BSA content is much less than this.  The double bands seen 
on the protein stain in Figure 4.2 do not appear to be due to the presence of 
BSA in the sample as this level of BSA would be unlikely to be detected on 
the protein stained membrane. 
 
As a comparison, a purified sr-LHR-C sample was compared to a pre-purified 
sample of culture supernatant using HRP-conjugated anti-BSA western blot 
(Figure 4.4).  FCS contains 1.8 g dL-1 BSA so the pre-purified sample on this 
blot contains approximately 3.6 µg BSA and is obviously overloaded at this 
kDa       M      BSA   BSA    BSA       A1      A2       A3       F1     F2   F3  
                      1μg    0.5μg   0.25μg  
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amount.  In comparison the amount of BSA in the purified sample was very 
small.  
 
 
Figure 4.4 BSA contamination in a pre- and post-purified sample.  Western 
blot with HRP-conjugated anti-BSA on post purification sr-LHR-C sample and 
pre-purified cell culture supernatant, M=marker. 
 
It was suspected in Protein Production section 3.3.3 that mouse Ig from the 
column was present in some of the eluates.  When tested with HRP-
conjugated anti-mouse Ig, mouse Igs are found in the acid eluted but not the 
3XFLAG eluted preparations (Figure 4.5).  The acid eluted protein shows 
several bands, a more heavily stained band at approximately 50 kDa which 
corresponds to mouse IgG heavy chains.  A minor band at around 20 kDa 
corresponds to mouse IgG light chains that can appear at 20-25 kDa (Wilson 
et al., 2002).  The other bands are probably due to denatured mouse IgG 
fragments.  No mouse IgG was detected in the 3XFLAG eluted samples. 
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Figure 4.5 Mouse IgG contamination in sr-LHR-C samples eluted with acid 
and 3XFLAG.  Three sr-LHR-C samples eluted with acid are in lanes 1, 2 and 
3.  Three sr-LHR-C samples eluted with 3XFLAG are in lanes 4, 5 and 6.  All 
were immunoblotted using HRP-conjugated anti-mouse immunoglobulin. 
 
To ensure that antigenicity of the eluted protein was not affected by the elution 
technique, CAT inhibition tests were performed.  One sample known to 
contain anti-KN antibodies with sufficient volume (3440H) and previously 
shown to be inhibited by sr-LHR-C (but not sr-LHR-D) was selected and all six 
sr-LHR-C eluates were used in the inhibition test (Materials and Methods 
section 2.5.3).  Results after inhibition were compared with neat plasma and a 
PBS dilution control i.e. PBS was used instead of sr-LHR-C in the inhibition 
stage (Figure 4.6).  All the eluates inhibited the anti-KN antibody confirming 
that the antigenicity (and therefore the conformation) of the protein was 
retained by both elution methods. 
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Figure 4.6 CAT inhibition tests using acid and 3XFLAG eluted sr-LHR-C 
preparations.  Three acid eluted and three 3XFLAG eluted sr-LHR-C samples 
were used to inhibit patient plasma containing anti-KN antibodies.  Positive 
tests scored on a scale of 1 to 5 where 5 is the strongest reaction, negative 
test = 0. 
 
4.3.2 Number of uses of the gel 
To assess how many times the gels could be used, identical 100 mL aliquots 
of cell culture supernatant containing sr-LHR-C were successively applied to a 
1 mL gel (Figure 4.7).   
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Figure 4.7 Effect of number of uses of the affinity gel columns on protein yield.  
Protein yield from one affinity gel column when supernatant containing sr-
LHR-C was applied successively.  Six aliquots of supernatant were applied 
and protein was eluted from the gel column with acid elution each time.   
 
The user manual for anti-FLAG M2 affinity gel advises that if the gel is used to 
purify recombinant protein from periplasmic extracts from E.coli then the gel 
may be used up to 20 times without loss of binding capacity (Sigma-Aldrich, 
2010) but if E.coli crude extracts are used then the gel should only be reused 
three times before loss of binding capacity is observed.  Six applications was 
the maximum that could be achieved with the amount of cell culture 
supernatant available and lies between the three and twenty times 
recommended.  The results show that there was no decrease of yield after six 
uses of the gel, in fact there did appear to be a slight increase in yield after 
five and six uses.  However, this work was only performed once so no 
statistical analysis could be applied.  From these results, six uses of the gel 
would be acceptable for purifying the cell culture supernatants.  There was no 
difference in mobility of the purified protein on SDS-PAGE gels as shown in 
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Figure 4.8 and the size corresponded to that expected for sr-LHR-C.  Double 
bands can again be seen in the sr-LHR-C samples. 
 
 
Figure 4.8 Comparison of protein in sr-LHR-C eluates from a used affinity gel 
column.   Eluates from six successive applications of identical supernatant 
containing sr-LHR-C to an affinity gel column werewestern blotted and protein 
stained.  They are shown in lanes 1 to 6 indicating 1st to 6th use of the affinity 
gels.  M=marker. 
 
Western blots with HRP-conjugated anti-BSA and HRP-conjugated anti-
mouse IgG were performed.  With anti-BSA the results were the same as for 
acid eluted samples seen in Figure 4.3 (i.e. very little BSA detected) and the 
bands were consistent for all 6 samples tested (results not shown).  Low 
levels of mouse IgG was detected in the samples from the first four uses of 
the gel but by the 5th and 6th there did not appear to be much mouse IgG 
eluted from the gel (Figure 4.9). 
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Figure 4.9 Mouse IgG contamination of sr-LHR-C eluates from a used affinity 
gel column. Eluates from six successive applications of identical supernatant 
containing sr-LHR-C to an affinity gel column were immunoblotted with HRP-
conjugated anti-mouse IgG.  They are shown in lanes 1 to 6 indicating 1st to 
6th use of the affinity gels.  M=marker. 
 
CAT inhibition tests were performed using the six eluates to inhibit a patient 
sample containing anti-Kn antibodies and known to be inhibited with sr-LHR-C 
(Table 4.1).  Results of the CAT IAT after inhibition were compared to neat 
uninhibited plasma and a dilution control where PBS was added to patient 
plasma instead of sr-LHR-C in the inhibition stage.  All six sr-LHR-C eluates 
inhibited the KN antibody. 
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Table 4.1  CAT inhibition tests using eluted sr-LHR-C from used affinity  gels 
 
LHR-C eluate used for 
inhibition / use of gel 
Reaction vs 
Screening cell 
Neat uninhibited plasma 1 
PBS dilution control 1 
1st 0 
2nd 0 
3rd 0 
4th 0 
5th 0 
6th 0 
 
Samples are labelled from 1st to 6th use of the affinity gel.  The sr-LHR-C 
samples were used to inhibit patient plasma containing anti-KN antibodies.  
Positive reactions scored on a scale of 1 to 5 where 5 is the strongest 
reaction, negative test = 0. 
 
4.3.3 Recovery of sr-LHR-C protein from anti-FLAG affinity gels 
Recovery of protein eluted from the affinity gels was assessed by using 100 
mL aliquots of cell culture supernatant ‘spiked’ with 50 μg purified sr-LHR-C 
protein.  Percentage protein recovered is shown in Figure 4.10.  A mean of 
56% (28 μg) of protein was retrieved on the first run through the gels (first 
elution).  A further 34% (17 μg) was retrieved from flow through material i.e. 
applying the material again to a gel (first elution FT).  An additional elution 
was performed after the first in each case (second elution, second elution FT), 
to assess whether any protein remained on the column after elution.  From 
these two elutions 10% (5 μg) protein  was retrieved.  All the protein was 
retrieved when the yield from the two extra elutions were added.  The gels 
have a binding capacity of 600 μg mL-1 so it would have been expected that 
all of the protein would have bound on the first run through, however, a 
significant amount of protein was recovered from the flow through material.  
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The best protocol to adopt appears to be to retain the flow through from the 
first run and apply it again to the gel. 
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Figure 4.10 Percentage recovery of protein from three spiked samples.  Error 
bars represent standard deviations calculated from the data (n=3).   
 
In addition the last wash from three Vivaspin tubes was tested by BCA assay 
but no protein was detectable, indicating that no protein was lost through 
being retained in the tubes on the filtration membranes.  
 
The three first elution samples were pooled together as were the first elution 
FT samples to ensure that enough sample was available for subsequent 
testing.  These pooled samples were run on SDS-PAGE gels and blotted onto 
PVDF membranes.  A Coomassie protein stain and western blots with HRP-
conjugated anti-BSA and HRP-conjugated anti-mouse IgG were performed 
(Figure 4.11).  The protein stain shows the same diffuse bands for sr-LHR-C 
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as seen before at approximately 65 – 80 kDa.  There is no difference seen 
between the sample first applied to a new gel and then the flow through from 
that purification then being applied to a new gel.  It is just possible to see 
double bands in the sr-LHR-C samples on the protein stained membrane. 
 
 
Figure 4.11 Protein content and contaminants in sr-LHR-C first elution and 
flow through samples.  Western blots are a) protein stained, b) immunoblotted 
with HRP-conjugated anti-mouse Ig c) immunoblotted with HRP-conjugated 
anti-BSA.  Lanes 2, 5 and 7 contain eluted sr-LHR-C from supernatant applied 
to an affinity gel column for the first time.   Lanes 3, 6 and 8 contain sr-LHR-C 
from the supernatant collected from the first application which was applied to 
a new affinity gel and eluted.  Lanes 10, 11 and 12 show BSA standards 
containing 1 µg, 0.5 µg and 0.25 µg BSA respectively.  Molecular markers are 
shown in lanes 1, 4 and 9. 
 
Mouse Ig is seen in both samples which would be expected as the samples 
were acid eluted.  There appears to be more mouse Ig present in the flow 
through samples.  BSA was also detected at around 0.5 µg which indicates 
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more BSA present than previously detected, but these samples were pools of 
three so both mouse Ig and BSA were more concentrated than previously and 
had had twice as many acid eluates performed as would be expected during 
normal purification.  There were insufficient samples left to perform CAT 
inhibition tests but it was shown that sr-LHR-D flow through samples inhibited 
KN antibodies (section 4.3.5) and other sr-LHR-C flow through samples 
produced have inhibited KN antibodies (personal experience) so applying the 
cell culture supernatant to a gel again does not appear to affect the 
conformation of the protein.   
 
4.3.4 Cost to purify protein for use in NHSBT laboratories 
The KNIR reagent that will be distributed to NHSBT laboratories consists of 
equal volumes of sr-LHR-C and sr-LHR-D, both at a starting concentration of 
1 mg mL-1.  The total cost to purify enough protein to supply 1 mL KNIR to 
nine NHSBT laboratories was calculated and the cost of performing acid or 
3XFLAG elution was compared.  The cost of equipment and reagents was 
calculated from the point when the cell culture supernatant was filtered prior to 
application onto the affinity gel columns, up to when the concentrated protein 
was harvested from the Vivaspin centrifuge tube.  The glass 10 mL columns 
used to hold the affinity gel and the pumps used to run the supernatant 
through the affinity gels have not been included in the costs as they are 
reusable.   
 
From section 4.3.1 the mean yields from elution of 100 mL cell culture 
supernatant using acid or 3XFLAG elution respectively were 140 μg (in 170 
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μL) PBS and 148 μg (in 180 µL) PBS.  This means that for two applications 
through the one mL gel yields would be approximately 210 μg and 222 μg for 
acid and 3XFLAG elution respectively in approximately 340 µL PBS from 100 
mL cell culture supernatant.  As 1 mL KNIR will contain  500 μL of each sr-
LHR (at a starting concentration of 1 mg mL-1), then 300 mL cell culture 
supernatant applied to the columns in three 100 mL batches with the flow 
through material from each batch also applied to the column should be 
sufficient to produce 500 μL of sr-LHR at a concentration of 1 mg mL-1.  This 
will result in six applications to each affinity gel, which from section 4.3.2 is 
acceptable.  This will require two affinity gels, one for each sr-LHR as these 
cannot be purified on the same gels.  Twelve elutions with 3XFLAG peptide 
would use 600 µL peptide.  Acid costs are not included as these reagents are 
available in the laboratory at negligible cost (Table 4.2). 
 
Table 4.2 Comparison of equipment and reagent costs for acid and 3XFLAG 
eluted protein 
 
Equipment / Reagent Cost  Quantity used Total cost 
Vacuum filtration unit £51.01 for 12 2     £8.50 
Anti-FLAG M2 affinity gel   £89.60 mL-1 2 mL £179.20 
3XFLAG peptide £28 (5mg mL-1) 
(100 μg used per 
elution equals 
56p per elution) 
600 μL      £6.72 
Vivaspin centrifuge tubes £170 for 25 tubes 6 tubes   £40.80 
  Total 3XFLAG  £235.22 
  Total Acid £228.50 
 
Costs are to produce 1 mL KNIR containing 500 µL of sr-LHR-C and sr-LHR-
D. 
Assuming a band 6 Biomedical Scientist (BMS) on the midpoint of their scale 
performed the work then with 22% added ‘on costs’ for National Insurance 
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and pension payments the hourly rate would be £18.77.  Staff costs shown in 
Table 4.3 assumed that three purification ’sessions’ were performed, running 
two columns at the same time. 
 
Table 4.3 Staff costs to produce acid and 3XFLAG eluted protein 
 
Elution technique Time for two 
gels 
simultaneously 
(hours) 
Three procedures 
using two gels 
each time (hours) 
Total cost 
3XFLAG 4.66 13.98 262.41 
Acid 3.83 11.49 215.67 
 
Calculations are based on two columns being run at the same time with a total 
of 300 mL being applied to the columns twice. 
 
The process described above would produce 1 mL of KNIR but 9 mL is 
needed for NHSBT laboratories for one year.  The total yearly costs are 
shown in Table 4.4.  The saving using acid elution rather than using 3XFLAG 
for elution is £481 per year. 
 
Table 4.4 Total cost to prepare a year’s supply of inhibition reagent for 
NHSBT laboratory use 
 
Elution technique Equipment / 
reagent costs 
Staff costs (£) Total cost 
(£) 
3XFLAG 2116.98 2361.69 4478.67 
Acid 2056.50 1941.03 3997.53 
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4.3.5 Purification of culture supernatant containing sr-LHR-D 
Following the findings in this study the purification method of choice is to 
purify 100 mL cell culture supernatant on 1 mL affinity gels and elute with 
glycine-HCl pH 3.5, retain the flow through from this and then apply it to the 
same affinity gel again and elute again with the acid.  The gels can be used 
up to six times.  This method is preferred because there is a small annual cost 
saving and a saving in staff time.  It is also a method already in use in 
BITS/IBGRL for elution of other sr-proteins.  It would mean a more 
standardised approach to affinity gel purification in the laboratory. 
   
The work in this section has all been performed on sr-LHR-C, so this method 
was used to purify some sr-LHR-D from cell culture supernatants.  This work 
was performed by a member of staff following the protocol as described from 
this study. The affinity gels had already been used twice so the purifications 
performed represented the third and fourth uses of the affinity gels.  The mean 
yield (n=3) from the three gels was 287 μg for the first run through the gels 
and 181 μg for the flow through material.  Inhibition tests were performed 
using the first run through and the flow through samples.  A patient sample 
containing anti-KN previously shown to be inhibited by sr-LHR-D was tested 
with the six samples of purified sr-LHR-D and was inhibited (results not 
shown).  Sr-LHR-C and sr-LHR-D were tested by SDS-PAGE.  A Coomassie 
stained protein gel and a western blot using HRP-conjugated anti-FLAG are 
shown in Figure 4.12.   
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Figure 4.12 Comparison of protein and FLAG tagged protein in sr-LHR-C and 
sr-LHR-D preparations.  Sr-LHR-C and sr-LHR-D are shown on a) a protein 
stained SDS-PAGE gel and b) a western blot with HRP-conjugated anti-
FLAG. M=marker 
 
The double bands previously noted for sr-LHR-C can be seen in the protein 
stain but not with the anti-FLAG.  Sr-LHR-D appears as a diffuse band rather 
than a double band.  Sr-LHR-C appears to be about 65-80 kDa which is 
consistent with other results seen in this study, with a more prominent band at 
the bottom of the two bands seen.  In the western blot, sr-LHR-D appears to 
be a slightly larger molecule as the band has not migrated quite so far as sr-
LHR-C.  Both proteins are more uniformly stained with anti-FLAG so it 
appears that all of the protein is FLAG tagged which again seems to rule out 
BSA being present and causing the band seen in sr-LHR-C at approximately 
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65 kDa.  The diffuse bands and double band in sr-LHR-C might be explained 
by N-glycosylation of the sr-LHR-C and sr-LHR-D, especially as the CR1 
protein is glycosylated (Furtado et al., 2008) and glycosylated protein can 
migrate on SDS-PAGE gels as diffuse bands (Nguyen and Strong, 2007).  N-
glycosylation can potentially occur at any asparagine in the sequence 
asparagine-x-serine or threonine where x can be any amino acid except 
proline.  The potential sites for glycosylation for sr-LHR-C and sr-LHR-D are 
shown in Figure 4.13.  
 
              
              GHCQAPDHFL FAKLKTQTNA 
961 SDFPIGTSLK YECRPEYYGR PFSITCLDNL VWSSPKDVCK RKSCKTPPDP VNGMVHVITD   
1021 IQVGSRINYS CTTGHRLIGH SSAECILSGN TAHWSTKPPI CQRIPCGLPP TIANGDFIST  
1081 NRENFHYGSV VTYRCNLGSR GRKVFELVGE PSIYCTSNDD QVGIWSGPAP QCIIPNKCTP  
1141 PNVENGILVS DNRSLFSLNE VVEFRCQPGF VMKGPRRVKC QALNKWEPEL PSCSRVCQPP  
1201 PEILHGEHTP SHQDNFSPGQ EVFYSCEPGY DLRGAASLHC TPQGDWSPEA PRCAVKSCDD  
1261 FLGQLPHGRV LFPLNLQLGA KVSFVCDEGF RLKGSSVSHC VLVGMRSLWN NSVPVCEHIF  
1321 CPNPPAILNG RHTGTPSGDI PYGKEISYTC DPHPDRGMTF NLIGESTIRC TSDPHGNGVW  
1381 SSPAPRCELS VRAG 
 
        HCKTPE QFPFASPTIP INDFEFPVGT SLNYECRPGY FGKMFSISCL  
1441 ENLVWSSVED NCRRKSCGPP PEPFNGMVHI NTDTQFGSTV NYSCNEGFRL IGSPSTTCLV  
1501 SGNNVTWDKK APICEIISCE PPPTISNGDF YSNNRTSFHN GTVVTYQCHT GPDGEQLFEL  
1561 VGERSIYCTS KDDQVGVWSS PPPRCISTNK CTAPEVENAI RVPGNRSFFT LTEIIRFRCQ  
1621 PGFVMVGSHT VQCQTNGRWG PKLPHCSRVC QPPPEILHGE HTLSHQDNFS PGQEVFYSCE  
1681 PSYDLRGAAS LHCTPQGDWS PEAPRCTVKS CDDFLGQLPH GRVLLPLNLQ LGAKVSFVCD  
1741 EGFRLKGRSA SHCVLAGMKA LWNSSVPVCE QIFCPNPPAI LNGRHTGTPF GDIPYGKEIS  
1801 YACDTHPDRG MTFNLIGESS IRCTSDPQGN GVWSSPAPRC ELSVPA 
 
Figure 4.13 The potential N-glycosylation sites for sr-LHR-C and sr-LHR-D.  
These are marked in green on the amino acid sequence for sr-LHR-C (top) 
and sr-LHR-D (bottom).  N-glycosylation can occur at asparagine in the 
sequence asparagine-x –serine where x is any amino acid except proline. 
  
There are five potential N-glycosylation sites for sr-LHR-C and seven potential 
sites for sr-LHR-D, although Furtado et al., (2008) when modelling the CR1 
molecule speculated that there were three glycosylated sites for LHR-C and 
four for LHR-D for their best fit CR1 molecular model.  Glycoproteins often 
migrate at a different rate than anticipated from a calculated molecular weight 
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(Kelly and Barthmaier, 2003).  Both sr-LHR-C and sr-LHR-D would be 
approximately 50 kDa when calculated from the number of amino acids in 
each protein.  However, glycans attached to the protein can affect the 
migration of glycoproteins on SDS-PAGE gels.  The branched structures of 
glycans make the molecule more bulky and hydrophilic (Roth et al., 2012).  
The charge-to-mass ratio of the glycoprotein is also altered by the detergent 
used in the process.  The bulky shapes and the charge-to-mass ratios are not 
the same as those of the protein molecular marker used for estimation of size 
so molecular weight estimations can vary from the predicted size.  N-linked 
oligosaccharides may contribute 3.5 kDa or more per structure to the mass of 
the glycoprotein (Sigma-Aldrich, 2007).  This would mean that sr-LHR-C and 
sr-LHR-D would be approximately 60 kDa and 64 kDa with three or four N-
glycosylated sites respectively.  These masses correspond more closely to 
those observed in this study. 
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4.4 Discussion 
 
Purification using an affinity tag system has many advantages over other 
techniques, such as allowing a simple, one step process (Lichty et al., 2005).  
However, it is not a quick process and the affinity gels used can be very 
expensive.  In this study the effectiveness of various aspects of the 
purification process were investigated with the aim of determining the fastest, 
most cost effective route to produce a product of the required specificity and 
purity. Small volumes of cell culture supernatant were purified on the affinity 
gels and with the gel binding capacity stated as >0.6 mg protein mL-1 (Sigma-
Aldrich, 2010), one mL columns should have been sufficient to bind all the 
protein in the first run.  The studies using ‘spiked’ samples showed that 34% 
protein was not recovered on the first run through the column despite there 
being substantially less protein present than the gel’s binding capacity.  The 
cell culture supernatant had to be applied to the column a second time to 
achieve retrieval of 90% of the 3XFLAG tagged protein.  The affinity gel 
binding capacity was determined using FLAG-BAP protein (Sigma-Aldrich, 
2010).  This is a control protein used to determine the functional integrity of 
anti-FLAG M2 monoclonal antibodies.  It is probable that binding capacity will 
be different for different proteins due to the conformation of the proteins and 
hence accessibility of the FLAG tag on the protein to the bound anti-FLAG 
antibodies in the affinity gel.  Yield may be increased by passing the sample 
through the column again providing that the same protein is applied (Sigma-
Aldrich, 2010).  If more protein was produced and larger volumes of 
supernatant were purified then scaling up to using larger affinity gel columns 
and the cost effectiveness of this would need to be considered.  Passing the 
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supernatant through the column again did not appear to affect protein 
structure as purified flow through material inhibited KN antibodies 
successfully. 
 
Ideally, elution from affinity gels should not affect the protein tertiary structure 
so that biological activity is not affected (Terpe, 2003).  Two elution methods 
recommended for the FLAG system (Sigma-Aldrich, 2010) were investigated, 
elution with glycine-HCl at pH 3.5 (acid elution) and competitive elution using 
3XFLAG peptide.  Although statistically there was significant difference 
between the two methods the acid elution at pH 3.5 gave comparable yields to 
competitive elution using 3XFLAG peptide; it is also a faster process as the 
final column wash with glycine-HCl recommended to regenerate the column 
after peptide elution by removing any residual 3XFLAG peptide is not needed.  
There is no difference in SDS-PAGE mobility of eluted product after acid or 
peptide elution, as shown on the protein stained SDS-PAGE gels.   
 
The affinity gel has mouse IgG monoclonal Anti-FLAG M2 antibodies 
covalently attached to it.  However, the manufacturer warns that some of the 
M2 antibody may not be conjugated to the resin and may appear in acid 
eluates as heavy and light chains at 50-60 kDa and 20-25 kDa respectively 
when using anti-mouse conjugated antibody in western blots (Sigma-Aldrich, 
2010).  It is recommended that an acid wash is performed before using the gel 
to remove unconjugated antibody.  Although an acid wash was always 
performed on new gels prior to their first use, in this study it was found that 
acid eluates contained mouse immunoglobulin whilst 3XFLAG peptide eluates 
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did not.  When the same column was reused up to six times in this study, it did 
appear from the western blots with HRP-conjugated anti-mouse antibody that 
the amount of mouse antibody decreased the more times the column was 
used.  This could be explained if unconjugated antibody had gradually all 
been stripped off by successive uses of the gel and elution with acid.  It would 
be useful to increase the number of acid washes at the start of the process to 
see if the amount of mouse antibody eluted decreased.  The other explanation 
for the presence of mouse antibody in the eluates is that the acid process 
might be more likely to remove non-bound or loosely bound Ig.  With the 
limited testing performed on reusing the affinity gel it did appear that the 
amount of mouse Ig in the eluates did decrease gradually and also there 
seemed to be no loss of protein yield when the gel was used up to six times.  
There was no mouse immunoglobulin found with 3XFLAG competitive elution, 
a much milder technique, but elution with peptide would not reduce the loss of 
antibody from the affinity gel as an acid wash stage is employed in the 
process to regenerate the gel if it is to be reused.  However, competitive 
elution would reduce the contaminating mouse Ig in the sr-protein 
preparations. 
 
At least 10% of the population have some antibodies to animal proteins.  
These are most often human anti-mouse antibodies (HAMA).  It is not known 
why these develop but increased use of immune therapy with mouse derived 
monoclonal antibodies could partly be responsible (Klee, 2000).  HAMA have 
been reported to cause some problems with immunological tests (Kricka, 
1999) but they are not detected in serological tests like the indirect 
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antiglobulin test even though anti-human immunoglobulin is used.  This is 
most likely to be because they cannot bind to antigens on the red cell surface.  
If the inhibition reagent produced contained mouse Ig then any anti-mouse 
antibodies present in patient plasma may well be inhibited but this would not 
matter in serological testing as anti-mouse antibodies would never be 
detected anyway. 
 
Since it is unlikely that the double bands seen on the protein stained western 
blots (Figures 4.2, 4.8 and 4.11) are due to the presence of BSA then they are 
probably due to differences in glycosylation of the sr-protein.  CR1 is not O-
glycosylated but it does have N-glycosylation.  There are 25 potential sites for 
N-glycosylation on the CR1 molecule but experimentally only 14 are known to 
be occupied (Furtado et al., 2008).  There are five potential sites in LHR-C 
and seven in LHR-D as shown in Figure 4.13.  It is not known which sites are 
glycosylated but potentially LHR-D could have more glycosylation than LHR-C 
and this could account for the apparent larger size of LHR-D on SDS-PAGE.  
Both proteins probably have some glycosylation as the Mr for both would be 
about 50 kDa if calculated from number of amino acids, but sr-LHR-C appears 
to be around 65-80 kDa and sr-LHR-D to be slightly larger.  The slight 
difference in size was seen by other workers (Tamasauskas et al., 2001).  In 
their study, both sr-LHRs were seen as quite diffuse bands.  Sr-LHR-C 
appeared to be around 80-90 kDa and sr-LHR-D about 85-95 kDa. The way 
the proteins have migrated in the SDS-PAGE gels in this study too could 
indicate that sr-LHR-D has more glycosylation than sr-LHR-C.  The lower 
band seen in the sr-LHR-C protein on gel analysis might be due to non-
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glycosylated protein that is smaller and has migrated further.  It might be 
possible to resolve whether the proteins are glycosylated by treating them with 
deglycosylation reagents.  If they were deglycosylated then their gel mobility 
should be increased and they should be seen to run as more discrete bands 
on SDS-PAGE gels rather than the diffuse bands seen in this study (Edge, 
2003).  There may also be a loss of antigen activity after deglycosylation as 
carbohydrate molecules may be involved in the antibody to antigen binding 
process (Sigma-Aldrich, 2007).  As both sr-proteins have antigens that are 
recognised by KN specific antibodies it is probable that they are glycosylated 
as this important post-translational modification is involved in maintenance of 
protein conformation and activity (Roth et al., 2012).  The conformation of the 
protein affects the accessibility of antibodies to the peptide epitopes 
(Lisowska, 2002).   
 
 The advantage of using mammalian system for protein production is that they 
can produce correctly glycosylated protein (Ariescu and Owens, 2013).  BSA 
was found to be a very minor contaminant of the purified protein that did not 
cause problems for inhibition testing.  When the product is produced for use in 
RCI laboratories though, a quality control procedure would be needed to 
ensure consistency between batches.  As mouse Ig contamination could not 
be detected on SDS-PAGE gels stained for protein then this could also be a 
requirement for validation of each batch. 
 
The aims of this chapter were to optimise a procedure for purification of sr-
LHR-C and sr-LHR-D protein.  The defined procedure is to use 1 ml affinity 
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gel columns, to apply the cell culture supernatant and elute bound protein. 
and then reapply the culture supernatant to the column and elute again to 
maximise yield and to reduce costs by using acid for elution of protein from 
the column. 
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5.0 DIAGNOSTIC USE OF SOLUBLE RECOMBINANT PROTEINS 
5.1 Introduction 
Serological techniques have been well established for many years for the 
detection and identification of red cell antibodies.  This includes inhibition 
techniques where various substances have been used to neutralise antibody 
activity (Torres et al., 2010). Soluble recombinant (sr) proteins with blood 
group antigen specificity are becoming more widely available and techniques 
using these proteins are in development (Seltsam and Blasczyk, 2009).  In the 
future it may be possible to automate antibody identification using single sr-
antigens in assays where reaction of serum, plasma or blood samples with sr-
protein indicates both the presence and specificity of an antibody (Seltsam 
2011).  There is, however, immediate application of recombinant proteins 
such as sr-LHR-C and sr-LHR-D in Red Cell Immunohaematology (RCI) 
laboratories for the detection, identification and inhibition of specific 
antibodies, in this case antibodies directed against KN antigens. 
 
The aim of this part of the study was to develop a technique, using the sr-
LHR-C and sr-LHR-D proteins, to aid in investigation of KN related antibodies.  
Two techniques were developed using sr-LHR-C, sr-LHR-D and a mixture of 
both these sr-proteins now called the KN inhibition reagent (KNIR). An ELISA 
antigenicity test was optimised to use the individual soluble recombinant 
proteins to determine whether antibodies had KN specificity (Materials and 
Methods, section 2.4.3).  A positive ELISA result indicated that KN related 
antibodies were present in the test plasma whereas a negative result 
indicated that there were no antibodies with anti-KN specificity.  A new 
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inhibition technique was developed, based on an indirect antiglobulin test in 
commercial gel cards, to inhibit KN related antibodies.  In the RCI laboratory, 
successful introduction of the inhibition test will save time and effort in 
investigation of patients with KN antibodies and ultimately the care of patients 
with these antibodies will be improved because faster provision of suitable 
units for transfusion will be possible. 
 
A standard protocol for use of KNIR in an IAT test was developed and then 
evaluated by different members of staff for reproducibility and ease of use. 
The stability of the inhibition reagent developed was assessed after storage at 
4ºC and -30 ºC.   
 
5.2 Materials and Method Development 
5.2.1 Antigenicity ELISA 
This ELISA technique is described in Materials and Methods section 2.4.3.  
Sr-LHR-C and sr-LHR-D were used to coat plates at a concentration of 10 μg 
mL-1 sr-protein.  Samples known to contain anti-KN antibodies when originally 
tested (confirmed by MAIEA technique, Materials and Methods section 2.4.4) 
were obtained from NHSBT IBGRL Reference Serology Laboratory, located at 
Filton.  Seventeen samples were obtained frozen and were stored at -30 ºC 
until thawed for use.     
 
5.2.2 CAT Inhibition Test 
This test is detailed in Materials and Methods section 2.5.3.  To assess 
whether sr-LHR-C and sr-LHR-D protein would inhibit Knops antibodies the 
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MAIEA positive samples were tested.  Before performing the CAT inhibition 
test it was important to determine that Knops antibodies could still be detected 
by CAT.  All samples were tested by CAT against a 3 Cell Screening Set 
(Materials and Methods section 2.5.2).  Antibodies were still detectable by IAT 
in 16 out of the 17 samples.  Some of these samples were used to determine 
the optimum dilution of sr-protein to use for effective inhibition.  A series of 
doubling dilutions of sr-LHR-C and sr-LHR-D was prepared in PBS and then 
25 µL of each dilution was incubated with 25 µL patient plasma for 30 minutes 
at RT.  The samples were then tested by CAT with a 1 in 2 dilution of patient’s 
plasma in PBS included as a dilution control. 
 
Following determination of the optimum dilution for inhibition, the technique 
was refined to allow addition of sr-LHR reagent directly into patient plasma 
samples.  This was to reduce the amount of sr-LHR reagent needed per test 
and also to reduce any dilution effect on any antibodies present.  
 
5.2.3 Samples tested by CAT inhibition test 
Once the CAT inhibition test was optimised it was used to test the IBGRL 
samples and a further 30 patient samples obtained from various RCI 
laboratories (the majority from Filton RCI).  All of these samples were also 
tested by antigenicity ELISA. 
 
Samples containing clinically significant antibodies but not KN related 
antibodies were obtained from RCI Filton and tested by CAT inhibition to 
ensure that clinically significant antibodies were not inhibited by this test.  
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Those antibody specificities considered to be clinically significant by RCI are:  
Anti-D, -C, -E, -c, -e, - Fya, -Fyb, -Jka, -Jkb, -S, -s, -M, -Kpa and -Cw.  Where it 
proved possible three examples of each antibody were tested by CAT 
inhibition.  
 
5.2.4 Sr-reagent storage and stability testing 
Several batches of sr-LHR-C and sr-LHR-D were prepared at a concentration 
of 1 mg mL-1 in PBS, with no preservatives added, and frozen at -30 ºC for 
future use.  Individual reagents sr-LHR-C batch C157 and sr-LHR-D batch 
D157 were frozen on 10/5/12 and thawed and used in the CAT inhibition test 
on 16/4/14 nearly two years later and a KNIR reagent batch CD229 was 
frozen on 11/9/13 and also used on 16/4/14 after being frozen for seven 
months.  Other sr-LHR reagents were frozen and thawed up to three times.  
Sr-LHR-C batch C187 and sr-LHR-D batch D216 frozen on 1/11/12 and 
9/5/13 respectively were thawed, tested and refrozen on three occasions: 
28/03/14, 04/04/14 and 25/04/14 and used in the CAT inhibition test.  A batch 
of KNIR reagent was stored at 4 ºC with no added preservative and used in 
the CAT inhibition test 19 and 24 weeks after storage. 
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5.3 Results 
5.3.1 Antigenicity ELISA 
An antigenicity ELISA currently used in BITS/IBGRL for evaluation of other sr-
blood group antigens was used to test whether the sr-proteins produced in 
this study showed KN specificity, prior to developing a serological inhibition 
assay based on the IAT (section 5.3.2).  Eleven plasma samples (KN1 to 
KN11) confirmed as containing anti-KN antibodies by the MAIEA assay were 
used to validate this test.  They were initially tested in one antigenicity ELISA, 
results shown in Table 5.1a and six further MAIEA positive samples (KN12 to 
KN17) were tested in a separate ELISA, results shown in Table 5.1b.  Tests 
were performed in duplicate and a mean absorbance calculated.  A negative 
control was included which was a plasma sample containing a blood group 
antibody that was not KN related.  Two groups of absorbance values were 
obtained on both plates for both sr-proteins.  In one group the absorbance 
values were clustered around the negative control and in the other group they 
were around twice the negative control value so a cut-off of twice the mean 
negative control value for each plate was used to define the results as positive 
(above x2 negative control) and negative (below x2 negative control).  Using 
this cut-off five samples, KN9 to KN12 and KN17, gave positive results with 
sr-LHR-C but were negative with sr-LHR-D.  Twelve samples KN1 to KN8, 
KN11 and KN14 to KN16 gave opposite reactions i.e. they were positive with 
sr-LHR-D but negative with sr-LHR-C.  The reactions obtained with samples 
containing known KN related antibodies confirmed that the sr-proteins 
produced had KN antigenicity.  The 30 patient samples were also tested by 
this technique (section 5.3.3).   
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Table 5.1 Antigenicity ELISA results for samples containing KN related antibodies 
Table 5.1a 
Sample LHR-C1 
OD492 
LHR-C2 
OD492 
LHR-C 
Mean 
 
LHR-D1 
OD492 
LHR-D2 
OD492 
LHR-D 
Mean 
KN1 1.348 1.353 1.351 3.832 3.48 3.656 
KN2 0.827 0.809 0.818 3.245 3.030 3.138 
KN3 0.964 0.864 0.914 2.922 3.027 2.975 
KN4 0.587 0.593 0.590 2.728 2.793 2.761 
KN5 1.056 0.957 1.007 2.645 2.568 2.607 
KN6 1.363 1.267 1.315 3.571 3.395 3.483 
KN7 1.415 1.566 1.491 3.210 3.268 3.239 
KN8 1.650 1.711 1.681 3.555 3.504 3.530 
KN9 3.355 3.434 3.395 1.538 1.486 1.512 
KN10 3.127 3.335 3.231 0.985 1.074 1.030 
KN11 0.866 0.813 0.840 3.238 3.212 3.225 
Control 1.194 1.194 1.194 1.066 0.856 0.961 
    
Table 5.1b 
Sample LHR-C1 
OD492 
LHR-C2 
OD492 
LHR-C 
Mean 
 
LHR-D1 
OD492 
LHR-D2 
OD492 
LHR-D 
Mean 
 
KN12 2.928 2.928 2.928 1.273 1.072 1.173 
KN13 2.939 2.888 2.914 1.233 1.222 1.228 
KN14 1.394 1.631 1.513 2.938 3.010 2.974 
KN15 1.538 1.469 1.504 2.987 2.987 2.987 
KN16 1.170 1.579 1.375 3.001 2.983 2.992 
KN17 2.913 3.007 2.995 2.267 2.110 2.189 
Control 1.267 1.384 1.326 1.779 1.882 1.831 
 
Tables 5.1a and 5.1b show results for two antigenicity ELISAa.  Negative control 
sample was patient plasma lacking KN antibodies.  Tests were performed in 
duplicate (C1 and C2, D1 and D2) and a mean calculated.  A ratio of greater than 2:1 
of mean test absorbance value to negative control absorbance values indicates a 
positive result i.e. presence of KN related antibody.  In Table 5.1a absorbance > 
2.388 for LHR-C and > 1.862 for LHR-D indicates a positive result (shaded orange).  
In Table 5.1b absorbance > 2.652 for LHR-C and > 2.662 for LHR-D indicates a 
positive result (shaded orange). 
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5.3.2 CAT Inhibition test 
Three antibody samples KN12, KN13 and KN17, which gave positive 
reactions with sr-LHR-C but were negative with sr-LHR-D by ELISA, and three 
antibody samples KN14, KN15 and KN16,  which gave positive results with sr-
LHR-D but not sr-LHR-C, were incubated with decreasing concentrations of 
stock sr-LHR-C and sr-LHR-D respectively.  The starting stock material i.e. 
purified sr-LHR-C and sr-LHR-D contained 1 mg mL-1 protein.  Doubling 
dilutions of sr-LHR from 1/2 to 1/2048 (with plasma sample KN15 dilutions of 
sr-protein were extended to 1/8192) were prepared in PBS, 25 µL of these 
dilutions were incubated with 25 μL plasma for 30 minutes at RT.  After 
incubation a CAT test was performed using reagent cells shown to react with 
anti-KN antibodies.  A 1 in 2 dilution of plasma sample in PBS (25 μL plasma 
+ 25 µL PBS) was also included as a dilution control.  The results of these 
tests are shown in Table 5.2.   
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Table 5.2 Determination of dilution of sr-LHR to use for the CAT inhibition test 
 
Sample Inhibited 
with LHR- 
Plasma 
+ PBS 
2 4 8 16 32 64 128 256 512 1024 2048 4096 8192 
KN12 LHR-C 3 0 0 0 0 0 1 1 2 2 3 3 NT NT 
KN13 LHR-C 2 0 0 0 0 0 0 0 0 0 0 1 NT NT 
KN17 LHR-C 2 0 0 0 0 0 1 1 2 2 2 2 NT NT 
KN14 LHR-D 2 0 0 0 0 0 0 0 0 1 1 2 NT NT 
KN15 LHR-D 3 0 0 0 0 0 0 0 0 0 0 0 1 1 
KN16 LHR-D 2 0 0 0 0 0 1 2 2 2 2 2 NT NT 
 
Results of CAT inhibition test using doubling dilutions of sr-LHR reagents.  
Plasma + PBS indicates plasma diluted 1 in 2 in PBS.  Dilutions are 
expressed as reciprocals e.g. 2 = 1 in 2 dilution.  Grading of reactions on gel 
IAT card:  0=negative.  Positive reactions are graded 1 to 5 in order of 
increasing strength of reaction.  NT = not tested. 
 
There was wide variation in the concentration of sr-LHR protein that was 
needed to inhibit the KN antibodies.  The lowest concentration needed was 
seen for sample KN15 where a 1 in 2000 dilution, 0.5 µg mL-1, brought about 
inhibition.  Three samples KN12, KN17 and KN16 were inhibited up to a 1 in 
32 dilution or 30 µg mL-1 sr-LHR reagent.  Similar variability was seen when 
using sr-LHR-C or sr-LHR-D.  From these results a dilution of 1 in 20 (50 μg 
mL-1) was chosen for the inhibition test as at this dilution, for both sr-LHR 
reagents, inhibition was effected with all plasma samples tested and choice of 
this dilution erred on the side of caution rather than picking a 1 in 40 dilution.  
A gel card CAT inhibition test showing reactions of a representative sample, 
KN12, is shown in Figure 5.1.  
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Figure 5.1 Representative sample showing inhibition with dilutions of LHR-C.  
Doubling dilutions of LHR-C were prepared and incubated with patient plasma 
(KN12).  A score of 0 = negative.  Positive reactions are graded 1 to 5 in order 
of increasing strength.  A negative result indicating inhibition is seen at 1 in 32 
but from 1 in 64 onwards positive reactions can be seen indicating that the 
anti-KN antibody has not been inhibited at these dilutions.  Plasma diluted 1 in 
2 in PBS was included as a dilution control. 
 
5.3.3 Patient samples tested by CAT inhibition test 
When the optimum dilution of sr-LHR reagent had been decided then the 
technique for patient plasma testing was modified to make the 1 in 20 dilution 
directly into patient’s plasma.  This meant that a stock dilution could be made 
in one tube, for example to test inhibited patient plasma against a 10 cell ID 
panel 14 µL sr-LHR was added to 266 μL plasma for a 1 in 20 dilution.  After 
the inhibition incubation stage, 25 μL of this mixture was then added to each 
well of a gel card containing 50 µL test cells.  The amount of sr-LHR per test 
was 1.25 µg. 
 
A total of 47 samples were tested (including the 17 IBGRL samples tested in 
sections 5.3.1 and 5.3.2) by CAT inhibition test.  Prior to performing the 
inhibition test they were tested by IAT to confirm that antibody could still be 
detected as KN antibodies can become undetectable on storage.  In the CAT 
Plasma         2              4            8            16         32          64           128       256          512         1024      2048+ 
+ PBS                               (reciprocal dilutions of LHR-C)  
   3             0              0            0            0           0            1             1            2             3             3            3 
                   Reaction strengths    
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inhibition test they were tested with individual sr-LHR reagents and also a 
mixture of the two reagents, the KNIR reagent.  This contained equal volumes 
of stock sr-LHR-C and sr-LHR-D, so contained 500 μg mL-1 of each protein 
and was therefore diluted 1 in 10 for use.  The peptide ELISA was also 
performed on all the samples using individual sr-LHR reagents.  The pattern 
of reactions fell into four groups.  Those inhibited by sr-LHR-C alone (group 
one – 15 samples), those inhibited by LHR-D alone (group two – 25 samples) 
and those not inhibited at all (group three –five samples).  In these groups 
there was agreement between the results obtained by ELISA and CAT 
inhibition test, where CAT inhibition was performed, as in one sample (KN9) 
antibody was no longer detectable by CAT (it was detectable by ELISA).  The 
last group (group four – two samples) reacted with both sr-proteins by ELISA. 
 
5.3.3.1 Group one samples 
These were inhibited by sr-LHR-C and KNIR and reactive with sr-LHR-C only 
by peptide ELISA.  Five samples (KN9, KN10, KN12, KN13 and KN17) were 
positive by MAIEA and therefore known to contain KN related antibodies.  
However, antibodies were no longer detectable in sample KN9 by CAT. Two 
patient samples were reported to contain KN related antibodies: sample 
2904A contained anti-McCa and sample 4337G contained anti-Sc2 (although 
the amount of sample 4337G was limited so it was only tested with KNIR by 
CAT inhibition).  The other samples contained antibodies that had reacted like 
HTLA antibodies in serological testing, results are shown in Table 5.3. 
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Table 5.3 Results of CAT, antigenicity ELISA and CAT inhibition for group one 
samples. 
 
 CAT 
Screening cells 
ELISA 
Reactions with 
CAT inhibition test 
Inhibition with  
Notes 
 1 2 3 LHR-C LHR-D LHR-C LHR-D KNIR PBS  
KN9 0 0 0 + 0 NT NT NT NT MAIEA positive 
KN10 1 2 1 + 0 Y N Y N MAIEA positive 
KN12 1 3 1 + 0 Y N Y N MAIEA positive 
KN13 0 2 1 + 0 Y N Y N MAIEA positive 
KN17 0 0 2 + 0 Y N Y N MAIEA positive 
4337G 1 3 0 + 0 NT NT Y N Limited sample 
anti-Sc2/K 
8204R 1 3 3 + 0 Y N Y N  
2904A 2 3 3 + 0 Y N Y N Anti-McC
a
 
5635H 3 2 3 + 0 Y N Y N  
5839I 0 1 2 + 0 Y N Y N  
0598L 2 0 0 + 0 Y N Y N  
92241 3 1 0 + 0 Y N Y N  
05452 0 1 2 + 0 Y N Y N  
1587B 2 3 2 + 0 Y N Y N  
5948K 2 1 2 + 0 Y N Y N  
 
Group one samples tested by CAT using a 3 Cell Screening Set.  Positive 
reactions for the CAT test are graded 1 to 5 in order of increasing strength or 
0 for no reaction.  For the antigenicity ELISA, + = positive reaction 0 = 
negative reaction.  In the CAT inhibition test PBS is a dilution control, Y = 
inhibition, N = no inhibition, NT = not tested, KN9 because antibody activity 
was no longer detectable by CAT and sample 4337G due to being a limited 
sample.    Previously defined antibody specificities or if positive by MAIEA test 
is indicated in the final column.   
 
The results of CAT inhibition testing performed on sample 2904A as a 
representative sample are shown in Figure 5.2.  Sample 2904A was known to 
contain a KN antibody, anti-McCa. A 3 Cell Screening Set was used to 
perform the test, rather than a full ten cell ID panel.  Plasma was diluted with 
the same volume of PBS as sr-LHR reagents as a dilution control.  Negative 
reactions were seen after incubation of patient’s plasma with sr-LHR-C and 
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the KNIR reagent (containing sr-LHR-C) for this sample indicating that the 
antibody had been inhibited.  Positive reactions are still seen after incubation 
with sr-LHR-D, indicating that this reagent did not inhibit the anti-McCa.  There 
are no underlying antibodies as shown in the negative reactions obtained with 
all three screening cells after incubation with sr-LHR-C.  The PBS dilution 
control gave positive reactions as expected. 
   
 
Figure 5.2 Gel card CAT inhibition test for a representative group one sample.  
Results of testing sample 2904A by CAT inhibition test using a 3 Cell 
Screening Set, labelled screening cell SC1, SC2 and SC3.  The PBS dilution 
control gave positive reactions with all three screening cells.  This activity was 
inhibited on incubation with sr-LHR-C and KNIR reagent but positive reactions 
were still obtained after incubation with sr-LHR-D.  A score of 0 = negative.  
Positive reactions are graded 1 to 5 in order of increasing strength. 
 
For the four MAIEA positive samples (KN10, KN12, KN13 and KN17) the CAT 
inhibition test was repeated with sr-LHR-D but with 25 μL patient plasma 
inhibited with 25 µL sr-LHR-D (starting concentration 1 mg mL-1).  The 
antibodies were still not inhibited with sr-LHR-D even though this represented 
a ten fold increase of sr-LHR-D i.e. 12.5 μg sr-LHR-D per test (results not 
shown). 
 
 0         0         0        2         3         3           0         0         0        2         3        3 
    sr-LHR-C                   sr-LHR-D               sr-LHR-C+D                  PBS                        
                                      (KNIR)                     
      SC1      SC2      SC3       SC1      SC2      SC3         SC1     SC2       SC3      SC1      SC2     SC3 
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5.3.3.2 Group two samples 
These were inhibited by sr-LHR-D and KNIR reagent but not by sr-LHR-C.  
They were positive in the ELISA with sr-LHR-D but not sr-LHR-C.  Twelve of 
these samples had anti-KN antibodies as determined by MAIEA test.  Two 
others had been reported as having anti-Kna and McCa specificity; one 
contained anti-McCa alone.  One sample contained anti-Yka and two others 
contained a mixture of anti-Kna and anti-K.  The rest had been referred for 
investigation because they had reacted like HTLA antibodies during 
investigation in RCI.  The results are shown in Table 5.4.  For one sample, 
4033B, the reactions obtained when tested against a standard 10 cell ID 
panel of reagent red cells, used for antibody identification, are shown in Table 
5.5.  An antibody with probable anti-K specificity could be seen as reactions 
with K+ cells (cells 2, 6 and 7) were stronger than other reactions seen with 
the panel.   However, other reactions were obtained against panel cells 1, 3, 
5, 8 and 10.  Following RCI policy at least two positive and two negative 
reactions are required to determine antibody specificity.  It would not be 
possible from the results of the CAT test to decide whether these reactions 
were due to the presence of other antibodies.  RCI has access to another two 
antibody identification and these would both need to have been set up to 
exclude the presence of anti-S, -s, -Fya, -Fyb, -Jka and -Jkb i.e. clinically 
significant antibodies.  The inhibition test has inhibited these reactions against 
the first panel cells so they are likely to have been due to an anti-KN antibody 
present together with the anti-K.  The anti-K can be clearly seen in the 
inhibited plasma and it can be confirmed that no more clinically significant 
antibodies are detectable in the plasma.  In routine use this would 
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considerably simplify testing samples with mixtures of antibodies like sample 
4033B. 
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Table 5.4 Results of CAT, antigenicity ELISA and CAT inhibition for group two 
samples. 
 
 CAT 
Screening cells 
ELISA 
Reactions with 
CAT inhibition test 
Inhibition with 
Notes 
 1 2 3 LHR-C LHR-D LHR-C LHR-D KNIR PBS  
KN1 1 2 1 0 + N Y Y N MAIEA positive 
KN2 1 1 1 0 + N Y Y N MAIEA positive 
KN3 1 2 1 0 + N Y Y N MAIEA positive 
KN4 1 2 0 0 + N Y Y N MAIEA positive 
KN5 0 1 0 0 + N Y Y N MAIEA positive 
KN6 1 2 0 0 + N Y Y N MAIEA positive 
KN7 1 1 0 0 + N Y Y N MAIEA positive 
KN8 2 2 1 0 + N Y Y N MAIEA positive 
KN11 2 3 1 0 + N Y Y N MAIEA positive 
KN14 0 2 0 0 + N Y Y N MAIEA positive 
KN15 1 0 3 0 + N Y Y N MAIEA positive  
KN16 1 0 2 0 + N Y Y N MAIEA positive 
47581 3 0 3 0 + N Y Y N Anti-Kn
a
/McC
a 
93683 4 5 3 0 + N Y Y N Ant-E/C
w 
5786E 3 3 3 0 + N Y Y N Anti-Yt
a
/E/Fy
a
/Yk
a 
65986 0 0 3 0 + N Y Y N  
5804P 2 3 2 0 + N Y Y N Anti-Kn
a
/K 
4033B 2 1 3 0 + N Y Y N Anti-Kn
a
/K 
2555K 3 3 3 0 + NT NT Y N Limited sample 
Anti-Kn
a
/McC
a 
2929T 1 2 2 0 + N Y Y N Anti-McC
a
 
54967 3 3 3 0 + N Y Y N  
5532V 2 3 2 0 + N Y Y N  
5619H 3 3 3 0 + N Y Y N  
57359 1 0 2 0 + NT NT Y N Limited sample 
5948K 0 3 0 0 + N Y Y N  
 
 
Group two samples tested by CAT using a 3 Cell Screening Set.  Positive 
reactions for the CAT test are graded 1 to 5 in order of increasing strength or 
0 for no reaction.  For the antigenicity ELISA, + = positive reaction 0 = 
negative reaction  In the CAT inhibition test PBS is a dilution control, Y = 
inhibition, N = no inhibition, NT = not tested, 2555K and 57359 because they 
were limited samples.    Previously defined antibody specificities or if positive 
by MAIEA test is indicated in the final column. 
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Table 5.5 Sample 4033B tested with a standard 10 cell ID panel used in RCI for antibody identification.    
 
NHSBT Reagents  Panel 1 Antibody Investigation Worksheet  
Sample name  Requestor  Database ref No.  Tested by  
Date of Birth  Hosp no  Sample No. 4033B Date Tested  
Product Lot No. Product Lot No. Product Lot No. Product Lot No. 
Panel in Alsevers R144 3254 Panel in CellStab R154 3254 Panel in CellMedia NA Panel in LISP R146 3254 
Panel Papainised in Alsevers R143 3254 Panel Papainised in CellStab R153 3254 Panel Papainised in CellMedia NA EXPIRY DATE: 2012.09.20 
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CAT Patient’s plasma plus:  
LHR
-C 
LHR 
-D 
KNIR PBS 
1 R1
w
R1 0 + 0 + 3 0 0 + 0 0 + 0 + 0 + weak Lub 2 2 0 0 2  
2 R1R1 + 0 + 0 0 0 + + 0 0 0 + 0 + 0  3 3 3 3 3  
3 R2R2 0 + 0 + 2 0 0 + 0 + 0 + 0 0 +  1 1 0 0 1  
4 r’r 0 + 0 + 0 0 0 + 0 + 0 0 + + +  0 0 0 0 0  
5 r’’r + 0 + 0 0 0 0 + 0 0 + 0 + + 0  2 2 0 0 2  
6 rr + + 0 + 2 0 + 0 0 + 0 0 + + 0  3 3 3 3 3  
7 rr 0 + 0 + 0 0 + + 0 0 + + 0 0 + Ch- 3 3 3 3 3  
8 rr + 0 + 0 3 0 0 + + + 0 0 + 0 +  1 1 0 0 1  
9 rr 0 + + 0 4 0 0 + 0 0 + + 0 + 0  0 0 0 0 0  
10 rr + 0 0 + 4 + 0 + 0 + 0 0 + 0 +  1 1 0 0 1  
Auto                        
Neat plasma from sample 4033B reacted with all panel cells tested by CAT except cells 4 and 9.  Incubation prior to testing with sr-LHR-D on its own or when 
contained in cocktail KNIR (sr-LHR-C and sr-LHR-D) shows that an antibody with KN specificity is present in the plasma (reacting with cells: 1, 3, 5, 8 and 10 
and when this is removed it is easy to identify anti-K also present reacting with K+ cells numbers: 2, 6 and 7 (shaded in grey)).  No other antibodies were 
present.  A score of 0 = negative.  Positive reactions are graded 1 to 5 in order of increasing strength.  PBS indicates a dilution control.
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Another sample in group two contained two clinically significant antibodies, 
anti-E and anti-Cw, as well as an antibody with KN specificity.  Testing the 
plasma by CAT, using the 3 Cell Screening Set, shows reactions with all three 
screening cells but after inhibition only positive reactions with cells 1 (Cw 
positive) and cell 3 (E positive) are seen.  The gel card results for this sample, 
93683, are shown in Figure 5.3. 
 
 
Figure 5.3 Gel card results for a sample containing multiple antibodies.  A 
column agglutination gel card showing reactions of CAT and CAT inhibition 
testing for sample 93683.  CAT shows reactions with all three screening cells.  
After inhibition with KNIR reagent the reactions with the screening cell 2 
disappear.  Reactions with screening cells 1 and 3 remain as they are due to 
anti-Cw reacting with Cw positive screening cell 1 and anti-E reacting with E 
positive screening cell 3.  Reactions with screening cell 2 were due to anti-KN 
antibody that was inhibited by KNIR reagent.  A score of 0 = negative.  
Positive reactions are graded 1 to 5 in order of increasing strength. 
 
For the twelve MAIEA positive samples (KN1 to 8, KN11, KN14 to KN16) the 
CAT inhibition test was repeated with sr-LHR-C but with 25 μL patient plasma 
inhibited with 25 µL sr-LHR-C (starting concentration 1 mg mL-1).  The 
Reaction 
strength      4                     3                      5                  4                      0                   5 
Reactions    
due to: anti-C
w
+KN         -KN                 -E+KN           -C
w
                                        -E 
 
Sample 93683 tested by: 
                         CAT     CAT Inhibition 
SC1            SC2         SC3            SC1                   SC2                  SC3 
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antibodies were still not inhibited with sr-LHR-C even though this represented 
a ten fold increase of sr-LHR-C i.e. 12.5 μg sr-LHR-C per test. 
 
5.3.3.3 Group three samples 
The antibodies in these samples were not inhibited in the CAT inhibition test 
and were negative by ELISA.  None of these antibodies had been defined as 
KN antibodies but their reactions by IAT were non-specific and they were 
referred for testing as possible KN antibodies.  Results are shown in Table 
5.6.  During investigation in RCI, sample 3387C had been tested against 
reagent ID panel cells that had been treated with 2-aminoethylisothiouronium 
(AET), because anti-KN specificity was suspected.  KN antigens are 
destroyed by AET and this technique can be used in the laboratory to help 
identify KN antibodies.  In this case, however, the antibody did not appear to 
be KN related from the results of the ELISA and CAT inhibition. 
 
Table 5.6 Results of CAT, antigenicity ELISA and CAT inhibition for group 
three samples.  
 
 
CAT 
Screening cells 
ELISA 
Reactions with 
CAT inhibition test 
Inhibition with  
Notes 
 1 2 3 LHR-C LHR-D LHR-C LHR-D KNIR PBS  
3387C 3 3 3 0 0 N N N N  
42106 0 2 1 0 0 N N N N  
8385M 1 0 0 0 0 N N N N Anti-C 
4984S 2 2 2 0 0 N N N N  
59215 3 3 2 0 0 N N N N  
 
Group three samples, results of antibody screening by CAT using a 3 Cell 
Screening Set.  Positive reactions for the CAT test are graded 1 to 5 in order 
of increasing strength or 0 for no reaction.  For the ELISA, + = positive 
reaction 0 = negative reaction.  In the CAT inhibition test PBS is a dilution 
control, Y = inhibition, N = no inhibition.  Previously defined antibody 
specificities or if positive by MAIEA test is indicated in the final column. 
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Further investigation was performed on sample 3387C; full ID panels were 
tested against inhibited plasma (Table 5.7).  Referral to IBGRL at Filton for 
more specialist investigation revealed that this antibody had anti-AnWj 
specificity.  These antibodies are clinically significant as examples have 
caused severe haemolytic transfusion reactions (Xu et al., 2012).  AnWj is a 
high frequency antigen occurring at >99% in the Caucasian population (Xu et 
al., 2012).  The antigen is also destroyed by AET treatment.  Prior to inhibition 
testing this antibody had been reported by RCI as a KN related antibody 
based on the serological pattern of reactions by CAT i.e. reacting with all cells 
and the fact that it did not react with AET treated panel cells.  The specificity 
was amended in RCI and a new report sent to inform the hospital that anti-
AnWj had been confirmed.  Fortunately, the patient had not required 
transfusion.   
 
Of the other samples in group three, sample 42106 was found to contain anti-
Csa.  The Csa antigen is another high frequency antigen and the antibody 
reacts in a very similar way to KN antibodies and it is often included in the 
HTLA category.  The antibody is not clinically significant (Moulds, 2010).  One 
sample was found not to have any detectable antibodies, and a further sample 
contained anti-C but no other antibodies.  The anti-C could be seen in the 
screening results as only SC1 is C positive and this is the only cell this sample 
reacted with.  It did not react typically like an HTLA antibody.  The final two 
samples in this group were determined to contain non-specific ‘cold reacting’ 
antibodies.  Pre-warming cells and plasma before performing the IAT can stop 
these samples from giving positive reactions by IAT.  These are normally due 
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to the antibodies fixing complement and then this being detected due to anti-
complement contained in the AHG reagent. They are not clinically significant 
antibodies. 
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Table 5.7 Sample 3387C tested with a standard 10 cell ID panel used in RCI for antibody identification.    
NHSBT Reagents  Panel 1 Antibody Investigation Worksheet  
Sample Name  Requestor  Database ref No.  Tested by  
Date of Birth  Hosp no  Sample No. 4033B Date Tested  
Product Lot No. Product Lot No. Product Lot No. Product Lot No. 
Panel in Alsevers R144 3254 Panel in CellStab R154 3254 Panel in CellMedia NA Panel in LISP R146 3254 
Panel Papainised in Alsevers R143 3254 Panel Papainised in CellStab R153 3254 Panel Papainised in CellMedia NA EXPIRY DATE: 2012.09.20 
 Rh M N S s P1 Lu
a
 K k Kp
a
 Le
a
 Le
b
 Fy
a
 Fy
b
 Jk
a
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b
 Other 
CAT Patient’s plasma plus: AET 
LHR
-C 
LHR 
-D 
KNIR PBS 
1 R1
w
R1 0 + 0 + 3 0 0 + 0 0 + 0 + 0 + weak Lub 2 2 2 2 2 0 
2 R1R1 + 0 + 0 0 0 + + 0 0 0 + 0 + 0  2 2 2 2 2 0 
3 R2R2 0 + 0 + 2 0 0 + 0 + 0 + 0 0 +  2 2 2 2 2 0 
4 r’r 0 + 0 + 0 0 0 + 0 + 0 0 + + +  2 2 2 2 2 0 
5 r’’r + 0 + 0 0 0 0 + 0 0 + 0 + + 0  2 2 2 2 2 0 
6 rr + + 0 + 2 0 + 0 0 + 0 0 + + 0  2 2 2 2 2 0 
7 rr 0 + 0 + 0 0 + + 0 0 + + 0 0 + Ch- 2 2 2 2 2 0 
8 rr + 0 + 0 3 0 0 + + + 0 0 + 0 +  2 2 2 2 2 0 
9 rr 0 + + 0 4 0 0 + 0 0 + + 0 + 0  2 2 2 2 2 0 
10 rr + 0 0 + 4 + 0 + 0 + 0 0 + 0 +  1 0 1 1 1 0 
Auto                  0      
Neat plasma from sample 3387C reacted with all panel cells tested by CAT except patient’s own cells, designated as ‘Auto’ in the panels (antibody is 
therefore an alloantibody).  Incubation of patient’s plasma with sr-LHR-C, sr-LHR-D, KNIR (sr-LHR-C and sr-LHR-D) or PBS prior to testing by CAT shows no 
antibody inhibition.  Treatment of panel cells with AET and then testing by CAT shows no positive reactions i.e. the antigen on the panel cells must have been 
destroyed by the AET treatment. 
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5.3.3.4 Group four samples 
Only two samples reacted with both sr-LHR reagents.  Neither sample reacted 
by CAT so neither were tested by CAT inhibition.  Results are shown in Table 
5.8.   
Table 5.8 Results of CAT, antigenicity ELISA and CAT inhibition for group four 
samples. 
 
 
CAT 
Screening cells 
ELISA 
Reactions with 
CAT inhibition test 
Inhibition with  
Notes 
 1 2 3 LHR-C LHR-D LHR-C LHR-D KNIR PBS  
42874 1 0 0 + + NT NT NT NT Ant-C+E+M+S+ 
Co
b
+Kn
a
/McC
a 
57375 0 0 0 + + NT NT NT NT KN related 
 
Table 5.8 Group four samples, results of antibody screening by CAT using a 3 
Cell Screening Set.  Positive reactions for the CAT test are graded 1 to 5 in 
order of increasing strength or 0 for no reaction.  For the ELISA, + = positive 
reaction 0 = negative reaction.  In the CAT inhibition test PBS is a dilution 
control,  NT = not tested.  Previously defined antibody specificities or if 
positive by MAIEA test is indicated in the final column. 
 
The ELISA was repeated and these results were confirmed.  Sample 42874 
was tested by IAT in RCI and only the anti-C was detected as seen here with 
the weak positive result by CAT against SC1, the only C positive cell.  Sample 
57375 was reported as an HTLA antibody possibly KN related.   It appears 
that the ELISA detected KN related antibodies when they were at a level that 
was undetectable by IAT as seen in these two samples and sample KN9. 
 
5.3.4 Testing clinically significant antibodies by CAT inhibition test 
As well as proving that the KNIR reagent inhibited KN antibodies, it was 
important to show that no clinically significant antibodies were inhibited.  
Patient samples containing clinically significant antibodies were tested by CAT 
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inhibition test.  Three examples of each antibody were tested, where possible.  
Reactivity for all antibody specificities tested was not affected by incubation 
with the inhibition reagent.  Representative results are shown in Figure 5.3, 
where it can be seen the clinically significant antibodies, anti-E and anti-Cw 
are not inhibited by KNIR reagent.  Numbers of each antibody tested by CAT 
Inhibition are listed below in parentheses: Anti-D (3), anti-C (3), anti-E (3), 
anti-c (3), anti-e (3), anti-K (3), anti-Fya (3), anti-Fyb (2), anti-Jka (3), anti-Jkb 
(1), anti-S (3), anti-s (3), anti-M (3) anti-Cw (3) and anti-Kpa (3).   
 
Some of the above antibodies were also tested by antigenicity ELISA.  All 
gave negative results:  anti-D (2), anti-C (1), anti-E (2), anti-c (1), anti-e (2), 
anti-K (1), anti-Fya (2), anti-Jka (2) anti-Jkb (1), anti-s (1), anti-M (1) and anti-
Cw (1). 
 
5.3.5 Inhibition test validation 
Prior to distribution of KNIR reagent to RCI laboratories a validation process 
will be followed for each batch to ensure that the reagent is fit for purpose and 
to reduce inter assay variability.  This will include ensuring that: the protein 
concentration is 1 mg mL-1; BSA and mouse IgG contamination is assessed; 
protein stained SDS-PAGE gels show a protein band at the correct molecular 
mass and an unrelated sr-blood group antigen does not inhibit KN related 
antibodies.  Inhibition will be determined using known examples of KN related 
antibodies and clinically significant antibodies.  Each time KNIR is used it will 
be a requirement to use a PBS diluted plasma sample as a dilution control.    
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A standard operating procedure (SOP) has been developed (Appendix 1) to 
describe the CAT inhibition test and use of KNIR reagent.  This was tested by 
staff in RCI and IBGRL.  RCI staff performed the CAT inhibition test in gel 
cards.  IBGRL use glass tubes routinely for IAT testing rather than commercial 
gel cards.  They performed their testing following the SOP but used tubes 
instead of gel cards.  Whether using gel cards or tubes the results obtained by 
other members of staff were in 100% concordance with those expected.   
 
5.3.6 Storage of sr-reagents and KNIR 
Results of testing sr-LHR-C and sr-LHR-D reagents and a KNIR reagent 
which had all been frozen and thawed are shown in Table 5.9.  Sr-LHR-C 
batch C157 and sr-LHR-D batch D157 were frozen for nearly two years and 
KNIR reagent batch CD229 was frozen for seven months.  These reagents 
were thawed and used in CAT inhibition tests to inhibit KN antibodies in two 
samples: group one sample 5635H and group two sample 5786E.  Inhibition 
results were as expected in that the KN related antibody in sample 5635H was 
inhibited with sr-LHR-C but not sr-LHR-D and opposite results were seen for 
sample 5786E where the antibody was inhibited with sr-LHR-D but not sr-
LHR-C.  The KNIR reagent mixture inhibited both samples as expected. 
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Table 5.9  Effect on inhibition using frozen / thawed batches of reagent 
Sample number PBS dilution 
control 
sr-LHR-C 
C157 
sr-LHR-D 
D157 
KNIR 
CD229 
5635H 1 0 1 0 
5786E 3 3 0 0 
 
Batches C157 and D157 had been frozen for nearly two years, KNIR reagent 
batch CD229 had been frozen for seven months.  There was no deterioration 
in their ability to inhibit KN antibodies.  Positive reactions for the CAT test are 
graded 1 to 5 in order of increasing strength or 0 for no reaction. 
 
Samples frozen and thawed up to three times were still able to inhibit KN 
antibodies.  Sr-LHR-C batch C187 and sr-LHR-D batch D216 were frozen, 
thawed and tested on three occasions.  All testing results were as expected 
compared to previous testing.  Unfortunately, it was not possible to test the 
same patient samples again on each occasion due to limited sample sizes but 
at least one sample from group one (inhibited with sr-LHR-C but not sr-LHR-
D) and one sample from group two (inhibited with sr-LHR-D but not sr-LHR-C) 
were tested on each date.  Results of CAT inhibition testing on samples 
containing KN antibodies are shown in Table 5.10. 
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Table 5.10 Effect of freeze-thawing reagents used to inhibit KN antibodies 
tested by CAT inhibition 
 
Sample 
number 
25/02/14 28/03/14 04/04/14 
 Plasma C187 D216 Plasma C187 D216 Plasma C187 D216 
5893I 2 0 2       
2929T 3 3 0       
8204R    1 0 1    
KN3    2 2 0    
KN10       1 0 1 
5619H       3 2 0 
 
The same sample batches C187 (sr-LHR-C) and D216 (sr-LHR-D) was 
thawed, used and frozen again on the dates shown.  There was no 
deterioration in ability of the sr-LHR reagent samples frozen and thawed up to 
three times to inhibit KN antibodies.  Samples 58931, 8204R and KN10 are 
group one samples.  Samples 2929T, KN3 and 5619H are group two 
samples.  Positive reactions for the CAT test are graded 1 to 5 in order of 
increasing strength or 0 for no reaction. 
 
A batch of the KNIR inhibition reagent was stored refrigerated at 4ºC with no 
added preservative.  It was used at 19 weeks with no decrease in reactivity.  
However, after 24 weeks storage it failed to inhibit known KN antibodies. 
 
5.3.7 Time savings if the CAT inhibition was used to investigate patient 
samples in NHSBT laboratories 
 
No cost savings could be determined for RCI if the KNIR reagent was used.  
This is because reducing the complexity of investigation with use of the KNIR 
reagent would currently result in passing on a reduced charge for work to our 
customers.  However, RCI has committed to an Operational Improvement 
Programme to become more efficient and save “hands-on” testing time.  Time 
savings are estimated to be two hours per sample investigated.  The KNIR 
reagent supplied would allow up to 30 ID panels to be set up which is based 
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on the current number of cases investigated in RCI that would benefit from 
use of the KNIR reagent (personal experience).  Assuming 30 cases with a 
reduction in two hours testing time, this would be 60 hours per RCI laboratory 
saved per year, 480 hours for RCI per year for the eight RCI laboratories.  
This time saving would count towards RCI achieving its planned time savings 
and would be for BMS band 6 time.  
 
Use of the KNIR reagent would mean that Filton RCI laboratory would no 
longer prepare an AET treated panel which would save approximately one 
hour per week.  There would also be less reliance on the use of rare cells 
which in some instances and in some laboratories may not be available for 
use.   
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5.4 Discussion 
It had been shown that a complete sr-CR1 protein could be used to inhibit KN 
system antibodies (Moulds and Rowe, 1996).  Later workers speculated that 
using smaller parts of the CR1 protein for inhibition may be more efficient and 
cost effective.  They showed that individual sr-LHRs of CR1 could be 
produced and that sr-LHR-D and to a lesser extent sr-LHR-C could inhibit 
most examples of antibodies with KN specificity (Tamasauskas et al., 2001).  
In this study sr-LHR-C and sr-LHR-D proteins were produced, purified and 
then used in two techniques to identify and inhibit KN system antibodies.  
Individual sr-LHR-C and sr-LHR-D were used in both the antigenicity ELISA 
and CAT inhibition test and also a mixture of the two LHRs, KNIR, was used 
in the inhibition test.   
 
The inhibition test using sr-CR1 has previously been performed in a tube IAT 
test using 6 µg sr-CR1 per test (Moulds and Rowe, 1996).  Inhibition using 
individual sr-LHRs was also based on a tube IAT test but the concentration of 
individual sr-LHRs used for inhibition was not known.  Inhibition was brought 
about by incubation of equal volumes of sr-LHR and patient plasma containing 
KN antibodies (Tamasauskas et al., 2001).  In this current study, a 
commercial gel card based IAT, was used for the CAT inhibition test using 
1.25 µg sr-LHR to effect inhibition.  During the course of this current study 
another group also investigated inhibition of KN antibodies, although they only 
produced and used sr-LHR-D (Seltsam et al., 2014).  They distributed their 
reagent to several laboratories to evaluate and after the inhibition incubation 
stage some of the laboratories used a tube IAT test, whilst others used a gel 
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card IAT test as in this study.  Their LHR-D reagent was supplied either on its 
own or as part of a mixture containing other sr high frequency blood group 
antigens.  Inhibition was performed using 0.5 to 1.5 μg sr-LHR per test.  
Independently, both this current study and Seltsam’s work showed that a 
similar concentration of LHR protein could be used to bring about inhibition 
when based on a 30 minute incubation time of sr-reagent with patient’s 
plasma.  A smaller amount of sr-LHR reagent than complete sr-CR1 could be 
used for inhibition of KN antibodies. 
 
In their study, Seltsam et al. (2014) found that when using the single sr-LHR-D 
reagent 12 out of 14 samples were inhibited.  On increasing the amount of 
inhibition reagent used from 0.5 µg to 1.5 μg they found that the other two 
antibodies were also inhibited.  Using their mixture of other sr-proteins which 
included sr-LHR-D, 21 examples of KN related antibodies were successfully 
inhibited, three samples needed 2 μg or more to effect inhibition, whilst six KN 
related antibodies were not inhibited even with 10 µg of protein.  In this 
current study there were no examples found where increasing the inhibition 
reagent concentration brought about inhibition, even when ten times as much 
inhibition reagent was used (12.5 μg).  In Seltsam’s study therefore six out of 
21 samples were not inhibited by sr-LHR-D (22%).  Tamasauskas et al., 
(2011), tested six examples of anti-Kna and found that three were inhibited by 
sr-LHR-C alone and three with LHR-D alone (50%). In this study 38% KN 
related samples were not inhibited by sr-LHR-D but were inhibited by sr-LHR-
C either on its own or as part of the KNIR reagent.  This illustrates the 
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effectiveness of using both sr-LHR-C and sr-LHR-D together in the inhibition 
test to detect KN system antibodies. 
  
The antigenicity ELISA is a useful test to confirm KN specificity of an antibody.  
Using the separate sr-LHR reagents in both ELISA and CAT inhibition tests 
has given some interesting findings.  All the amino acid polymorphisms 
responsible for KN blood group system antigens have now been localised to 
the LHR-D region (Veldhuisen, 2011).  However, this study and two others 
have found that not all CR1 related antibodies are inhibited by sr-LHR-D.  
(Tamasauskas et al., 2001 and Seltsam et al., 2014).   Seltsam speculates 
that these antibodies may be directed to so far undefined epitopes not 
expressed on LHR-D.  In this study it was shown that most KN related 
antibodies react with one sr-LHR or the other but not usually both.  It does not 
appear that this is a quantitative effect as increasing the concentration of sr-
protein used to attempt to inhibit these antibodies did not effect inhibition.  Of 
those antibodies with known KN specificity, two out of 11 anti-Kna antibodies 
and one out of two anti-McCa antibodies reacted only with sr-LHR-C.  One 
other study (Tamasauskas et al., 2001) only found anti-Kna antibodies 
reacting with sr-LHR-C alone.  The two LHR regions show high homology 
(Moulds et al., 2004).  This can be seen in Figure 5.4 where the proteins are 
aligned, particularly from approximately 252 amino acids from the start of both 
proteins. The Kna antigen has valine at position 1561.  Around this amino acid 
there is the sequence FELVGERSIYCTS starting at 164 amino acids from the 
beginning of LHR-D.  On LHR-C at 165 amino acids from the start the 
sequence is:  FELVGEPSIYCTS with the exception of proline (P) instead of 
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arginine (R) as the seventh amino acid, this sequence is identical.  The 
closely matching sequences around the Kna / Knb polymorphism are 
highlighted in Figure 5.4.  It could be that the conformations of the proteins are 
very similar around this point and that some anti-Kna antibodies are directed 
against this epitope and not that on LHR-D.  If models of the two molecules 
are compared and matched around the Kna / Knb SNP, the predicted 
conformation can be seen to be very similar (Figure 5.5).   
 
LHR-C  HCQAPDHFLFAKLKTQTNASDFPIGTSLKYECRPEYYGRPFSITCLDNLVWSSPKDVCKR 
       ::..:..: ::.     :  .::.::::.::::: :.:. :::.::.:::::: .: :.: 
LHR-D  HCKTPEQFPFASPTIPINDFEFPVGTSLNYECRPGYFGKMFSISCLENLVWSSVEDNCRR 
 
LHR-C  KSCKTPPDPVNGMVHVITDIQVGSRINYSCTTGHRLIGHSSAECILSGNTAHWSTKPPIC 
       :::  ::.: :::::. :: : :: .::::. : ::::  :. :..:::.. :. : ::: 
LHR-D  KSCGPPPEPFNGMVHINTDTQFGSTVNYSCNEGFRLIGSPSTTCLVSGNNVTWDKKAPIC 
 
LHR-C  QRIPCGLPPTIANGDFISTNRENFHYGSVVTYRCNLGSRGRKVFELVGEPSIYCTSNDDQ 
       . : :  ::::.:::: :.:: .:: :.::::.:. :  :...:::::: ::::::.::: 
LHR-D  EIISCEPPPTISNGDFYSNNRTSFHNGTVVTYQCHTGPDGEQLFELVGERSIYCTSKDDQ 
 
LHR-C  VGIWSGPAPQCIIPNKCTPPNVENGILVSDNRSLFSLNEVVEFRCQPGFVMKGPRRVKCQ 
       ::.::.: :.::  :::: :.:::.: :  :::.:.:.:...::::::::: : . :.:: 
LHR-D  VGVWSSPPPRCISTNKCTAPEVENAIRVPGNRSFFTLTEIIRFRCQPGFVMVGSHTVQCQ 
 
LHR-C  ALNKWEPELPSCSRVCQPPPEILHGEHTPSHQDNFSPGQEVFYSCEPGYDLRGAASLHCT 
       . ..: :.:: ::::::::::::::::: ::::::::::::::::::.:::::::::::: 
LHR-D  TNGRWGPKLPHCSRVCQPPPEILHGEHTLSHQDNFSPGQEVFYSCEPSYDLRGAASLHCT 
 
LHR-C  PQGDWSPEAPRCAVKSCDDFLGQLPHGRVLFPLNLQLGAKVSFVCDEGFRLKGSSVSHCV 
       ::::::::::::.:::::::::::::::::.:::::::::::::::::::::: :.:::: 
LHR-D  PQGDWSPEAPRCTVKSCDDFLGQLPHGRVLLPLNLQLGAKVSFVCDEGFRLKGRSASHCV 
 
LHR-C  LVGMRSLWNNSVPVCEHIFCPNPPAILNGRHTGTPSGDIPYGKEISYTCDPHPDRGMTFN 
       :.::..:::.::::::.:::::::::::::::::: :::::::::::.:: ::::::::: 
LHR-D  LAGMKALWNSSVPVCEQIFCPNPPAILNGRHTGTPFGDIPYGKEISYACDTHPDRGMTFN 
 
LHR-C  LIGESTIRCTSDPHGNGVWSSPAPRCELSVRA 
       :::::.:::::::.:::::::::::::::: : 
LHR-D  LIGESSIRCTSDPQGNGVWSSPAPRCELSVPA 
 
 
Figure 5.4 Comparison of LHR-C and LHR-D protein sequences.  The two 
sequences of LHR-C and LHR-D were aligned using LALIGN software.  The 
yellow highlight shows the similarity between LHR-C 165 amino acids from the 
start of the sequence and LHR-D 164 amino acids from the start.  The greyed 
out area shows the highly homologous parts of the two molecules.  The dots 
indicate degree of homology with two dots indicating complete homology and 
one dot indicating partial homology, whilst no dots indicates no homology. 
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Conformation of the molecules could also be affected by glycosylation as 
discussed in Protein Purification section 4.3.5.  Figure 5.5 shows that around 
the yellow highlighted area (shown in Figure 5.4) the molecular conformation 
is very similar for LHR-C and LHR-D.   
 
   
Figure 5.5 Comparison of the structure of LHR-C and LHR-D molecules.  A 
model of LHR-C (blue) and LHR-D (red) matched around the Kna / Knb 
polymorphism on LHR-D and the corresponding part of the molecule on LHR-
C is shown.  The green line indicates a matching area of the molecules.  
Models from Furtado et al., (2008) aligned using the Swiss-Prot database at 
www.ebi.ac.uk/swissprot. 
 
In practice the mixed inhibition reagent will be used for inhibition in RCI 
laboratories so the differences seen when using individual sr-LHRs would not 
be seen.  However, a strategy for RCI might be for RCI laboratories to refer 
any inhibited plasma samples to RCI, Filton.  Samples could be batched and 
then tested by an antigenicity ELISA using the individual sr-LHRs.  This would 
enable data to be gathered on the reactivity of KN antibodies and so would 
add to knowledge of the KN blood group system. 
 
Redacted due to copyright
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KN antibodies are difficult to investigate in the laboratory.  The current RCI 
protocol for investigation of antibodies includes an algorithm which specifies 
that if an antibody reacts with all or most reagent panel cells by IAT and 
enzyme techniques with variable or weak reaction strengths then the 
possibility of the presence of a KN related antibody should be considered.  
The next step is to test with cells that lack antigens such as Kna, Yka and 
McCa.  If negative with one or more of these cells then the antibody may have 
KN specificity.  However, these cells are rare and may not be available to the 
laboratory.  If they are available they are usually frozen and need to be 
recovered for use.  It might be necessary to refer the sample to IBGRL who 
have access to plasma and red cells from previously investigated cases or 
who can perform the monoclonal antibody-specific immobilization of 
erythrocyte antigens assay (MAIEA) test.   However, if blood is required for 
the patient, the antibody may react with all panel and donor cells that it is 
tested with and the presence of underlying clinically significant antibodies 
needs to be confirmed or excluded.  At this point it becomes difficult to resolve 
the investigation and if transfusion is urgently required, donor units may have 
to be selected that give the weakest reactions by IAT, which is not ideal for 
the patient.  Some RCI laboratories will use RBCs treated with AET to 
denature KN antigens for antibody investigations but AET also denatures 
other antigens, for instance AnWj.  This is particularly dangerous as seen in 
this study where retrospective testing of a patient sample indicated that an 
anti-AnWj was wrongly reported as a KN related antibody.  KN antibodies are 
not clinically significant but anti-AnWj is and has caused severe haemolytic 
transfusion reactions (Xu et al., 2012). 
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In other countries e.g. USA (Judd, 2006) and Argentina (Torres et al., 2010) it 
seems that greater emphasis is placed on trying to identify KN and other 
HTLA antibodies.  RBCs treated with the enzyme ficin, or the reducing agents 
DTT or AET may be used or serum inhibition and titration studies may be 
performed.  These workers will also try to use RBCs negative for high 
frequency HTLA antigens.  The rationale is that Ch/Rg and JMH antibodies 
will not react with ficin treated cells; anti-Ch/Rg antibodies are inhibited by 
pooled plasma; anti-JMH does not react with DTT treated cells.  KN 
antibodies react variably with ficin treated RBCs and usually do not react with 
DTT or AET treated RBCs.  Incubation of patient’s plasma with pooled plasma 
will inhibit Ch/Rg.  However, this extra testing takes time and may not, 
ultimately, reveal the identity of the antibody.  If an antibody is inhibited by the 
KNIR then it is immediately known that the antibody is KN related and even 
more importantly, the presence of underlying antibodies can be seen.  It was 
shown that no clinically significant antibodies are inhibited by either sr-LHR-C 
or sr-LHR-D.  Inhibition with the new KNIR reagent is a simple and fast 
technique that identifies the presence of a KN antibody and provides 
information on any underlying clinically significant antibodies that may be 
present in one test that takes one hour to complete, including setting up and 
reading gel cards; 30 minutes for the inhibition stage, 15 minutes for 
incubation on the gel card and 10 minute centrifugation step.   
 
Crossmatching is the process where a patient’s plasma is tested against 
donor red cells to ensure that the donations are compatible and safe to issue 
for transfusion.   The compatibility test is a CAT test (Materials and methods 
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section 2.5.2) where patient’s plasma is tested with red cell samples from the 
units selected for transfusion. CAT inhibition test could easily be used for 
crossmatching.  As the plasma would have been modified by inhibition, RCI 
protocol dictates that the crossmatch should be performed in parallel with 
normal, uninhibited patient’s plasma.  It would give reassurance that 
incompatibility was due to the presence of clinically insignificant antibodies if 
the KN antibody was inhibited and all the crossmatched units were compatible 
with the inhibited plasma.  The units issued would be suitable for issue, 
although not termed compatible, a term reserved for negative reactions 
obtained with unmodified patient plasma, but there would be reassurance that 
the units would benefit the patient.  The process from identification of KN 
antibody to issue of crossmatch suitable blood would be very rapid at less 
than two hours in comparison to current practice which would take 
approximately four hours (personal experience). 
 
Both techniques proved successful and will be valuable additions to the 
repertoire of RCI and IBGRL laboratories, where time taken for investigation 
and provision of suitable blood would be significantly reduced.  KNIR reagent 
stored for up to four months at 4ºC showed no deterioration in its ability to 
inhibit KN related antibodies.  However, after five months some deterioration 
was noted.  Samples stored for over a year once thawed did not show any 
difference in ability to inhibit, nor did samples that had been thawed and 
frozen up to three times.  In practice it would be useful to prepare frozen 
reagent in ready to use aliquots so that they could be stored in the individual 
laboratories, thawed for use and the appropriate volume of plasma added for 
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inhibition.  Currently, the Medicines and Healthcare Products Regulatory 
Agency (MHRA) indicate that NHSBT is assigned the status of a single Health 
Institution, so that supplying the KNIR reagent to RCI laboratories would be 
exempt from CE marking (personal communication from M. James, National 
Reagents Strategy Manager).  However, to sell the reagent to laboratories 
outside NHSBT would require it to be CE marked and this is discussed in the 
next section. 
 
The aim to use sr-LHR-C and sr-LHR-D proteins in a test to aid in antibody 
investigation was fully met.  The ELISA which was developed will not be used 
routinely due to a lack of equipment and expertise in this technique in RCI 
laboratories.  The inhibition technique utilises a primary antibody investigation 
technique, a gel card IAT test, in regular use in RCI.  Addition of an inhibition 
stage to this technique will provide an efficient and standardised testing 
method for samples containing KN related antibodies in RCI laboratories.  
Ultimately, patient care will be improved by faster identification of KN related 
antibodies and by simplifying the identification of clinically significant 
antibodies that may be masked by KN related antibodies.. 
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6.0 FINAL DISCUSSION 
6.1 Investigation of Knops antibodies 
This study aimed to produce a reagent to simplify investigation of Knops 
related antibodies in RCI laboratories.  Despite reports in the literature on use 
of whole sr-CR1 protein to inhibit anti-KN antibodies, no commercial reagent 
is available.  Also, the use of a single part of the CR1 protein, sr-LHR-D, has 
been advocated for use as an inhibition reagent but a commercial reagent 
based on just sr-LHR-D is not available either.  This study has shown that a 
cocktail containing both sr-LHR-D and sr-LHR-C is more effective at inhibiting 
Knops related antibodies, than sr-LHR-D on its own.  Sr-LHR-C and sr-LHR-D 
proteins were produced in HEK293 cells.  The proteins produced proved to 
have KN antigenicity so use of a mammalian system produced protein in the 
correct conformation to retain its blood group specificity.  The sr-proteins were 
produced as 3XFLAG tagged proteins.  The presence of the tag allowed a 
one-step purification of the desired proteins from other protein contained in 
the cell culture supernatant.  The proteins produced were antigenic with the 
FLAG tag attached so cleavage of the tag and further purification was not 
required.  There was little contamination with BSA after the purification 
process.  Although acid elution did elute a small amount of the mouse anti-
FLAG antibody from the affinity gel it was chosen as the elution method of 
choice due to slightly reduced cost over peptide elution, it being a quicker 
process than peptide elution and acid elution is already in use in BITS/IBGRL 
for elution of other sr-blood group proteins.  The presence of mouse 
immunoglobulin does not affect the serological IAT test or the antigenicity 
ELISA.  Also, the affinity gels could still be used up to six times after acid 
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elution.  The novel inhibition test in commercial IAT gel cards was developed 
for use in NHSBT laboratories.  When distributed to these laboratories it will 
be an invaluable reagent, providing a faster way of identifying KN related 
antibodies in patient’s plasma identifying whether there are any underlying 
antibodies in the plasma that might be clinically significant and ultimately 
ensure faster provision of compatible blood for patients. 
 
The cheapest cost to produce 9 mL reagent to distribute to NHSBT 
laboratories was calculated as £5,255 (production cost using T-175 flasks was 
£1,257 and purification using acid elution was £3,998).  If aliquoted into ready 
to use amounts and stored frozen until use, reagent activity would last for at 
least one year.  The 1 mL amount would easily allow 30, ten cell ID panels to 
be set up which should be enough for one year for each laboratory based on 
current activity and frequency of anti-Kn antibodies (personal knowledge).  
There would be a saving on use of rare KN negative cells and if a sample 
does not react with e.g. Kna negative cells it is only an indication towards 
presence of anti-Kna and so further investigation would be required.  The 
inhibition test confirms, in one test, that anti-KN antibody is present by the fact 
that it is inhibited.  In the Red Cell Reference laboratory, IBGRL, use of this 
reagent would replace use of the MAIEA test.  The Head of RCR (Nicole 
Thornton, personal communication) has said that performing the MAIEA 
would not provide any advantage to them if the KNIR reagent was available to 
use.  The MAIEA is a time consuming test and can only indicate that an 
antibody has KN specificity and this could be achieved more rapidly by use of 
KNIR reagent.  For RCI, time savings of approximately 560 hours for band 6 
169 
BMS staff would be achieved.  A further advantage of using KNIR reagent 
would be standardisation of investigation of KN related antibodies across RCI 
laboratories with a national standard operating procedure in place.  Currently, 
there is no consistent approach with some RCI laboratories having access to 
rare cells, others using AET treated panels. 
 
6.2 Future Developments 
6.2.1 CE marking of reagents 
Under current European Union (EU) guidelines the in vitro diagnostic device 
(IVD) includes reagents (European Union, 1998) and states that they should 
be CE marked (see below).  However, reagents produced within Health 
Institution laboratories for use in that environment are not covered by this 
directive as they are not subject to commercial transactions.  The current 
viewpoint from the Medicines and Healthcare Products Regulatory Agency 
(MHRA) under guidance issued in August 2013 is that NHSBT is regarded as 
a Health Institution so supplying reagent to NHSBT laboratories would be 
exempt from CE marking (personal communication from Malcolm James, 
NHSBT National Reagents Strategy Manager).  However, following a poster 
presentation about the findings of this study at the British Blood Transfusion 
Society (BBTS) annual meeting in October 2013 (Appendix 2), an enquiry has 
been received from a national testing laboratory in Finland asking if they could 
be supplied with the KN inhibition reagent.  To do this CE marking of the 
reagent would be required.   
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CE marking is verification by the manufacturer that the product meets EU 
safety, health or environmental requirements (European Union, 2010).  As 
there already is demand from abroad and there may be further demand and in 
case CE marking becomes necessary even for provision within NHSBT, it is 
the intention to CE mark the KN inhibition reagent cocktail.  This will require 
carrying out a conformity assessment, setting up a technical file, issue of the 
EC declaration of conformity and affixing a CE mark to the product.  If the 
reagent is supplied to a foreign country then a further complexity is the 
requirement to issue instructions and labels in the country’s specified 
language e.g. in the case of Finland labels would need to be in Finnish and 
Swedish.  As the intention would be to supply KNIR frozen then there would 
be a requirement to check that the product meets its intended purpose up to 
the date of expiry and at least one month beyond this for three separate 
batches. Also validation that the product meets its intended purpose once 
thawed for three separate batches.  This would involve sending the reagent to 
the furthest RCI laboratory at Newcastle via NHSBT transport in dry ice for 
them to test and also for them to send back a vial that could then be tested in 
Filton.  For Finland this would involve sending by air transport.  An EU 
declaration of conformity could be issued by RCI Reagents under self-
certification or through BITS/IBGRL who issue monoclonal antibodies and a 
CE mark could then be affixed to the reagent. 
 
6.2.2 Use of sr-blood group proteins in RCI 
Use of KNIR reagent will represent the first use of sr-blood group proteins in 
RCI laboratories.  The CAT inhibition test utilises a test system already 
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familiar to RCI staff.  Feedback on use of the reagent has been positive from 
both RCI and RCR laboratories.  A recent study showed that several sr-blood 
group antibodies could be incorporated into inhibition techniques (Seltsam et 
al., 2014).  Sr-blood group proteins expressing the most relevant and high 
prevalence antigens of the respective blood groups Scianna, Rodgers, Chido, 
Knops and JMH were produced and mixed together in a cocktail for use.  
Antibodies of these systems are all clinically insignificant so use of the cocktail 
would inhibit any of these antibodies if they were present in a single test.  This 
would eliminate the need to identify the exact antibody specificity.   
 
Sr-blood group antigens including sr-K, sr-k, sr-Fya, sr-Fyb and sr-Lub have 
been produced in BITS/IBGRL under a contract with a commercial company 
BioRad.  The cell lines and license to use them are owned by BioRad but they 
can be used internally within NHSBT (personal communication from K 
Ridgwell).  During the course of this study an antibody under investigation in 
RCI was found to react with all panel cells and was proving difficult to identify.  
Before examples of rare cells that were negative for high frequency antigens 
were thawed, the patient’s plasma was tested by CAT inhibition test using sr-
Lub kindly provided by Fran Green from BITS/IBGRL.  The antibody was 
inhibited and thus identified as anti-Lub, a clinically significant antibody.   
  
 
6.2.3 Collaboration between research and diagnostics laboratories 
within NHSBT    
 
The above use of sr-Lub to resolve a patient antibody investigation in RCI 
highlights one of the most satisfying aspects of this project and that is the 
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collaboration that has grown between RCI and BITS/IBGRL.  The need for a 
reagent to inhibit KN antibodies was identified by RCI and working together a 
reagent has been produced.  Ultimately the reagent will be produced in 
BITS/IBGRL according to the recommendations made in this study.  Frozen 
HEK293 cells prepared in this study have been retrieved and grown by Amelia 
White in BITS/IBGRL.  She has grown them successfully in T-175 flasks and 
purified the protein on affinity columns according to the protocol described 
here.  She has found growth in T-175 or the bigger T-225 flasks to be the best 
method for growing the cells and is currently trying to produce enough protein 
for distribution to the nine NHSBT laboratories. 
 
PUBLICATIONS AND PRESENTATIONS 
An abstract for the British Blood Transfusion Society annual meeting in 
October 2013 was accepted for a poster presentation, Appendix 2. 
An oral presentation was given at a BITS/IBGRL Work in Progress meeting 
held in March 2014. 
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APPENDIX 1 
 
Sequence analysis for the primer designed to sequence around the Kna / 
Knb polymorphism.  The fragment shown in figure 3.5 lies between bases 
178 and 192.
182 
APPENDIX 2 Standard operating procedure KN (Knops) antibody inhibition test 
 
 
STANDARD OPERATING PROCEDURE  
This SOP replaces 
NEW 
 Copy Number 
    
 Effective DRAFT 
FOR EVALUATION 
Summary of Significant Changes 
N/A 
 
Purpose 
To inhibit KN antibodies to aid in their identification and allow detection of any underlying clinically 
significant alloantibodies. 
 
 
Responsibilities  Restrictions 
   
 
 
Definitions 
Column agglutination test (CAT) Indirect 
antiglobulin test (IAT) performed in gel cards 
KN Inhibition Reagent (KNIR) – a mixture of 
soluble recombinant proteins carrying KN 
antigens.  Store frozen at -30°C. 
KN system (Knops) – contains 9 antigens:  
KN1 (Kn
a
), KN2 (Kn
b
), KN3 (McC
a
), KN4 (Sl1), 
KN5 (Yk
a
), KN6 (McC
b
), KN7 (Vil), KN8 (Sl3), 
KN9 (KCAM) 
 CAT Inhibition test – CAT test performed with 
plasma inhibited with KNIR 
RT – Room temperature 
 
 
Items Required 
Automatic pipette 
Pipette tips 
Indelible pen 
BIO-RAD AHG cards 
Reagent cells in CellStab 
 
 INF335 – Grading of Reactions 
SOP1180 – Compatibility testing 
KNIR reagent – supplied as aliquots of 30 μL 
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STEP DETAILS INFORMATION 
1. Perform inhibition 1.1 Thaw tube of KNIR inhibition 
reagent 
1.2 Label tube with test identity 
1.3 Add 270 μL of patient’s 
plasma to tube and mix well 
1.4 In a separate tube add 30 
μL PBS to 270 µL patient’s 
plasma and mix well    
1.4 Incubate both tubes at RT 
for 30 minutes  
   
KNIR is provided frozen in 30 μL 
amounts 
 
This represents a 1 in10 dilution 
 
Dilution control 
 
2. Perform CAT Inhibition test 2.1 Label card(s) with test 
identity 
2.2 Place 50µL of 0.8% CellStab 
ID-panel cells in the reaction 
chambers of AHG cards 
2.3 Add 25µL of inhibited 
plasma or patient’s plasma 
with PBS to each well 
2.4 Place tests in a 37°C air 
incubator 
2.5 Centrifuge in an appropriate 
centrifuge 
2.6 Read results 
2.7 Write results on worksheet 
 
 
 
 
 
Incubate for 15 minutes 
3. Result interpretation 3.1 Compare results between 
the initial CAT, CAT using 
the dilution control and CAT 
using inhibited plasma 
If antibodies with KN specificity 
are present positive results 
obtained by CAT and with the 
dilution control will be negative by 
CAT Inhibition test 
4. Crossmatching 4.1   Use inhibited plasma for 
crossmatching in parallel 
with untreated plasma 
SOP1180 
 
This copy is uncontrolled unless printed on ‘Controlled’ paper (Template Version 
07/10/08) 
Author(s): Wendy Etheridge  
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APPENDIX 3 - Poster presented at British Blood Transfusion Society 
meeting October 2013 
 
 
 
 
